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This thesis describes an investigation of the permeability of three antiretroviral 
(ARV) drugs (that are under development as vaginal microbicides) using the human 
endometrial epithelial cell line, HEC-1A, as an in vitro model.  
Barrier properties of HEC-1A cells in transwell cultures were determined by 
measurement of transepithelial electrical resistance (TEER), immunofluorescent 
staining of tight junctions and determination of the bi-directional permeability of, the 
paracellular marker, mannitol. Expression of specific uptake and efflux transporters 
were demonstrated by western blotting and compared with human tissue. Findings 
indicate that HEC-1A cells provide a physiologically relevant model to investigate 
permeability of candidate vaginal microbicides. In contrast, the commercially 
available EpiVagina™ model showed sub-optimal barrier properties. 
Permeabilities of three ARV drugs Tenofovir (TFV), Darunavir (DRV) and Dapivirine 
(DPV) were investigated in the HEC-1A model. Efflux ratios of all drugs were 
approximately 1 indicating transporter-independent permeability across the 
epithelium. Apparent permeability (Papp) values for TFV were consistent with 
paracellular diffusion while those for DRV and DPV were indicative of transcellular 
diffusion. No drug-drug interactions were observed when drugs were co-
administered in double combinations. To model the effects of inflammation on drug 
uptake, HEC-1A cultures were stimulated with a variety of toll-like receptor (TLR) 
ligands. The TLR-3 ligand Poly I:C stimulated pro-inflammatory cytokine production 
by HEC-1A cells but did not affect permeability of the drugs and no effect on TEER 
values was evident.  
Permeability of DRV was also assessed using ex vivo rat and macaque 
cervicovaginal epithelial tissue. Consistent with findings from the HEC-1A model, 
DRV transfer across rat epithelium was transporter-independent although the Papp 
values were significantly lower. Preliminary data from macaque tissue indicate DRV 
may be effluxed. 
Development of a robust and physiologically-relevant in vitro model will contribute to 
development of vaginal microbicides by allowing rapid measurement of drug 
transporter dependency, drug-drug interactions and testing of formulations aimed at 
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optimising tissue distribution. In this study, all of the ARVs showed transporter-
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(MOTIF) Microbicide Optimisation Through Innovative Formulation 
(MVC)  Maraviroc 
(N SITE) Nucleotide binding site 
(NBDs) Nucleotide Binding Domains 
(NC)  Nucleocapsid 
(NHP)  Non-Human Primate 
(NNRTIs) Non-Nucleotide Reverse Transcriptase Inhibitors 
(NPC)  Nuclear Pore Complex 
(Nt/NRTIs) Nucleotide/Nucleoside Reverse Transcriptase Inhibitors 
(OAT) Organic Anion Transporter 
(P loop) Phosphate binding Loop 
(PAMPS) Pathogen-Associated Molecular Patterns 
(Papp)  Apparent Permeability 
(PBS)  Phosphate Buffered Saline 
(PC)  Polycarbonate     
(PCR)  Polymerase Chain Reaction     
(PD)  Pharmacodynamics 
(PDB)  Protein Database 
(PDZ)  PSD59-D1gA-ZO-1 
(PE)  Polyester 
(PEP)  Post-Exposure Prophylaxis 
(PEPT) Peptide Transporters 
(PFA)  Paraformaldehyde 
(P-gp)  P-glycoprotein 
(PIC)  Pre-Integration Complex 
(PIs)  Protease Inhibitors 
(PK)  Pharmacokinetic 
(PMTCT) Prevention of Mother-To-Child Transmission 
(POT)  Proton-dependent Oligopeptide Transporters 
(PR)  Protease 
(PRO2000) Polynaphthalene Sulphonate 
(RPM)  Revolutions Per Minute 
(RT)  Reverse Transcriptase 
(SD)  Standard Deviation 
(SDS)  Sodium Dodecyl sulphate 
(SEM)  Scanning Electron Microscopy 
(SIV)  Simian Immunodeficiency Virus 
(SLC)  Solute Carrier 
(SP)  Spacer Peptide   
(STDs)  Sexually Transmitted Diseases 
(STIs)  Sexually Transmitted Infections 
(TAF)  Tenofovir Alafenamide 
(TDF)  Tenofovir Disoproxil Fumarate 
(TEER) Transepithelial Electrical Resistance 
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(TFV)  Tenofovir 
(TFV-DP) Tenofovir Diphosphate 
(THF)  Tetrahydrofuran 
(TLR)  Tool-Like Receptor 
(Tm)  Melting Temperature 
(TMD)  Transmembrane Domain 
(TMH)  Transmembrane α-Helices 
(VMMC) Voluntary Male Medical Circumcision 
(ZO-1)  Zona Occludens-1 
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Chapter 1 Introduction 
In 2015, 36.7 million people were estimated to be living with human 
immunodeficiency virus (HIV) and 1.1 million to have died from HIV [1]. Although the 
number of deaths has reduced from the peak of 2 million per year over the period 
2004-2006, acquired immunodeficiency syndrome (AIDS) remains a major global 
health concern and new approaches to prevent infection are urgently required. 
Recently, clinical trials of vaginally applied anti-retroviral (ARV) drug formulations 
have shown some success in preventing HIV infection.  
The demonstration in a phase IIb clinical trial (CAPRISA 004) that vaginal 
application of a gel formulation of the nucleotide reverse transcriptase inhibitor, 
Tenofovir (TFV), conferred 39% protection against infection with HIV [2] provided a 
significant boost to the development of topical microbicides based on anti-retroviral 
drugs. However, in a subsequent phase III trial of the same vaginal TFV gel (FACTS 
001 trial) no overall protection was observed. Adherence was estimated by 
measurement of drug levels in vaginal fluid in a subgroup of participants. Findings 
indicated low adherence with women using the product on average in 50-60% sex 
acts [3]. Subgroup analyses of women with detectable TFV in vaginal fluid in this 
trial, however, showed significant protection against HIV infection of approximately 
52% [4]. These findings suggest that topical microbicides may be effective but 
emphasise the need for improving use of any product. 
More recently two phase III clinical trials (IPM027, RING study and MTN020, 
ASPIRE study) of the non-nucleoside reverse transcriptase inhibitor Dapivirine 
(DPV) in an intravaginal ring formulation were completed. These trials demonstrated 
reductions in HIV infections of 31% (RING) and 27% (ASPIRE), respectively when 
compared to placebo [5, 6]. Furthermore, in both studies, in women aged >21 
higher levels of protection were observed with 37% in the RING study and 56% in 
the ASPIRE study. Further analyses confirmed higher levels of adherence in this 
age group compared with women aged 18-21.  A phase I study to assess the safety, 
pharmacokinetics and pharmacodynamics of single and 14 days dosing with two 
vaginal microbicide formulations containing Darunavir (DRV), or DPV plus DRV 
presenting no adverse effects. 
In contrast to earlier generation microbicides that targeted HIV fusion and entry or 
aimed at disruption of the virus particle (and which were not effective in clinical 
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trials), efficacy of ARV-based microbicides requires transfer of ARVs across the 
mucosal epithelium and uptake by sub-mucosal T cells that form the initial targets 
for HIV infection. Permeability of ARVs may be influenced no only by 
physiochemical properties of the drug but also by the activity of drug transporters 
(solute carrying efflux and uptake transporters) expressed at apical and basolateral 
surfaces of mucosal epithelial cells. The work described in this thesis aims to 
characterise the factors that affect permeability of ARVs at vaginal mucosa. It was 
undertaken as part of a collaborative multi-partner project: Microbicide Optimisation 
Through Innovative Formulation of Microbicides for Vaginal and Rectal Delivery 
(MOTIF). Other aspects of the project included characterisation of drug transporter 
expression in vaginal and rectal mucosae of humans and animal models, 
development of approaches for co-formulation of ARVs and pharmacokinetic (PK) 
and pharmacodynamics (PD) studies in animal models and tissue explants. 
The overall aim of the work described in this thesis was to investigate factors that 
influence the permeability of three anti-retroviral drugs TFV, DPV and DRV across 
vaginal epithelium. Specific objectives were: 
1. To develop and optimise an in vitro dual chamber model of vaginal 
epithelium for assessment of drug permeability. 
2. To investigate permeability of three ARVs (TFV, DRV and DPV) across 
model epithelium 
3. To develop a model of in vitro inflammation and assess effects on drug 
permeability 
4. To compare drug permeability in different models including ex vivo epithelial 
tissue. 
 
The work described in Chapter 4 focuses on the further development of a cell 
culture model for studies specific of vaginal drug permeability. The Human 
Endometrial Adenocarcinoma cell line, HEC-1A, was particularly suitable for 
permeability screening since it forms tight junctions and produces a stable epithelial 
barrier that forms within 6-10 days of culture. In addition, HEC-1A cells express 
several uptake and efflux drug transporters with a pattern of expression that, 
although not identical, is similar to that of human cervical and vaginal tissue. With 
regard to formation of a barrier epithelium in the dual chamber culture system, the 
HEC-1A model resembles the well-established, FDA (Food and Drug 
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Administration) approved intestinal permeability model based on Caco-2 cells [7]. 
Modelling of inflammation by stimulation of HEC-1A cultures with Toll-like receptor 
(TLR) ligands in the form of molecules acting as pathogen associated molecular 
patterns (PAMPS) was also investigated. 
Chapter 5 assesses the cellular pharmacokinetics of single and double formulations 
of the three ARV drugs by measurement of bi-directional apparent permeability 
(Papp), drug distribution and efflux ratio (ER). These experiments demonstrate low 
TFV permeability via the paracellular pathway, while DRV and DPV show high 
permeability by passive diffusion via the transcellular pathway. This study also 
shows that permeability is drug transporter-independent and an absence of drug-
drug interactions when drugs are combined. The effect of PAMP stimulation on drug 
permeability was also investigated 
Chapter 6 is a comparison of alternative in vitro models to assess ARV permeability. 
Models investigated were the MatTek EpiVaginal™ primary cell-based model, and 













Chapter 2 Literature Review 
2.1 Introduction 
This review outlines the epidemiology and origins of HIV/AIDS as well as the events 
involved in the HIV lifecycle and targets for prevention. Microbicides are described 
in some detail, including their mechanisms of action. Reference is made to the role 
of the vaginal epithelium as a barrier to HIV-1 and as a site for drug delivery. Finally, 
details of drug transporter expression and their mechanisms of action are described 
as well as the physiochemical properties of the drugs that form the focus of this 
study. 
2.2 Epidemiology of HIV infection 
In 1984 a human T-cell lymphotropic retrovirus was linked to the pathogenesis of 
the earlier discovered AIDS [8-10]. This retrovirus is now known as HIV-1 and AIDS 
has become a major health issue worldwide. In total, HIV-1 has infected almost 70 
million people worldwide and AIDS is accountable for the death of over 34 million 
people. More than 30 years later, infection rates remain high with an estimated 2.1 
million new infections and 1.1million deaths from AIDS-related illnesses during the 
year 2015 [11]. However, since 1997 there has been a significant decrease in new 
HIV infections from 3.5 million to 2.1 million in 2014 (Figure 2.1A). Additionally, as 
illustrated in Figure 2.1A the number of AIDS related deaths is also declining with 
approximately 1.1 million AIDS deaths in 2015, down from the estimated plateau of 
2 million annually between 2004 and 2006. With increasing access to treatment, the 
number of people living with HIV is increasing and in 2015 was 36.7 million (Figure 
2.1B).  
HIV can be transmitted through sexual contact, the sharing of contaminated 
needles, infected mother to child transmission and by blood transfusions. 
Heterosexual transmission, however, accounts for the vast majority of infections. In 
2015 there were approximately 5,700 new infections per day. Of these new 
infections the majority occurred in the developing world, and in particular Sub-
Saharan Africa which remains the region most severely affected by the AIDS 
epidemic. In this region nearly 1 in every 20 adults is living with the virus. In 2015, 
an estimated 25.6 million people were living with HIV, (approximately 70% of the 
global HIV burden). In the same year, there were an estimated 2.1 million new HIV 
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infections and 1.1 million AIDS-related deaths. Nonetheless, between 2005 and 
2015, the annual number of new HIV infections among adults in Sub-Saharan Africa 
has declined by approximately 40%. Conversely, new HIV infections in the Middle 
East and North Africa have increased by 4%, between 2010 and 2015. In Eastern 
Europe and Central Asia, new HIV infections have also increased by 57% during the 




Figure  2.1 Plots of data from UNAIDS/WHO reports showing numbers of people living 
with HIV, new HIV infections, AIDS related deaths and access to HIV treatment. (A) 
Numbers of people living with HIV, new HIV infections and AIDS related deaths from 1990-
2015. (B) Numbers of people accessing HIV treatment from 2005-2015. 
2.2.1 Phylogeny and origin of HIV-1  
The isolation of viruses, shown to be related to HIV by genome analyses, from 
several species of non-human primates (as well as other animal species) suggested 
that HIV originated by zoonotic transfer to humans [12]. These viruses are termed 
simian immunodeficiency virus (SIV) although not all cause immunodeficiency in the 
animal host. In particular, a strain of SIV, isolated from a chimpanzee (Pan 
troglodytes troglodytes) and termed SIVcpz showed identical genetic organisation to 
HIV-1 including the presence of the HIV-1-specific vpu gene and the lack of the vpx 
gene common to SIV [13]. Although the divergence in sequence between this strain 
and HIV-1 did not provide conclusive evidence for SIVcpz as the origin of HIV, 
subsequent analyses of further SIVcpz strains confirmed the close phylogenetic 
relationship between SIVcpz and HIV-1 and the significant distance from SIV 
isolates of species other than P. t. troglodytes [14]. Further phylogenetic analyses of 
SIV from various species of non-human primates demonstrated close clustering of 
SIVcpz Pol genes (encoding protease, reverse transcriptase and integrase) with 
those of SIVrcm isolates from red-capped mangabeys (Cercopithecus nictitans) 
while SIVcpz Envelope (Env) genes clustered closely with those of SIVgsn isolates 
from greater spot-nosed monkeys (Cerocebus torquatus) [15]. Acquisition of SIVrcm 
and SIVgsn by a single chimpanzee is suggested to result from predation [15] and 
led to recombination resulting in SIVcpz which was transmittable to other 
chimpanzees and subsequently by zoonotic transfer to humans [16]. 
The four different groups of HIV (M, N, O and P) each represent a single 
transmission event of SIVcpz to humans. Group M represents the pandemic form of 
HIV-1 accounting for the millions of infections worldwide. It contains 11 subtypes or 
clades (A1, A2, B, C, D, F1, F2, G, H, J and K). To investigate the early spread of 
HIV-1, all group M sequences in the HIV sequence database [17] (focussing on 
those encoding the Env C2V3 region) from countries in the Congo River basin were 
used together with sampling dates and geographical location in phylogenetic 
analyses to identify the Democratic Republic of the Congo (DRC) as the country 
from which group M HIV-1 spread [18]. Further phylogeographic analyses of 
sequences from different locations within the DRC as well as the neighbouring 
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Republic of Congo identified Kinshasa as the origin of the group M pandemic. The 
time of the most recent common ancestor of group M was estimated to be 
approximately 1920 [18]. Kinshasa was a convenient transport hub for roads, 
railways and rivers and entertained a growing sex trade around this time. The high 
population of migrants and sex trade might explain how HIV spread along these 
infrastructure routes, firstly to Brazzaville by 1937 and then onto Lubumbashi and 
Mbuji-Mayi respectively. The most prevalent HIV genetic forms are subtypes A, B, 
and C. Subtype A viruses are predominantly found in areas of central and Eastern 
Africa and Eastern Europe. Subtype B is the most geographically dispersed subtype 
and dominates Europe, Australia and the US. Subtype C is the most dominant HIV 
strain currently accounting for almost 50% of all HIV infection worldwide [19]. It is 
mainly located in southern and eastern Africa as well as in India. 
2.3 Epidemiology of HIV infection in women 
As of 2015 there were approximately 17.8 million women aged 15 years and older 
living with HIV; making up almost 48.5% of the people living with HIV worldwide and 
80% residing in Sub-Saharan Africa. Here, women are disproportionately impacted 
by the HIV epidemic accounting for 58% of the total number of people living with 
HIV. There are almost 390 000 new HIV infections among adolescent girls and 
young women (15–24 years old) around the world every year. In Sub-Saharan 
Africa women acquire HIV infection at least 5–7 years earlier than men and young 
women (15–24 years old) are twice as likely to be living with HIV than men [1]. 
Women are particularly vulnerable to HIV infection for a variety of biological and 
socio-cultural reasons.  
2.3.1 Socio-cultural factors associated with HIV infection in women 
The disproportionately high HIV incidence amongst women (especially young 
women) is determined by sexual behaviour and patterning. Whilst women, when 
compared to men, share similar ages of sexual debut in Sub-Saharan Africa it has 
been shown that young women generally engage in sexual relationships with older 
men [20, 21]. This difference in age between partners maximises the risk of HIV 
acquisition by the younger partner since older individuals are more likely to be 
infected with HIV [21]. Additionally, women may struggle to negotiate condom use 
with their male counterpart. HIV rates can be high within young women reporting 
only a single lifetime partner and very limited sexual intercourse [20]. Other 
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behavioural factors such as douching and intra-vaginal practices may alter the 
vaginal flora [22, 23] which can potentially lead to inflammation, increasing the risk 
of HIV acquisition. 
2.3.2 Biological factors associated with HIV infection in women 
High HIV incidence per-coital act in young women [24] indicates that behavioural 
factors are unlikely to be solely responsible for increased susceptibility to infection 
[25]. An important factor that increases susceptibility to HIV infection is the much 
larger mucosal surface area of the female genital tract (FGT), the site of initial HIV 
exposure in women, compared with that of the penis and foreskin. Women may also 
be exposed for a longer duration to HIV as semen can remain within the FGT for up 
to three days post-coitus [26]. The mucosal immune environment is another 
important factor that may be responsible for increased vulnerability to infection. 
Cervical-associated CD4+ T cells express higher levels, compared to blood-derived 
CD4+ T cells, of the HIV co-receptor CCR5 and the α4β7 integrin that not only 
mediates lymphocyte homing to mucosal lamina propria but also binds to HIV gp120 
and may facilitate virus attachment [20]. Similar findings have been reported for 
foreskin-derived CD4+ T cells [27, 28]. The increased expression of HIV co-
receptors may further facilitate HIV infection. Finally, young women are more at risk 
to HIV infection compared to older women as the morphology within areas of the 
FGT gradually changes with age, particularly in the first pregnancy. The ectocervix 
transitions from a simple columnar and stratified squamous epithelium to a more 
mature predominantly squamous epithelium, a process known as squamous 
metaplasia. This simple columnar physiology of the ectocervix of a younger woman 
is more vulnerable to microabrasions during coitus [29, 30] which therefore provides 
a portal for HIV entry as well as entry for sexually transmitted infections (STI’s) that 
contribute to HIV susceptibility, such as Chlamydia trachomatis and Neisseria 
gonorrhoea [31-33]. 
2.4 Targeting the viral lifecycle of HIV 
2.4.1 HIV structure 
The HIV-1 virion is approximately 150nm in diameter and like all retroviruses, 
possesses an inner core (Figure 2.2). This inner core contains two identical copies 
of 9.2kb single-stranded (sense) RNA molecules that are associated with the 
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nucleocapsid (NC) protein or p7. The inner core, the viral enzymes crucial for virus 
infection and replication (protease (PR), reverse transcriptase (RT), integrase (IN)) 
and the regulatory proteins tat, rev, nef, vif, vpr, and vpu are enclosed within the 
capsid (CA) protein p24. The capsid itself is surrounded by a lipid bilayer that 
derives from the infected host cell lipid membrane. The inner surface of this 
envelope is coated by the matrix (MA) protein p17, whereas the external surface 
exposes the Env glycoproteins gp120 and gp41 which are embedded within the lipid 
bilayer and responsible for binding and fusion of the virus to the host cell 
membrane. Cryo-electron tomography has shown that the late budding stage of a 
mature virion from the lipid bilayer represents an almost completely closed sphere 
whilst the inner HIV CA exhibits a tubular and coned morphology [34]. 
 
Figure 2.2 Basic diagram of a mature HIV-1 virion.  HIV forms a spherical structure with 
the Env proteins gp120 and gp41 projecting through the lipid membrane. The inner surface 
of the bilayer is coated by the MA protein. The inner viral CA bilayer surrounds crucial 
proteins (PR, IN, RT and Tat) necessary for virus maturation. The cone shaped CA also 
houses the viral RNA genome that is associated with the NC proteins. 
2.4.2 HIV-1 lifecycle 
The HIV-1 lifecycle involves multiple stages. These included HIV-1 binding, fusion, 
reverse transcription, integration, transcription and translation, assembly, release 
and maturation and are described further below. 
 26 
 
2.4.2.1 HIV-1 binding, fusion and reverse transcription 
HIV infection of target cells requires fusion of the viral membrane and host cell 
membrane which is initiated by binding of the CD4 receptor and one of two 
chemokine receptor molecules CXCR4 or CCR5 with the virus envelope 
glycoprotein 120 (gp120). Primary infection involves exclusively binding of gp120 to 
the CCR5 [35, 36] receptor in both mucosal and intravenous transmission of HIV 
infection. Conversely, viruses that bind to the CXCR4 receptor are more commonly 
found in later stages of infection as the disease progresses to AIDS [37]. Once 
bound to CD4, a conformational change in gp120 is triggered which leads to the 
exposure of the co-receptor binding site. Binding of gp120 (through the V3 loop) to 
the co-receptor further triggers a conformational change in gp41 that leads to 
exposure of the N-terminal hydrophobic fusion peptide of gp41 that can penetrate 
into the host cell membrane. Further conformational changes in gp41 lead to 
shedding of gp120 and formation of a 6 α-helical bundle structure that promotes 
fusion of viral and host cell membranes. The HIV-1 capsid is then released and 
uncoats discharging the viral core into the host cell cytosol where reverse 
transcription is initiated. Recent experimental evidence suggests that three 
sequential mechanisms are involved in the uncoating process namely, immediate 
uncoating, cytoplasmic uncoating and nuclear pore complex (NPC) uncoating [38]. 
RT has two enzymatic activities; a DNA polymerase that synthesises the 
complementary DNA strand from the tRNA primer carried within the virus particle 
associated with the RNA genome, and an RNAse H that cleaves RNA that is part of 
an RNA/DNA duplex only. These two enzymatic processes convert viral RNA to 
double stranded viral cDNA [39].  
2.4.2.2 HIV-1 integration, transcription and translation 
Full length double stranded HIV cDNA is translocated into the host nucleus 
catalysed by the viral enzyme IN which interacts with cellular co-factors. The viral 
DNA is part of a large nucleoprotein complex known as the Pre-integration Complex 
(PIC), which derives from the viral core [40]. The PIC travels towards the nuclear 
envelope via a microtubule network [41] and subsequently enters the nucleus 
through the nuclear pore complex. A series of DNA breaking and joining reactions, 
along with the catalytic activity of IN, efficiently mediates the integration of the viral 
DNA within the PIC into the target DNA. Once integrated, short completely spliced 
mRNAs (produced by HIV-1) encoding the viral regulatory proteins Tat and Rev are 
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produced. Incompletely spliced mRNAs are also produced as the infection 
progresses; these encode the Env protein gp160 and the accessory genes Vif, Vpr, 
and Vpu. Full length unspliced transcripts are also synthesised and act both as the 
virion genomic RNA and the mRNA for the Gag-Pol polyprotein (discussed below). 
Tat and Rev promote transcription of the integrated HIV genome and nuclear export 
of intron-containing viral RNAs, respectively (reviewed in [42]).    
2.4.2.3 HIV-1 assembly, release and maturation 
The viral envelope glycoprotein Env is transported to the plasma membrane in 
vesicles via a secretory pathway during which it is cleaved by furin or furin-like 
proteases to produce gp120 and gp41 which remain non-covalently complexed. The 
viral polyproteins Gag and Gag-Pol are synthesised following Rev-mediated export 
from the nucleus of the intron-containing viral RNAs. Gag, a 55kDa precursor 
protein that is myristoylated at the N-terminus contains the MA, CA, NC, p6 proteins 
as well as two spacer peptides (SP1 and SP2) (Figure 2.3). The MA domain directs 
Gag to the plasma membrane promoting the incorporation of the viral Env 
glycoproteins into the newly produced virions. Gag molecules anchor in the plasma 
membrane by inserting the amino-terminal myristoyl group into the lipid bilayer and 
by direct interactions with acidic phospholipids [43, 44]. The CA domain mediates 
assembly of the Gag multimers and the p6 domain recruits the cellular endosomal 
sorting complex required for transport (ESCRT) apparatus which is important for 
completing the budding process of the virus [45]. Gag-Pol is a 165kDa polyprotein 
precursor which comprises Gag as well as the viral enzymes PR, RT and IN. After 
release of the immature virion, the viral PR is activated and cleaves the Gag 
precursor in a highly ordered, stepwise processing cascade [46] to form functional 




Figure 2.3 Structural model of the Gag polypeptide. Derived from high-resolution 
structures and models of isolated domains. Arrowheads indicate PR cleavage sites [48]. 
2.4.3 Structure of HIV-1 reverse transcriptase and protease  
2.4.3.1 HIV reverse transcriptase 
HIV RT is an asymmetric heterodimer comprising two related subunits p66 and p51. 
The p66 subunit is 560 amino acids in length and the p51 subunit, formed by 
proteolysis of p66 is 440 amino acids in length. Both subunits share four common 
amino terminal domains. These domains are referred to as “fingers”, “palm”, 
“thumb” and “connection” [49] (Figure 2.4). The larger p66 subunit of the RT 
heterodimer possesses both DNA polymerase and RNAse H activity. The smaller 
p51 subunit plays a more structural role and is important for stabilising the p66 
subunit. The reverse transcription reaction starts with the binding of RT to the 
nucleic acid substrate leading to a conformational change of the p66 thumb from a 
“closed” to “open” state [39]. Requiring a primer (provided by the tRNA- Lys 3) and 
template, RT binds double stranded nucleic acid in the correct pairing orientation 5’-
3’ at the priming site (P site) which is adjacent to the polymerase active site [50, 51]. 
Nucleotide incorporation involves binding of the incoming deoxynucleotide 
triphosphate (dNTP) to the nucleotide binding site (N site) forming a ternary 
complex [51]. The polymerisation reaction is a conformational change in which a 
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portion of the fingers of the p66 subdomain close down on the dNTP which helps to 
align the 3’-OH of the viral RNA strand, the α-phosphate of the dNTP, and the 
polymerase active site to form the phosphodiester bond linking the nucleotide to the 
growing DNA strand [52]. Once the new nucleotide has been incorporated the 
fingers open and the substrate is released permitting the arrival of the next incoming 
dNTP. This process continues until single stranded viral RNA is transcribed into a 
viral hybrid RNA/DNA double helix. RNAse H then breaks down the RNA and the 
polymerase completes the remaining DNA strand to form DNA/DNA double helix, 
producing proviral DNA containing the genetic material for HIV-1.  
 
Figure 2.4 The structure of p66 and p51 asymmetric heterodimeric HIV RT in complex 
with nucleic acid representing a hand like structure.   
The fingers (pink), palm (orange), thumb (green), connection (yellow), RNAse H domain 
(turquoise), polymerase active site (cream) and RNAse H active site subdomains of the p66 
RT subunit are shown. The p51 subunit is in grey and RNA in purple. Figure adapted from 
[53]. 
2.4.3.2 HIV protease  
The HIV protease is essential for virus maturation. The enzyme cleaves the viral 
Gag and Gag-Pol polyproteins in the immature virus particle that buds off from host 
cells, at 9 different processing sites to produce active forms of the proteins required 
for infection [54]. The protease (molecular weight 21.6 kDa) is formed by packing 
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together of two identical subunits (99 amino acid residues each) to form a flattened 
dome-like structure. More than 700 structures of the protease have been deposited 
in the protein data bank [55]. 
 
Figure 2.5 Structure of HIV-1 protease. The structure is represented as a ribbon diagram 
derived from crystal structure determined at a resolution of 1.8Å [56]. Panel (A) shows the 
arrangement of 8 β-strands (blue) and the single α-helix (red) in each of the monomers that 
form the protease structure. The side-chain of the catalytic Asp 25 is shown (arrowed) and 
the N- and C-termini are indicated. Panel (B) shows the structure of the homodimer with 
bound substrate (DRV). Strands d and a′ from each monomer are pulled down towards the 
active site forming a lid-like structure. Structures were drawn using Swiss PDB viewer with 
coordinates from the Protein Data Bank (PDB ID 5E5K). 
The structure of the protease shown in Figure 2.5 by a ribbon diagram was 
determined at a resolution of 1.8Å [57]. Each monomer folds as a series of 8 β-
strands with hairpin loops and a single α-helix. The β-strands show two fold 
pseudosymmetry and are labelled a,b,c,d and a′, b′,c′,d′ , respectively. Strands c 
and d′ and strands c′ and d form two pairs of parallel strands while strands b and c 
and strands b′ and c′ form anti-parallel sheets. The two monomers fold together to 
form the protease with a single catalytic site where the conserved Asp (or Asn) 
residues (position 25) from each monomer are in proximity. Strands d and a′ form 
flexible flap structures that in the liganded structure (panel b) move downwards 
towards the active site (closed state), as shown in (Figure 2.6A). In the absence of 
substrate, the flaps shift to a semi-open state (Figure 2.6B) that allow substrates to 





Figure 2.6 The two conformations of HIV-1 protease (top and side view). (A) The β-
hairpin flaps in their “closed” conformation with a substrate bound to the active site (crystal 
structure from PDB code 1HVR is shown at a resolution of 1.8Å) (B) The “open” 
conformation of the flaps following an unbound substrate at the active site allowing it to 
become accessible (crystal structure from PDB 1HHP is shown at a resolution of 1.8Å).The 
two top views highlight the change in flap structure when in “open” and “closed” states. 
Illustration adapted from [58]. 
2.4.4 Prevention of HIV-1 infection 
Recommendations for HIV prevention involve the use of condoms, sexual 
abstinence, and male circumcision [59, 60]. Compliance with the first two 
approaches is low. Voluntary male medical circumcision (VMMC) is partially 
effective [61] and programmes to expand the provision of VMMC are in progress in 
14 countries in Africa with the aim of achieving 80% coverage in men [62]. 
Alternative methods of prevention are urgently needed. 
An alternate prophylactic approach under investigation is the development of 
antiretroviral (ARV) agents that are designed for topical application at the vaginal or 
rectal mucosae to prevent infection. These products are known as microbicides and 
several different formulations in various delivery systems have been investigated 
including gels, capsules, tablets, films and intra-vaginal rings (IVR) [2, 63-66]. 
Microbicides are designed to be applied either at the time of coitus or on a daily 
basis and provide women with the opportunity to discreetly protect themselves. 
These dosage forms provide the ability to self-administer directly at the site of 
infection and limit systemic drug delivery. Requirements for an ideal vaginal 
microbicide are that it should: 
 32 
 
• retain anti-HIV activity in the presence of semen and over a pH range that 
includes the low pH of the vagina 
• not disrupt the normal vaginal microbiota 
• not induce inflammation or impair barrier properties of the vaginal epithelium 
• be amenable to formulation that are compatible with condom use  
• have potential for topical or sustained release formulation 
• deliver the active pharmaceutical ingredient to target tissues in sufficient 
concentrations to prevent infection 
• have potential for large-scale production at an affordable cost [67-69]. 
2.5 Microbicides and their mechanisms as a preventative measure 
against vaginal HIV infection 
Initial development of microbicides focused on a class of agents targeting the earlier 
stages of the HIV lifecycle by disrupting HIV virions or preventing virion fusion and 
cell entry [70]. Such compounds included surfactants, polyanions and acid buffering 
agents. One of the early attempts to prevent HIV was by using the surfactant 
nonoxynol-9, however, in a phase 3 clinical trial involving female sex workers , an 
increase in infection in the treatment group was observed when compared to the 
placebo group [71]. Nonoxynol-9 displayed the capabilities of mediating epithelial 
toxicity as increasing frequency of lesions correlated with escalating doses of 
nonoxynol-9 in the vaginal and cervical epithelium of women [72]. Additionally, 
epithelial toxicity was shown to compromise the integrity of the murine vaginal 
epithelium [73].  
Other early generation compounds considered were long chain polyanionic 
molecules that could prevent HIV infection in vitro as they were able to prevent 
infection by binding to the gp120 envelope protein [74] on the virion surface, thereby 
restricting the viral binding to target cells [75]. Clinical trials of vaginal gel 
formulations of polyanions such as cellulose sulphate, polynaphthalene sulphonate 
(PRO-2000) and a specific form of the sulphated polysaccharide carrageenan 
(Carraguard) showed no protection against HIV infection [76].  
With these early generation microbicides failing to demonstrate efficacy in clinical 
trials, the focus of microbicide development shifted to specific highly active ARV 
drugs. ARVs target post-fusion stages of the HIV cycle by preventing the replication 
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of viral genetic material, preventing the insertion of viral genetic material into human 
DNA and preventing the processing of viral proteins (Figure 2.7). ARVs are under 
investigation as potential microbicides from the following classes: 
nucleotide/nucleoside reverse transcriptase inhibitors (Nt/NRTIs), non-nucleotide 
reverse transcriptase inhibitors (NNRTIs), integrase inhibitors and protease 
inhibitors (PIs).  
 
Figure 2.7 HIV lifecycle and targets for intervention with microbicides. Microbicides 
products that have been developed to target various stages of the HIV-1 lifecycle [70].  
2.5.1 NRTIs/NtRTIs 
NRTIs were the first class of drugs developed for HIV therapy [77]. They were also 
shown to be effective in post-exposure prophylaxis (PEP) and in prevention of 
mother-to-child transmission (PMTCT) [78]. This class of drug is able to block 
reverse transcription (Figure 2.8) by mimicking endogenous intracellular nucleoside 
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triphosphates for incorporation into the growing HIV DNA strand. These 
nucleoside/nucleotide analogues lack the 3’ OH group found in normal dNTPs and 
therefore cannot form 3’-5’ phosphodiester bonds with adjacent dNTPs, resulting in 
the formation of a dead end complex (DEC) that prevents production of viral cDNA 
[79]. Activation of NRTIs requires three consecutive phosphorylation reactions by 
intracellular kinases, whereas NtRTIs carry a phosphonate group and require only 
two consecutive phosphorylation reactions for activation [70, 80]. TFV, a small 
water-soluble NtRTI is currently the most advanced candidate in microbicide 
development. In a pivotal NHP (non-human primate) vaginal challenge study, 1% 
TFV gel showed full protection against SIV infection [81]. This provided a rationale 
for further development leading to a double-blinded, randomised, placebo controlled 
phase IIb clinical trial in South Africa [2]. The CAPRISA 004 trial demonstrated for 
the first time that an ARV-based microbicide could reduce HIV infection in women 
by 39% over a 30-month period, compared to hydroxyethycellulose (HEC) placebo 
gel. Furthermore, at 1 year, protection was 50% and amongst women who used the 
gel efficiently (>80% compliance), the overall reduction was 53% [2].  
 
Figure 2.8 The action of NRTI such as TVF. (1) HIV virus releases its viral core into the 
host cell. This includes the viral protein RT which is responsible for creating HIV DNA for 
insertion into the host cell’s DNA. (2) Normally, using nucleotides (dNTPs) RT converts 
single stranded HIV RNA into HIV DNA. (3) NRTIs such as TFV lack the 3’ OH groups found 
in normal dNTPs but mimic the remaining nucleotide structure and are inserted into the new 
HIV DNA chain. (4) The next incoming nucleotide is unable to bind to the already 
incorporated hydroxyl lacking nucleotide which leads to the development of a DEC, resulting 
in the termination of the growing viral DNA chain. Illustration adapted from [68]. 
Nonetheless, replicating such data has proven more difficult than expected. A phase 
IIb trial, VOICE (MTN-003), designed to test the efficacy of an oral dosage form of 
TFV (Truvada) as well as TFV vaginal gel showed no significant protection [82]. 
Adherence to use of the gel product, estimated by measurement of drug in blood 
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samples from trial participants, was determined to be approximately 29% and likely 
contributed to the observed lack of protection. In subgroup analyses of women 
using the vaginal gel and who had detectable drug in blood samples, significant 
protection was observed (66%). Similar lack of compliance was reported in a phase 
III trial of a vaginal TFV gel (FACTS 001 trial) which followed on from the CAPRISA 
004 trial. Again, the trial demonstrated no overall protection. Adherence was 
estimated by measurement of drug levels in vaginal fluid in a subgroup of 
participants. Findings indicated low adherence with women using the product on 
average in 50-60% sex acts [4]. Subgroup analyses of women with detectable TFV 
in vaginal fluid in this trial, however, showed significant protection against HIV 
infection of approximately 52% [3]. These trials demonstrate that vaginal 
microbicides have the potential to protect against HIV infection but emphasise the 
need to develop approaches to administration of the microbicide that will improve 
adherence. One such approach is discussed in the next section. 
2.5.2 NNRTIs 
The second class of reverse transcriptase inhibitors are NNRTIs. These non-
competitive inhibitors bind to an induced allosteric hydrophobic pocket located in the 
palm subdomain of p66 that is 10Å from the polymerase active site of the reverse 
transcriptase enzyme [83]. NNRTIs (Figure 2.9) induce the p66 thumb to adopt an 
open and extended position blocking the conformational flexibility of this region on 
the RT enzyme [84]. These movements by RT are necessary for the catalytic cycle 
of the enzyme as only a closed position allows transcription of RNA. This 
conformational change to the structure of the RT enzyme prevents incoming dNTPs 
from binding to the HIV RNA, thereby preventing the formation of HIV dsDNA. A 




Figure 2.9 The action of NNRTI such as DPV. (1) HIV virus releases its viral core into the 
host cell. This includes the viral protein RT which is responsible for creating HIV DNA for 
insertion into the host cell’s DNA. (2) The “fingers” region of the RT p66 subdomain close in 
order to align the HIV RNA strand and the dNTP. Once the new nucleoside has been 
incorporated the fingers open and the substrate is released permitting the arrival of the next 
incoming dNTP. (3) NNRTIs like DPV bind to a hydrophobic pocket located in the palm 
subdomain inducing the p66 thumb into an open and extended position blocking the 
conformational flexibility of this region on the RT enzyme. This conformational change to the 
structure of the RT enzyme prevents incoming dNTP’s from binding to the HIV RNA, thereby 
preventing the further formation of HIV DNA. Illustration adapted from [68]. 
Current NNRTIs being developed as microbicides include Dapivirine, (TMC120), 
UC781, MIV-150, MIV-160, MIV-170, MC1220, and IQP-0528. Of these, Dapivirine 
(DPV) is the most advanced along the development pathway (Figure 2.9). In pre-
clinical studies, intravaginal administration of a radiolabelled [14C]DPV gel 
formulation showed high levels of drug accumulation in tissue 1hour after the final 
dose, and remained detectable at 24 hours in rabbits (mean, ≥2.5 ng/g) and 48 
hours in macaques (mean, >80 g/ng) [85]. Minimal radioactivity levels were 
detected in the plasma and were undetectable in the draining lymph nodes of 
macaques. Moreover, drug related material (DRM) was detected by 
microautoradiography on the surfaces of vaginal and cervical tissues of both rabbits 
and macaques. In macaques DRM was shown to concentrate in the keratinised 
epithelial layer and penetrate deep into the germinal layer of vaginal epithelia [85]. 
The hydrophobic nature of DPV may be advantageous for topical application 
resulting in high concentrations locally with minimal systemic exposure. DPV has 
undergone phase I and phase II PK trials in both gel and intravaginal ring (IVR) 
formulations. More recently the IVR formulation has been tested in two phase III 
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clinical trials (IPM027, RING study and MTN020, ASPIRE study). These trials 
demonstrated reductions in HIV infections of 31% (RING) and 27% (ASPIRE), 
respectively when compared to placebo [5, 6]. Furthermore, in both studies, in 
women aged >21 higher levels of protection were observed with 37% in the RING 
study and 56% in the ASPIRE study. Further analyses confirmed higher levels of 
adherence in this age group compared with women aged 18-21. In the younger age 
group, little or no protection was observed in women. The relative success of these 
trials suggests that a sustained release formulation of vaginal microbicides may be 
more attractive to users than the gel applicators used in trials of TFV gel. 
2.5.3 Integrase inhibitors 
While very important for the treatment of HIV, microbicides containing integrase 
inhibitors are yet to be as extensively studied in comparison to the other ARV 
microbicides. In a two-step reaction, HIV-1 integrase is able to integrate proviral 
reverse-transcribed DNA into the host genome. However, oral raltegravir and 
elitegravir are two inhibitors that are able to specifically inhibit this proviral DNA-
strand transfer, resulting in potent in vitro activity against HIV-1. Raltegravir is used 
for treatment of HIV infection and is approved for twice-daily oral administration [86, 
87]. Long acting injectable formulations of integrase inhibitors to be administered by 
the intramuscular route are also being developed. This may be a means of 
improving adherence. The integrase strand transfer inhibitor (INSTI) GSK 1265744 
has recently showed promising potent antiviral activity when given as an 800 mg 
intramuscular dose [88]. Similarly, a long lasting injectable formulation of rilpivirine is 
under investigation for prophylaxis against infection [89]. 
2.5.4 Protease Inhibitors 
Virus maturation mediated by HIV protease have become a major target for anti-HIV 
drugs, leading to the development of PIs [90]. PIs inhibit HIV maturation by blocking 
the active site of the HIV-1 PR enzyme [54]. This interaction keeps the active site 
covered as the flaps of the enzyme are in the closed conformation, preventing 
binding of the viral protein substrates thus inactivating the enzyme. Of 26 anti-HIV 
compounds approved by the FDA 10 are PIs, these include saquinavir, indinavir, 
ritonavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, and 
DRV. Most of these inhibitors are associated with serious side effects such as 
dyslipidaemia, insulin-resistance, lipodystrophy/lipoatrophy, cardiovascular and 
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cerebrovascular diseases when used long term [91-94]. DRV shows high in vitro 
and in vivo potency against a broad range of HIV-1 strains, including wild type and 
multidrug-resistant (MDR) clinical strains [95, 96]. DRV was effective against PI-
resistant recombinant viruses (1,401 strains) derived from clinical samples [95]. 
DRV binds with high affinity to the protease active site forming hydrogen bonds 
directly or via water molecules with residues in both the catalytic site and the flap 
regions (Figure 2.10). Ritonavir boosted DRV (DRV 800 mg plus ritonavir 100 mg) is 
a current first-line antiretroviral regimen associated with minor side effects. 
 
Figure 2.10 Darunavir in the HIV-1 protease binding site. Close up view of substrate 
binding with strands labelled as in Figure 2.5. Residues that form H-bonds with DRV are 
shown. H-bonding of the backbone nitrogen atoms of Ile 50 at the C-terminal of strand d 
from both subunits to DRV is via a highly conserved tetrahedrally coordinated water 
molecule. In the catalytic site, Asp 25 and Asp 29 from both subunits form H-bonds with 
DRV as does the backbone nitrogen of Asp 30. Structure was drawn using Swiss PDB 
viewer with coordinates from the Protein Data Bank (PDB ID 5E5K). 
2.5.5 Combination-based microbicides 
To improve the efficacy of microbicides, approaches such as formulations 
containing combinations of drugs has been considered. These combination-based 
microbicides provide improved efficacy by providing protection against the 
transmission of resistant viral strains [97] and targeting different stages of the 
lifecycle providing greater protection [68]. Additionally, combination-based 
microbicides may allow exploitation of useful drug–drug interactions either as 
additive or synergistic inhibitors or as a potential means of increasing drug uptake 
and retention in local tissues by effects on drug transporters for drug metabolism 
[70]. Such interactions may allow for lower initial drug doses and thereby minimise 
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the systemic exposure and adverse effects. While successful double combination 
regimens are currently used for orally administered HIV treatment (as described 
above), combination gel-based products are under investigation. Macaques 
administered with 3ml 1% TFV gel with 5% emtricitabine showed 100% protection 
against SHIV infection with less than 0.05% of both drug detected in the blood 
plasma after 30 minutes exposure [98]. More recently a DRV and DPV gel has been 
tested in a phase 1 clinical trial, showing no adverse effects. Additionally, a 
combination of DPV and the CCR5 inhibitor maraviroc (MVC) vaginal ring 
demonstrated concentration-dependent inhibition of HIV-1 infection in cervical tissue 
by DPV, however MVC concentrations were consistently detectable only in cervical 
vaginal fluid (CVF) and not in plasma indicating an improved drug release of MVC 
rings is needed [99]. Polyvinyl alcohol-based films have been used to co-formulate 
MVC and TFV as well as MVC and DPV [70]. DPV has also been co-formulated 
with TFV [100].  
2.6 The vagina as a barrier to infection and vaginal HIV-1 transmission  
2.6.1 The vaginal epithelial environment  
The female genital tract consists of two different types of mucosal surfaces. The 
upper genital tract includes the endometrium and endocervix and represents the 
type I mucosal surface comprising of simple columnar epithelial cells. In contrast, 
the lower genital tract including the vagina and ectocervix represents the type II 
mucosal surface that is lined by 20-45 cell thick, multi-layered non-keratinising, 
stratified, squamous epithelium. The transition area from type I to type II mucosa is 
known as the cervical transformation zone (Figure 2.11). Forming the most 
superficial layer, these epithelial sheets are seeded with immune response cells 
such as CD4+ T cells, macrophages and Langerhans cells (LCs). Resting on an 
indistinct lamina propria- an underlying vascular submucosa, vaginal epithelial cells 
are interconnected by desmosomes, adherens junctions and tight junctions. The 
sub-epithelium of the lamina propria is made up chiefly of connective tissue 
intertwined with a dense network of blood vessels as well as numerous elastic 
fibres, leukocytes, lymphocytes and occasional lymph nodules with varying 
densities among different tissue sites [101]. This epithelial layer acts as a first line of 
defence to infections and plays a critical role in the immunological response to 
pathogens by immune cell recruitment through TLR signalling cascades triggered by 
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PAMPS. At menarche, the production of oestrogen stimulates the vaginal epithelium 
to fill with glycogen. An enriched vaginal microbiota therefore maintains a 
physiological pH of 3.5-4.5 by the bacterial conversion of glycogen to lactic acid 
[102] which prevents the proliferation of pathogenic bacteria and yeast. Along with 
pH, vaginal secretions play an important role in protecting the vagina against 
infection by the production of proteins such as mucins [102, 103]. Mucins such as 
MUC1 mediate immunoregulatory mechanisms such as immune activation through 
cell-cell interactions and transmembrane signal transduction events [104]. The 
epithelial environment of the FGT can be modulated by processes of the female 
menstrual cycle which has two phases: the follicular phase (mature follicles produce 
estradiol that induces endometrial growth) and the luteal phase (the corpus luteum 
secretes progesterone to stabilise the lining of the endometrium and prepare it for 
the implantation of the fertilised egg) [105]. Immunomodulatory effects of estradiol 
and progesterone result in suppression of some innate, humoral and cell mediated 
immune responses in the first 7-10 days of the luteal phase providing a window of 
vulnerability, in which HIV may be  enhanced (as reviewed in ‘A new strategy to 
understand how HIV infects women: identification of a window of vulnerability during 
the menstrual cycle’). 
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Figure 2.11 Anatomy of the female genital tract. The upper genital tract represents the 
type I mucosal surface comprising simple columnar epithelial cells and the lower genital tract 
represents the type II mucosal surface that is lined multi-layered non-keratinising, stratified, 
squamous epithelium. The transition area from type I to type II mucosa is known as the 
cervical transformation zone. Immune cells are densely located in the sub-epithelium.  
2.6.2 HIV-1 transmission through the vaginal epithelium 
The specific mechanisms involved in HIV transmission across the mucosal layer 
remain to be fully identified. In most cases HIV infection may be established by a 
single isolate as determined by single-genome amplification of the HIV-1 Env 
glycoprotein or of whole viral genome sequencing in HIV infected individuals [106, 
107]. In a study of rectal challenge in the rhesus macaque model, low dose virus 
stocks containing on average 48 different SIV Env sequences were administered. 
DNA sequence analyses of virus from the 13 (out of 18) animals infected showed 
that productive infection was either due to a single virus or a very low number of 
viruses (median 1; range 1-5) [108].  
SIV challenge experiments in NHP models identified small foci of sub-epithelial 
mucosal cells that were infected at 72 hours after vaginal exposure [109]. 
Furthermore, an ex vivo human vaginal model indicated that HIV targets CD4+ T 
cells early in the infection process, suggesting that these cells are the initial site of 
infection [31, 110, 111].  
Proposed HIV transmission mechanisms across the vaginal epithelium include; 
endocytosis by dendritic projections of LC [111] that are thought to extend to, or 
near, the luminal surface [101] or by the disruption of the integrity of the vaginal 
mucosa as a result of trauma, bacterial vaginosis, or inflammatory or ulcerative 
disease in the vagina [112] as shown in Figure 2.12. Using an ex vivo tissue model 
of human vaginal epithelium challenged with HIV followed by electron microscopy 
analyses of infected tissue, intact virions were readily observed in the cytoplasmic 
compartment of vaginal LCs up to 3 days post infection, suggesting that the 
persistent endocytosed virions remained accessible for trans infection of susceptible 
neighbouring CD4+ T cells [111]. However, LCs are not readily infected and do not 
appear to be critical for initial infection but may contribute to the formation of the 
self-sustaining foci of infected CD4+ T cells [113]. Other proposed mechanisms 
include HIV entry through transfer by direct cell-cell contact or via viral transcytosis 
across the epithelial cell [114, 115], via receptor mediated transport across M cells 
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[116] or by direct disruption of epithelial barrier integrity, opening tight junctions and 
increasing permeability to the virus [117]. 
Retroviral transmission has been shown to occur through the vaginal mucosa, as 
demonstrated by infections in a woman born without a uterus [118] and in 
macaques after surgical extirpation of the uterus [119]. Studies using macaque and 
human tissue also concluded that the less robust single layered columnar 
morphology of the type 1 mucosal surface and the differing epithelial cell types 
transitioning at the transformation zone are areas for primary portals for virus entry 
through the vaginal epithelium [109, 120]. More recently viral transmission sites 
have also been identified throughout the entire FGT in rhesus macaque models by 
using an SIV-based gene delivery vector modified into a dual reporter system 
containing the mCherry fluorescent protein and enhanced firefly luciferase. 
Monitoring of luciferase expression identified sites of infection within the intact FGT 
and fluorescent protein mCherry permitted the visualisation of single infected cells 
by spectral imaging and fluorescence microscopy. While high doses of this single 
round non-replicating SIV-based dual reporter system determined that the entire 
FGT including the vagina, ectocervix, endocervix, ovaries and draining lymph nodes 
contained infected cells 48hrs post inoculation, the primary site of infection was 
shown to occur at the squamous mucosal vaginal and ectocervical barriers of the 




Figure 2.12 Transmission of HIV virions through the vaginal epithelium. Located within 
the multi-layered squamous epithelium, dendritic processes from LCs extend towards the 
lumen. Cell free virions are able to bind to the LC via epithelial surface receptors CD4+ and 
CCR5+. Though tears in the vaginal mucosa promote viral access to the CD4+ T cells in the 
sub-epithelium, it is likely that virions crossing the mucous layer can directly reach these 
cells via the dendritic projections of LC.  
2.7 The vagina- a site for drug administration 
2.7.1 Vaginal drug permeability 
The vagina has been extensively used as a site for drug delivery with traditional 
delivery systems formulated as solutions, gels, suppositories, foams, tablets and 
vaginal rings. These vaginal products have been developed for various purposes 
including; contraception, anti-fungal, anti-bacterial, hormone therapy and induction 
of labour [122]. With the development of vaginal microbicides, the vaginal route of 
administration is a growing area of interest for these products. Drug absorption 
through the vaginal epithelium can provide greater bioavailability of localised drug 
when compared with the oral route as well as limiting systemic drug exposure. 
Increased bioavailability was observed with TFV gel when administered to healthy 
women, when compared to oral TFV (Truvada). Genital tissue concentrations of 
active drug were approximately 100 fold greater after local administration compared 
with those in genital tissue from women who had taken TVF (Truvada) orally. In 
contrast, serum concentrations of TFV were considerably lower following vaginal 
application when compared with oral dosing [123]. The transport of a drug molecule 
across the vaginal epithelial barrier may occur by several routes, as represented 




Figure 2.13 Drug transport routes across the vaginal epithelia. (A) Passive transcellular 
diffusion; (B) paracellular diffusion; (C) transporter-mediated absorption; (D) transporter-
mediated secretion; (E) transcytosis. 
2.7.1.1 Passive transcellular pathway 
The passive transcellular pathway requires permeation of solute through the apical 
and basolateral cell membranes. These membranes are composed of phospholipids 
assembled into bilayers that are packed with membrane proteins. This is the route 
for many lipophilic drugs that are in general well absorbed. This permeation does 
not require adenosine triphosphate (ATP) hydrolysis but involves partition of 
(uncharged) drug particles into the membrane by diffusion along a concentration 
gradient (Figure 2.13A). The drug diffuses to areas of low drug concentrations (e.g. 
from the vaginal lumen to the blood). However, in epithelial cells, drugs can become 
trapped in the apical membranes if they are too lipophilic as was observed in 
intestinal epithelial cell with the anti-HIV agent Cosalane resulting in poor 
bioavailability [124]. 
2.7.1.2 Paracellular pathway 
Paracellular permeation occurs through the gaps between adjacent epithelial cells 
and is restricted to polar drugs of low molecular weight which are generally poorly 
absorbed. The rate-limiting process in paracellular transport is diffusion through the 
barrier formed by tight junctions (Figure 2.13B) at the apical part of the intercellular 
space. Tight junctions show charge and size selectivity in their permeability, and ion 
transport across tight junctions is discriminative showing preference for anion 
selectivity as found in the rabbit colon and frog skin [125].  
2.7.1.3 Transporter-mediated absorption 
Solute transporter proteins are transmembrane proteins that act as gate keepers for 
cells and organelles. Their roles involve regulating the uptake and efflux of crucial 
endogenous substrates such as peptides, amino acids, sugars, nucleotides and 
inorganic ions. For uptake proteins acting in the absorptive direction, the apical cell 
membrane is able to actively shunt such nutrients across the phospholipid bilayer 
into the cell. Various substances display specific structural characteristics and are 
substrates for specific membrane bound transporters (Figure 2.13C). In order to use 
this pathway, a drug must represent some structural similarity with the normal 
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substrate. Most uptake transporters are classified as members of the solute carrier 
(SLC) transporter family, discussed further in section 2.7.3. 
2.7.1.4 Transporter-mediated secretion 
For transporter-mediated secretion, efflux proteins are able to secrete a variety of 
drugs. Efflux proteins actively remove toxic solutes that show substrate specificity 
(Figure 2.13D). The degree to which a drug accumulates within a tissue is often 
limited not so much by its ability to enter cells but by its tendency to leave. Such 
tendencies may arise from the activity of efﬂux proteins present in the cell 
membrane. These efﬂux mechanisms play a critical role in limiting the absorption 
and accumulation of potentially toxic substances [126]. Most efflux transporters are 
members of the ATP binding cassette (ABC) superfamily, discussed further in 
section 2.7.3. 
2.7.1.5 Transcytosis 
This mode of transport is a process by which a drug molecule gains entry into the 
cells without passing the phospholipid membrane bilayer but instead transport is 
within a membrane-bounded carrier formed by endocytosis (Figure 2.13E). 
Macromolecular solutes are transported from one side of a cell to the other. 
Strategies have been developed to take advantage of this mechanism for targeted 
drug delivery. Transport studies showed that permeability via the receptor-mediated 
transcytosis pathway increased the bi-directional bioavailability of insulin-Tf 
(conjugated with transferrin) by 5- to 15-fold, when compared to free insulin 
transport across Caco-2 cell monolayers [127].  
2.7.2 Other determinants of microbicide effectiveness 
Local drug delivery occurs in two main steps: drug dissolution in the vaginal fluid 
and a hydrodynamic layer on the walls of the vagina, followed by penetration into 
the epithelium based on a transport process with or without a concentration 
gradient. Drug stability and absorption are affected not only by the lipophilicity of the 
drug molecules but also by compatibility with properties of vaginal fluid, especially 
pH, enzymes, and microflora.  Variation in pH, following menses or coitus activity 
could influence the solubility, uptake, and release profile of pH sensitive substances 
within the FGT [128]. Increases in vaginal fluid volume due to estrogens and sexual 
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stimulants may improve the absorption of poorly soluble drugs; alternatively, a 
greater presence of mucus could slow down the interaction between drug and 
epithelium [129] .Additionally, vaginal fluids can remove and wash away 
formulations. Microbicide effectiveness may also be hindered by vaginal washing, in 
turn reintroducing the risk of HIV infection. The effects of microbicides on the 
vaginal microbiome has yet to be studied in detail, however modifications that lead 
to increased inflammation or activation of potential HIV host cells may enhance 
transmission [130].        
Topical vaginal application of ARV based microbicides delivers the active 
component to the site of transmission. However, the barrier formed by the mucus 
layer is often underestimated in drug delivery to the mucosa. This barrier relies on a 
thin sheet of mucus that lines the mucosal epithelial surface and is a hydrogel made 
up of mainly water that also contains mucin, glycoprotein, plasma proteins, 
enzymes, amino acids, cholesterol, lipids, and a range of inorganic ions. Mucins are 
high molecular weight glycoproteins with a mass range of 1-40 x 106 kDa and 
mucins can be classified into either secreted or cell bound forms [131]. The mucus 
barrier consequently forms a steric barrier due to its negative charge and 
hydrophobic domains [132]. However, the overall charge is hydrophilic and the 
mucus presents an interactive barrier that limits the free diffusion of drugs within 
and through the mucus [133]. The mucin protein backbone is rich in repeats of 
serine, threonine and proline and these domains are heavily glycosylated with 
fucose, galactose, sialic acids, N-acetylglucosamine and N-acetylgalactosamine. 
The glycosylated regions of mucins are hydrophilic whereas the non-glycosylated 
protein domains are hydrophobic. Such properties of the vaginal mucosa may 
present a barrier and impact drug delivery in the vagina. The presence of mucus 
can result in product dilution and can alter drug dissolution, affecting the efficacy of 
the drug by changing its concentration. Additionally, the hydrophilicity and viscosity 
of the mucus does not favour dissolution of hydrophobic drugs such as DPV and 
DRV, limiting drug diffusion across the epithelial barrier. Various ARV drugs behave 
differently in their ability to penetrate mucosal tissue, generally high protein-bound 
compounds do not gain access to the secondary layers because of their affinity for 
plasma proteins such as albumin and a1-acid glycoprotein [134]. PIs that have 
shown high binding affinities to plasma proteins (95-99%), achieve lower FGT 
concentrations when compared to NRTIs that present lower protein binding affinities 
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(<0.7-49%) but achieve higher drug concentrations in the mucosal tissue rather than 
in plasma [135]. 
To bypass the mucus barrier, permeability enhancement techniques are often 
implemented within drug formulations. This includes the general use of inactive 
excipients/surfactants that may be added externally to a drug formulation to 
enhance (due to their physiochemical properties) the permeation of the 
pharmacologically active pharmaceutical ingredient (API) to improve its 
bioavailability. Furthermore, hydrophobic microbicides such as DPV and DRV can 
be developed in aqueous based gels using such techniques. HEC gel formulations 
containing the solubilisation excipient cyclodextrin was shown to improve the 
permeability profile of DPV when tested in vitro. However, when using such 
excipients care should be taken to maintain equilibrium between solubility and 
permeability in order to obtain optimal flux [136].  
2.7.3 Drug transporters and expression in the FGT 
Drug transporters continuously protect the body from dietary and environmental 
toxins. However, the broad substrate specificity of these transporters do not restrict 
their activity to physiological substrates only, but are also capable of transporting 
drugs that resemble these physiological substrates [137]. Numerous ARV drugs 
have been identified as substrates for efflux and/or uptake transporters and may 
modulate transporter activity [138]. Tissue distribution of drugs may also be affected 
by activity of the cytochrome P450 (CYP) enzyme.  
Drug transporters are situated throughout the human body and patterns of 
expression vary in different tissues and cell types. Expression occurs highest mainly 
in tissues with barrier functions including the small intestine [139] which is involved 
in the absorption of dietary constituents into the bloodstream and the brain [140] 
which provides a protective function by modulating access of drugs and toxic 
substances into the central nervous system. Other tissues with barrier functions that 
express drug transporters include the kidney [141], liver [142] and placenta [143]. 
More recently expression has also been detected in the tissue of the FGT physical 
barrier [144-152]. The epithelial cells that border such barriers are polarised, as are 
the enterocytes of the intestine, proximal tubule cells of the kidney and the brain 
capillary endothelial cells of the blood-brain-barrier (BBB), forming apical and 
basolateral domains. Similarly, the epithelial cells that that form the FGT mucosal 
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surfaces are polarised with the apical domain facing the vaginal lumen and the 
basolateral domain facing the sub-epithelium (Figure 2.14B). This polarisation is 
reflected by the asymmetric distribution of drug transporters e.g. in epithelial cells of 
the small intestine the efflux and uptake transporters P-gp, BCRP, MRP2, MRP4, 
CNT1-3, OCT3, OATP1A2, OATP2B1 are expressed at the luminal surface while 
MRP1, MRP3, MRP5, OCT1, OAT2, ENT1-2 are expressed at the basolateral 
surface [138] (Figure 2.14A). While most drug transporters are polarised some are 
shown to be expressed on both the apical and basolateral surfaces [153], for 
example, ENT2 has been shown to be expressed on both surfaces of the choroid 
plexus [138]. 
 
Figure 2.14 Tissues with barrier functions and expression of drug transporters. (A) 
The intestinal barrier is split into an apical side (lumen) and the basolateral side 
(bloodstream). Epithelial cells located here are polarised and express a variety of efflux 
transporters. (B) The FGT can also be split into an apical side (vaginal lumen) and the 
basolateral side (sub-epithelium). More recently, only drug efflux transporter protein 
expression have been detected throughout the FGT, these include; P-gp, MRP2, MRP3, 
MRP4 and BCRP [146, 147, 149-151]. Orientation of the transporters indicated in the FGT is 
by analogy with those expressed in the intestine but has not been confirmed experimentally. 
Expression in the FGT may enhance or limit the absorption of drugs applied at the vaginal 
lumen, thus potentially playing a pivotal role in determining the bioavailability of topically 
applied drugs. Black arrows pointing inwards represent uptake transporters; arrows pointing 
outwards represent efflux transporters. 
To date more than 400 genes that encode transporter proteins have been identified 
in humans. There are two major superfamilies of transporters- the ABC efflux 
transporters and the SLC uptake transporter proteins [154]. While nomenclature of 
solute transporters has been standardised with different SLC families designated by 
numbers e.g. SLC1 and SLC2 etc and ABC transporter subfamilies designated by 
letters e.g. ABCA, ABCB etc, previous more descriptive names are often used as in 
the following section where both names are used. Additionally, the polarised 
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expression of drug transporters is important for mediating vectorial transport of 
drugs across epithelia. SLC and ABC transporter families show relatively broad and 
in some cases overlapping substrate specificities within their respective families as 
well as with different members from the two families. The latter has been 
demonstrated by the antiviral drug Adefovir, a substrate for SLC22A6 and ABCC4 
respectively [155, 156] suggesting that Adefovir may be taken into cells by 
SLC22A6 and then effluxed by ABCC4.   
2.7.3.1 Solute carrier transporters: structure and mechanisms of transport 
2.7.3.1.1 Introduction 
The SLC transporter family consists of 52 distinct subfamilies, including proton-
dependent oligopeptide transporters (POT, SLC15A), organic anion transporters 
(OAT, SLC21A), organic anion-transporting polypeptides (OATP, SLCO), organic 
cation transporters (OCT, SLC22A), concentrative nucleoside transporters (CNT, 
SLC28A), equilibrative nucleoside transporters (ENT, SLC29A), the 
monocarboxylate transporters (MCT, SLC16A) and peptide transporters (PEPT, 
SLC15). Those shown to be involved in the transport of antiretroviral drugs include 
the (OATP, subfamily SLCO), (OAT, SLC22), (OCT, SLC22), (CNT, SLC28), (ENT, 
SLC29) and (PEPT, SLC15) [138, 157]. The OATP subfamily are especially 
important in the uptake of ARV drugs in the intestine and the protease inhibitors 
DRV and SQV as well as the reverse transcriptase inhibitor TFV have been 
identified as substrates [158-160]. Additionally, the NRTIs lamivudine and 
zalcitabine are substrates for OCT1 and OCT2. Some SLCs mediate bi-directional 
transport e.g. the equilibrative transporter ENT1 is involved in the uptake and efflux 
of the anticancer drug cladribine [161, 162].  
2.7.3.1.2 Structure of SLC transporters 
Unlike the ABC transporters, the SLC’s display highly diverse structures that 
comprise a variety of folds which are unique to this superfamily. The two structural 
folds predicted to be the most common in the human SLCs are the structurally 
dissimilar major facilitator superfamily (MFS) and the Leucine transporter (LeuT)-like 
folds. The more common of the two structural folds is that of the MFS which is 
shared between numerous family members of human SLCs. The MFS fold contains 
12 transmembrane α-helices (TMH) [163] arranged in two inverted structural 
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pseudo-repeats of 6 TMHs [164] that are interconnected by multiple intracellular and 
extracellular short and long loops. The N and C-termini of the transporter are both 
intracellular. The N-terminal extracellular loop joining TMH 1 and TMH 2 contains 
sites for N-linked glycosylation while the extended intracellular loop joining TMH 6 
and TMH 7 possesses potential sites for protein kinase C-mediated phosphorylation 
[165]. Figure 2.15 is a representation of the secondary structure elements of MFS 
fold exemplified by the organic anion transporters (OATs, SLC 22 family). 
Mutagenesis studies indicate that residues in TMH 7 and TMH 8 that are highly 
conserved within SLC families are critical for substrate recognition and transport. 
More recently, these observations have been confirmed by determination of the 
crystal structure of the human glucose transporter GLUT1 (SLC2 family) at a 
resolution of 3.2 Å [166]. GLUT1 adopts the MFS fold in which TMH 1-6 form part of 
a pore structure that is completed by TMH 7-12 (Figure 2.16). Unlike the MFS fold 
the core of a LeuT-like fold possesses 10 TMHs, with two five TMHs inverted 
pseudo-repeats, where the first two TMHs in each of the two repeats are tilted 
relative to the three remaining TMHs of the repeat. This fold is adopted by multiple 
biomedically important families such as the SLC5 family of Na+/glucose transporters 
and the SLC6 family of Na+/Cl- dependent neurotransmitter transporters [164]. 
 
Figure 2.15 Transmembrane arrangement of SLC uptake proteins. SLCs comprise 12 
TMHs (numbered) linked by extracellular and intracellular loops with intracellular amino 
(NH2) and carboxy (COOH) termini. A large extracellular loop between TMDs 1 and 2 
includes sites for N-linked glycosylation (G) while the extended intracellular loop between 
TMDs 6 and 7 includes sites for phosphorylation (P) by protein kinase C. Basic and aromatic 
residues conserved in the OATs are shown in TMHs 7 and 8.  
The large extracellular loop linking TMH 1 and TMH 2 adopts an α-helical 
conformation. The long intra-cellular loop that connects TMH 1 and TMH 7 
comprised 4 short α-helices and may be unique to sugar transporters since it has 
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not been described in other MFS structures. Substrate binding involves H-bonding 
principally with residues in TMHs 7, 8 and 10. 
 
 
Figure 2.16 Crystal structure of the human GLUT1 glucose transporter. The 
arrangement of the 12 TMHs are shown in panel (A) with the approximate boundaries of the 
cell membrane indicated by dashed lines. TMHs 1-6 cluster to the right and 7-12 on the left. 
An extended intracellular domain comprising 4 short α-helices links TMHs 6 and 7 on the 
intracellular side of the membrane. Panel (B) shows the view looking down on the 
extracellular side where the pore structure is evident. The extracellular α-helix linking TMHs 
1 and 2 is arrowed at each end. Structures were drawn using Swiss PDB viewer with 
coordinates from the Protein Data Bank (PDB ID 4GCO). 
2.7.3.1.3 Mechanisms of SLC-mediated transport 
Two major types of alternating access mechanisms have been described for SLC 
transporters displaying the MFS and LeutT folds. The first includes the “rocker-
switch” mechanism; this involves the oscillating back and forth locomotion of the N- 
and C-terminal halves of the transporter to form alternately outward and an inward 
facing states along the symmetry axis perpendicular to the transmembrane. The 
characterisation of the “rocker-switch” mechanism was defined by analyses of the 
Escherichia coli Lactose Permease LacY an SLC37 homolog (Figure 2.17A and 
2.17B) [167]. The second is the “gated pore” mechanism; this involves the 
enclosure of the binding site by two gates. Binding of the substrate occurs when the 
outward-facing gate permits the binding of the substrate, leading to the opening of 
the second gate that is facing the cytosol which releases the substrate into the cell. 
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The “gated pore” mechanism was determined in Aquifex aeolicus LeuT, an SLC6 
homolog (Figure 2.17C and 2.17D) [168] .  
 
Figure 2.17 Models of the rocker switch and gated pore mechanisms. Rocker switch. 
(A) The outward-open bound structural conformation of the E. coli Lactose Permease LacY 
(PDB ID 40AA) with a cartoon depicting the N- and C-terminal halves in green and yellow, 
respectively, and the substrate in red. (B) Binding of substrate occurs within the V like 
conformation of the membrane that faces the extracellular membrane. The intermediate 
occluded state is triggered and the substrate is released from the inverted V-shape which 
orientates to an inward open conformation. Gated pore. (C) The outward-open bound 
structural conformation of LeuT (PDB ID 4FXZ) with a cartoon depicting the scaffold and 
bundle domains in grey and blue, with the substrate and ions in red and purple, respectively. 
(D) The scaffold maintains a static position, while the bundle domain undergoes 
conformational changes involved in binding and releasing of the substrate. The binding site 
is shielded by a thin gate on the extracellular side and a thicker gate on the intracellular side 
(ie. TMH1). Figure adapted from [164]. 
2.7.3.2 ATP-binding cassette (ABC) transporters: structure and       
mechanisms of transport 
2.7.3.2.1 Introduction 
The ABC drug transporters are primary active transporters that couple transport to 
ATP hydrolysis. The 49 ABC transporters identified in humans [169], are grouped 
into 5 families ABC A-G. ABC transporters are distributed in the small and large 
intestine, liver, kidney, brain, lymphatic system, placenta, and FGT [138, 170, 171].  
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The majority of ARV drugs are substrates, inhibitors and/or inducers of ABC 
transporters [172]. Intracellular concentrations of ARVs may therefore be profoundly 
affected potentially with adverse effects on antiviral activity. P-glycoprotein (P-gp, 
ABCB1) is a widely distributed drug transporter with high expression levels. All HIV 
PIs are high affinity substrates for P-gp (ABCB1) [138], MDR1a/b-knockout mice 
display enhanced brain accumulation of nelfinavir (40-fold), indinavir and saquinavir 
(8-10-fold), while systemic availability of these PIs is enhanced by 2.5-fold [173]. P-
gp also mediates the transport of NRTIs such as tenofovir disoproxil fumarate (TDF) 
[174, 175]. P-gp substrates are typically lipophilic and accumulate within the lipid 
bilayer. The MRPs mediate the efflux of many NRTIs in vitro as MRP4 (ABCC4) and 
MRP5 (ABCC5) are substrates for TFV [176, 177]. Furthermore, the NRTIs 
zidovudine, lamivudine, didanosine, and stavudine have shown to be substrates for 
breast cancer resistance protein (BCRP, ABCG2) expressed by human CD4+ T 
cells [178]. Similar to the SLCs, while most ABC drug transporters are polarised 
some have also shown to be expressed on both the apical and basolateral surfaces, 
for example, is has been reported that in mice the subcellular localisation of MRP4 
(ABCC4) within the BBB was basolateral and apical, respectively [179].  
2.7.3.2.2 Structure of ABC transporters 
ABC transporters contain a pair of conserved cytoplasmic domains termed 
nucleotide binding domains (NBDs). The roles of NBDs are to hydrolyse ATP and 
trigger conformational changes in the attached transmembrane domains (TMD1 and 
TMD2), thus permitting substrates to cross the membrane lipid bilayer to either be 
taken up (uptake) into or effluxed out of the cytoplasm. The core functional units 
shared by all ABC family members’ transporters comprise four functional domains: 
two TMDs typically made up of six TMHs each forming the substrate binding region 
and two cytosolic nucleotide binding domains (NBD1 and NBD2). These NBDs 
contain Walker A (G/AxxxxGKT/S, where x is any amino acid) and B (zzzzD or 
zzzzDE, where z is a hydrophobic amino acid) motifs as well as a C motif (LSGGQ) 
which are essential for ATP binding and hydrolysis [180, 181]. Most commonly a 
single polypeptide generally encodes all four of the functional units, including the 12 
TMHs regions and the ATPase motifs (Figure 2.18). However, there are a number 
of exceptions as MRP1 (ABCC1), MRP2 (ABCC2), MRP3 (ABCC3), MRP6 
(ABCC6) and MRP7(ABCC7) for example have an additional five TMHs whereas 
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BCRP has only 1 NBD with 6 TMHs (termed a “half transporter”) and forms 
homodimers [126, 182]. 
 
Figure 2.18 Transmembrane organisation of ABC transporter proteins. The domain 
arrangement of ABC transporters comprises NBD dimers, each with six TMHs and part of 
ATPase motifs (Walker A motif, Walker B motif and ‘C’ Motif) located on the cytosolic side. 
Modified from [183].  
The structure of murine P-gp (ABCB1, 87% amino acid sequence identity with 
Human P-gp) in the nucleotide-free and substrate-free form has been determined at 
3.8 Å [184] and subsequently refined [185] (Figure 2.19A). In this structure, the 
TMHs adopt an inward facing confirmation formed of two bundles of 6 TMHs that 
result in a large internal cavity opening to both the cytosol and the inner leaflet of 
the cell membrane with the NBDs separated by approximately 30 Å. In contrast to 
this inward facing conformation, crystal structure analyses of a prokaryotic ABC 
transporter (Sav 1866 from Staphylococcus aureus) in substrate-free and ADP-
bound form reveals an outward facing conformation [186] (2.19B). In this 
conformation, the large internal cavity is closed to the cytosol but accessible to the 
outer leaflet of the cell membrane and the extracellular space presumably allowing 
substrate release. Sav 1866 although a homodimeric “half transporter” shows 
significant amino acid sequence homology to murine and human P-gp and adopts a 
similar fold. 







               A                                                      B 
                       
Figure 2.19 Ribbon structures of murine and prokaryotic P-gp transporters. (A) Murine 
P-gp structural TMHs adopt an inward facing conformation with the internal cavity opening to 
both the cytosol and the inner leaflet of the cell membrane [185]. (B) In contrast, crystal 
structure analysis of prokaryotic ABC transporter (Sav 1866) in substrate-free and ADP-
bound form reveals an outward facing conformation. The large internal cavity is closed to the 
cytosol but accessible to the outer leaflet of the cell membrane and the extracellular space. 
Structural image adapted from [186]. 
2.7.3.2.3 Mechanisms of ABC transporter-mediated substrate efflux 
ABC transporter-mediated substrate efflux likely involves major conformational 
changes in the TMHs as described above. High resolution X-ray structures of the 
NBDs from prokaryotic ABC transporters indicate that in the ATP-bound 
conformation the NBDs associate as dimers in which 2 molecules of ATP are bound 
in equivalent sites at the dimer interface, termed a “sandwich dimer”. The ATP 
binding sites are formed by the phosphate binding loop (P loop) that includes the 
Walker A motif of one NBD and the C motif of the other [180, 181]. Dimerisation 
presumably induces further conformational changes in the TMHs to adopt the 
outward open (inward closed) structure. An important feature of these structural 
studies is that in both the outward and inward open structures, portals that allow 
substrate access from or to the inner leaflet and outer leaflet of the cell membrane 
respectively were identified. The major drug efflux transporters such as P-gp 
(ABCB1), BCRP (ABCG2) and MRP1 (ABCC1) mediate efflux of a large range of 
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hydrophobic substrates. A number of studies (as reviewed in [187]) indicate that 
such substrates may be taken up directly from the plasmamembrane and effluxed 
before accessing the intracellular compartment – termed the hydrophobic vacuum 
cleaner model as shown in Figure 2.20A [188]. A variety of ABC transporters have 
been shown to possess phospholipid translocase activity mediating movement of 
phospholipids from the inner to the outer leaflet of the cell membrane (termed 
“flippase” activity), reviewed in [189]. Such flippase activity may also be involved in 
efflux of hydrophobic drugs (Figure 2.20B). Although this has been proposed as a 
mechanism for efflux mediated by P-gp [190], the recent refined structure for murine 
P-gp [185] describes a pore structure for drug translocation that is lined by highly-
conserved (between mouse and human) hydrophobic residues including several 
with aromatic side chains. This is unlikely to be compatible with flippase activity but 
could provide an environment with strong affinity for hydrophobic substrates with 
lower constraints and therefore broader specificity than those required by 
electrostatic bonding. 
 
Figure 2.20 The hydrophobic vacuum cleaner model and drug flippase model of ABC 
transporters and the crystal structure of the drug vacuum cleaner model. (A) i. 
Vacuum cleaner model. Drugs partition into the lipid membrane and translocate to the inner 
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leaflet gaining access to the substrate-binding pocket located within the bilayer interior. 
Drugs are subsequently effluxed into the extracellular space before they are able to reach 
the inner cell membrane leaflet to enter the cell. ii. Flippase model. Drugs partition into the 
lipid membrane and translocate to the inner leaflet where they interact with the substrate 
binding pocket and are consequently flipped out to the outer membrane leaflet. Higher drug 
concentrations accumulate within the outer leaflet compared to the inner leaflet generating a 
concentration gradient, eventually drugs will rapidly partition from the two membrane leaflets 
into the extracellular aqueous phase (B) Structural view of the P-gp vacuum cleaner model i. 
External substrate (magenta) interacts with the substrate-binding pocket within the bilayer 
interior. ii. ATP (yellow) develops bonds with the NB domains forming a “sandwich dimer” 
which is the stimulus for initiating the power stroke necessary for the driving out of the 
substrate (magenta) in the form of the tweezer like conformation. Horizontal lines represent 
lipid bilayer and dashed horizontal lines separate the inner and outer bilayer leaflets. Figure 
adapted from [188] and [184], respectively. 
2.7.4 ABC and SLC transporter expression in the vaginal epithelium 
ABC drug transporter expression has been demonstrated throughout out the FGT 
[171]. Eight efflux transporters for ARVs (P-gp, BCRP and MRP1, MRP2, MRP4, 
MRP5 and MRP7) [138] were shown to be expressed in the uterus, ectocervix, 
endocervix and vagina [171]. In an oligonucleotide microarray study, 11 ABC 
transporters were shown to be moderately to highly  expressed among all genes 
expressed in the cervix and RNA analysis confirmed similar findings in the lower 
genital tract as well as expression in various vaginal epithelial cell lines [144, 148, 
191]. More recently expression of P-gp, BCRP and MRP4 has been analysed at the 
protein level by immunohistochemistry and Western blot [145, 146, 149]. Moderate 
to high expression of each transporter was demonstrated in ectocervix, endocervix 
and vaginal tissue of humans and macaques [145]. Additionally, 
immunohistochemistry confirmed expression of MRP2 and MRP3 [149, 150] and 
Western blotting confirmed expression of P-gp, BCRP, MRP2 and MRP4 in human 
cervicovaginal tissue [145-147, 149, 150, 192, 193]. The variation in expression of 
transporters along the FGT suggest that the pharmacokinetics of ARV drugs may 
vary at different areas of the FGT. Results from mRNA analyses and direct protein 
determination do not always correlate. MRP3 mRNA was not detected in vaginal 
tissue [144, 148] but expression was demonstrated by immunohistochemistry [149]. 
Expression of SLC drug transporters in the FGT has been reported primarily from 
analysis of mRNA by quantitative-PCR. Ten uptake transporters (SLC2A1, SLC6A9, 
SLC1683, SLC16A12, SLC22A18, SLC24A3, SLC35E1, SLC35E4, SLC38A10 and 
SLC44A1) for which ARVs are substrates were highly expressed in the human 
vaginal tract [149] and, in a microarray study mRNAs encoding 36 uptake 
transporters were expressed in the cervix [191]. Furthermore, RT-PCR analysis of 
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SLC transporters in human vaginal and ectoxervix tissue indicated that OAT2, 
OCT2, OCT3, ENT1, OATP-D, and OATP-E are the most highly expressed uptake 
transporters compared to their expression in liver [144]. Of the above transporters 
reported as expressed in the cervicovaginal epithelium, the SLC22 (OCT2 and 
OCT3), SLC28 (CNT) and SLC29 (ENT1) families have been associated with the 
transport of several nucleoside analogue ARV drugs [194]. Additionally, a study 
comparing 37 uptake transporter expression profiles between vaginal epithelial cells 
and tissue from various areas of the FGT further demonstrated expression of SLC 
transporters in vaginal tissue and epithelial cells at mRNA level [148]. SLC protein 
expression has yet to be detected by Western blot or immunohistochemistry in the 
FGT. 
2.8 Antiretroviral drugs that form the focus for this study 
2.8.1 Tenofovir  
2.8.1.1 Physiochemical properties 
TFV, (R)-9-(2-Phosphonomethoxypropyl)adenine, is an acyclic nucleotide analog of 
2’-deoxyadenosine monophosphate (dAMP) (Figure 2.21) and is a small anionic 
molecule with a molecular weight of 287 kDa. The active form of TFV is a deoxy 
ATP analogue that can be incorporated into the growing DNA strand synthesised by 
HIV reverse transcriptase but cannot form a phosphodiester bond with the next 
nucleotide resulting in the termination of the viral DNA chain. It comprises an 
aromatic fused pyrimidine-imidazole ring system, a phosphate group, and a methyl 
group. As TFV is a monophosphate, it undergoes intracellular diphosphorylation to 
form tenofovir diphosphate (TFV-DP), the active form, which has a long tissue half-
life of 164 hours [195, 196]. TFV is hydrophilic with aqueous solubility of 13.4 mg/ml 
in water and a Log P value of -1.6. TFV shows neutralising activity against HIV in 
both lymphocytes and macrophages [197], with in vitro IC50 (50% inhibitory 
concentration) and EC50 (concentration that gives 50% response) values in ranges 




Figure 2.21 Similarity in structures between the nucleotide dAMP and the NRTI TFV 
with physiochemical propertis. (A) dAMP contains a deoxyribose sugar group (B) TFV 
lacks a sugar group and is replaced by a methyl group, an important alteration required for 
its function in terminating the viral DNA chain. 
2.8.1.2 Pharmacology 
As described above TFV is phosphorylated intracellularly to its active metabolite 
TFV-DP which competitively inhibits the activity of HIV reverse transcriptase, 
preventing further HIV replication. An orally bioavailable form of TFV (TDF) is used 
as a treatment for HIV-1 due to TFV’s efficient intracellular activation, prolonged 
intracellular half-life and high barrier to resistance. Following a single dose of oral 
TDF 300 mg to HIV infected patients, maximum serum concentrations (Cmax) were 
achieved in 1.0 ± 0.4 hrs. Cmax and area under the curve (AUC) values were 0.30 ± 
0.09 μg/ml and 2.29 ± 0.69 μg·hr/μl, respectively [201]. At steady state, following 
intravenous administration at 1.0 mg/kg and 3.0 mg/kg, the volume of distribution is 
1.3 ± 0.6 l/kg and 1.2 ± 0.4 l/kg, with 7.2% of the drug binding to plasma protein. 
TFV is not a substrate for cytochrome P450 enzymes and 70-80% of intravenous 
TFV is recovered unchanged in the urine within 72 hours of dosing [201]. Following 
a single TDF oral dose of 300 mg, the elimination half-life of tenofovir is 
approximately 17 hours and intracellular half-life is >60 hours [202].  With multiple 
oral doses (under fed conditions), 32 ± 10% of the initial administered dose is 
recovered in the urine over a 24 hour period. TFV is eliminated by a combination of 
glomerular filtration and active tubular secretion [201].  
Phase 1 and PK studies have provided significant data regarding TFV 
concentrations in the genital tract and in rectal tissue.  Following oral TDF 
administration, TFV concentrations within the cervicovaginal fluid of the FGT relative 
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to blood plasma at first dose achieved a median of 135%, and 75% of that of blood 
plasma at steady state. Furthermore, TFV concentrations in genital secretions are 
2.5 times greater than in plasma [135]. At the end of 24 hour dosing the median 
cervicovaginal fluid concentrations of TFV at a steady state were 68ng/ml. Vaginal 
tissue concentrations of TFV at the end of a 24hr dosing interval were 6.8 ng/g and 
50 ng/g, respectively. TFV concentrations in rectal tissue following oral dosing with 
TVF-DP are 100 fold higher than that detected in vaginal and cervical tissue [203].  
Following the use of topically applied 1% TFV gel, TFV exposure was low in blood 
plasma after single-dose and multi-dose with median Cmax values of 4.0 and 3.4 
ng/ml, respectively. In cervicovaginal fluid the median Cmax was 1.9 x 10
6 ng/ml 
(range: 1.2 x 104 - 9.9 x 106 ng/ml) after single-dose and 1.4 x 106 ng/ml (range: 8.4 
x104 – 5.8 x 106 ng/ml) after multi-dose. From the same PK study, vaginal tissue 
TFV concentrations from biopsies (assessed by pooling of samples over a 24 hour 
period) demonstrated TFV concentrations ranging from 2.1 x 102 – 1.4 x 106 ng/ml 
with an average Cmax of 2.2 x 10
5 ng/ml. Vaginal tissue concentrations of the active 
metaboloite TDP were 100 fold higher following vaginal application compared with 
oral dosing [123].  
While orally administered TFV achieves effective blood plasma levels, this systemic 
exposure may lead to increased risk of adverse effects. Topically applied TFV not 
only provides effective levels directly to the site of infection, but also reduces the 
possibility of adverse effects as drug administered by this route leads to minimal 
blood plasma exposure. Additionally, data from the CAPRISA 004 study indicated 
that HIV incidence was considerably lower in women with TFV cervicovaginal 
concentrations of ≥1000 ng/ml when compared to placebo or drug concentrations 
≤1000ng/ml [204]. TFV gel demonstrates 1000-fold higher concentration in vaginal 
tissues compared to oral TDF, suggesting that repeated application may maintain 
effective levels of drug.  More recently TAF (tenofovir alafenamide) has been 
developed and has shown to be an effective prodrug of tenofovir diphosphate (TFV-
DP) [205]. TAF provides significantly higher intracellular tenofovir concentrations in 
blood cells and lower serum levels. However, unlike the prodrugs TDF and TAF, 
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Table 2.1 Drug transporters for which Tenofovir, Darunavir or Dapivirine are 
substrates, inhibitors or inducers [171, 201, 206].  
2.8.2 Dapivirine 
2.8.2.1 Physiochemical properties 
DPV, is the prototype of diarylpyrimidines (DAPY), formerly known as TMC120 or 
DAPY R147681 (IUPAC name: 4-[[4-(2,4,6- trimethylphenyl)amino]-2-
pyrimidinyl]amino]-benzonitrile) of molecular weight 329.4 kDa. DPV comprises a 
pyrimidine ring covalently bound by a benzene ring on one side and a benzonitrile 
ring on the other, forming a “horseshoe” structure (2.22). This drug binds with high 
affinity in the induced hydrophobic pocket of the p66 subunit of HIV RT. DPV is 
highly hydrophobic with Log P of 5.3. Permeation of DPV may be via the passive 
transcellular pathway in which DPV partitions into cell membranes. DPV has shown 
potent neutralising activity in cell based models and human explants with IC50 
values in the low (0.2-10) nM range [207, 208] and an EC50 of 1 nM in vitro [209]. 
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Figure 2.22 Horseshoe structure of DPV with its physiochemical properties. A central 
pyrimidine bound by benzene ring on one side (left) and benzonitrile ring on the other (right). 
This structural formation has been successful in binding to the hydrophobic pocket of the 
p66 subunit of HIV RT. 
2.8.2.2 Pharmacology 
Studies using rhesus macaques and rabbits [85] showed that intravaginal 
administration of [14C]DPV gel (0.1 mg/ml to rabbits and 1 ml/day to macaques) over 
a 7 day period resulted in high DPV levels associated with vaginal and cervical 
tissue samples 1 hour after the final dose. In rabbits, high levels of DPV (246-
16,241 dpm/ml corresponding to >3,000 ng/g) were measured in plasma and 
vaginal/cervical tissue samples, respectively. Furthermore, levels in tissue remained 
detectable (>2.5 ng/g) 24 hours after the final dose. In macaques, plasma 
radioactivity and DPV levels were lower (≤83 dpm/ml and ≤0.226 ng/ml, 
respectively). Due to the hydrophobic properties of DPV [210], it is plausible that the 
drug may partition into the cellular membrane with only a small amount of drug 
entering blood. 
In humans, the PK of DPV was assessed in a randomised, placebo-controlled 
phase 3 DPV ring trial [211]. Healthy, sexually active women, 18-40 years of age 
were administered a vaginal ring containing 25 mg of DPV or placebo (in a 3:1 ratio) 
over a 56-57 day period. Multiple rings were used within this timeframe, with a 3-day 
washout period between selected ring changes. DPV concentrations were 
quantified in plasma, vaginal fluid and cervical tissue. Quantifiable DPV plasma 
concentrations were detected at the earliest scheduled time point (after 4 hours 
from insertion of the first ring) for all participants indicating the rapid release of DPV 
from the ring. Generally, plasma concentrations of DPV were low with maximal 
individual concentrations no higher than 553 pg/ml. Mean DPV plasma 
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concentrations over the ring use period were generally similar, at approximately 
260-270 pg/ml. However, there was a 60% decrease in plasma concentration during 
a 3-day washout period between the first and second ring use periods. 1 month 
prior to removal of the final ring, DPV plasma concentrations were very low for the 
majority of participants at 3.38-8.89 pg/ml. DPV was detected in vaginal fluid 4 
hours after insertion of the first ring with values ranging between 4,222-8,133 ng/g 
which were at least 1200-fold above the DPV concentration required in vitro for 99% 
inhibition (IC99) of provirus integration into cervical tissue following challenges with 
HIV-1BAL [207]. Within 24 hours, maximal DPV concentrations were rapidly 
reached following ring insertion with highest concentrations near the ring.  In 7 
participants, menses appeared to result in temporarily lower vaginal fluid 
concentrations of DPV with or without the use of a tampon, nonetheless no 
difference was observed in DPV plasma concentrations [211]. Tampons may reduce 
drug levels in vaginal fluid due to either adsorption to the tampon or increased blood 
levels in the vagina, or both. During the menses cycle, the lowest vaginal fluid 
concentration of DPV was 490 ng/g, 100-fold higher than the in vitro IC99. In 
cervical tissue biopsies from all DPV users, the DPV concentrations ranged 
between 46-4770 ng/g, approximately 14 to 1000 times higher than IC99. This also 
reflected inter-participant variability of DPV concentrations within cervical tissue. 
2.8.3 Darunavir 
2.8.3.1 Physiochemical properties 
DRV, (3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxypropyl)-
carbamic acid hexahydrofuro-[2,3-b]furan-3-yl ester or TMC114 has a molecular 
weight of 548 kDa. This PI contains cyclic ether bonds with a central phenylalanine 
amino acid bound to a bis-Tetrahydrofuran (THF) ligand to one side and a p-
aminobenzenesulfonamide on the other; the drug is administered as its ethanoate 
salt (Figure 2.23). DRV binds with high affinity to the active site of the HIV-1 
protease [212] and selectively blocks the cleavage of the HIV Gag-Pol polyprotein to 
prevent maturation of viral particles into infectious virions. The IC50 and EC50 values 
of DRV both range from 1 to 8.5 nM [95]. DRV exhibits lipophilic properties with a 
predicted Log P of 1.89 and with aqueous solubility of 0.15 mg/ml. DRV is 
metabolised almost exclusively by the hepatic CYP3A4 enzyme. The absolute 
bioavailability of oral DRV is 37% but increases to 82% when co-administered with 
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ritonavir. Ritonavir is an inhibitor of the CYP3A4 enzyme as well as the efflux 
transporter P-gp [213] of which DRV is a substrate [214]. 
 
Figure 2.23 Structure of DRV with its physiochemical properties. DRV contains a 
central phenylalanine amino acid bound to a bis-Tetrahydrofuran (THF) ligand to one side 
(left) and a p-aminobenzenesulfonamide on the other (right). These features provide high-
affinity binding to the pocket of the HIV-1 protease. 
2.8.3.2 Pharmacology 
In Caco-2 monolayers DRV shows intermediate to high levels of absorption [213]. 
Saturation of the active transport process occurs with increased DRV concentration, 
this may occur by the saturation of the P-gp efflux pump indicating an interaction 
between DRV and P-gp (Table 2.1).  In vitro equilibrium dialyses of plasma samples 
demonstrate high (95%) binding of DRV to human plasma proteins [215]. DRV 
primarily undergoes oxidative metabolism [216] and is extensively metabolised by 
cytochrome P450 (CYP450) enzymes, largely by CYP3A [217]. DRV also inhibits 
CYP3A, however, it is not as potent as ritonavir (RTV) which increased DRV plasma 
concentrations. In a study of HIV-negative, healthy individuals, (100 mg) increased 
the absolute bioavailability of DRV (600 mg once daily) from 37% (DRV only) to 
82% (DRV+RTV) [218]. A pharmacokinetic enhancement, such as the activity of 
RTV, indicates that the first pass elimination of DRV can almost be completely 
inhibited.. With this elimination taken into account, there was a 14-fold overall 
increase in the AUC for DRV when taken with RTV 100 mg twice daily versus DRV 
when taken alone.  It has been shown however that increasing the dose of RTV to 
200 mg twice daily with DRV 600 mg does not result in any significant increase in 
DRV plasma concentration, indicating that the maximal pharmacokinetic inhibitory 
effect was achieved with the lower RTV dose [216, 219]. 
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In a DRV mass balance study where healthy volunteers were given a single dose of 
radiolabelled [14C]DRV (400 mg) + low dose RTV (100 mg), metabolism after 48 hrs 
was found to be extensive when DRV only was administered but was significantly 
reduced when DRV was co-administered with RTV. In the absence of RTV the 
proportion of uncharged drug eliminated was 8% (6.8% in the faeces and 1.2% in 
urine) compared to 49% (41.2% faeces and 7.7% in urine) the presence of RTV 
[216, 217]. After a period of 168 hrs post administration [14C]DRV or metabolites of 
[14C]DRV were excreted mainly in the faeces (80%) and to a lesser extent in the 
urine (14%) [217].    
A combination microbicide vaginal ring containing DRV (300 mg) and DPV (100 mg) 
was tested in macaques. Serum concentrations of both drugs were maintained 
between 10 - 100 pg/ml. Vaginal fluid levels ranged between 103 and 104 ng/ml and 
between 104 and 105 ng/g for DPV and DRV, respectively. In each tissue type, DPV 
and DRV showed very similar concentration levels: vagina (1.8x103 – 2.8x103 ng/g), 
cervix (9.4x101-3.9x102) ng/g, uterus (0-108 ng/g), rectum (0-40 ng/g). In this study, 
IC50 values obtained were <2 ng/ml for both drugs [220]. 
2.9 Conclusions 
This review has demonstrated that there is ample data concerning the mechanisms 
of HIV infection and a surge in recent research that addresses the methods for 
prevention of HIV. Such methods include advances in the development of vaginally 
and rectally applied ARV based microbicides. The permeability of the drugs that 
serve as the active agents of these products are yet to be extensively studied, 
especially with regards to interactions with membrane bound drug transporters. This 
provides scope for the further investigation into determining their precise transport 
kinetics. In addition, the relevance of these transporters, especially at the vaginal 
mucosal surface remains unknown.  
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Chapter 3 Materials and Methods 
3.1 Cell Culture Methods 
All cell culture methods were undertaken under a laminar flow hood along with the 
necessary aseptic conditions. All experiments involved the use of the vaginal 
epithelial cell line HEC-1A. This cell line was isolated in 1968 by H. Kuramoto and 
associates from a 71 year old woman with stage IA endometrial cancer [221]. The 
cell line was kindly provided by collaborators at Imperial College London and the 
University of Aberdeen. This is the only vaginal epithelial cell line that is reported to 
form tight junctions [222], a crucial characteristic for dual chamber- based drug 
transport kinetic studies. 
3.1.1 Cultivation of HEC-1A (human endometrial adenocarcinoma 1a) 
HEC-1A cells were maintained in McCoys 5A modified cell culture medium 
(Invitrogen, Paisley, UK) containing L-glutamine 0.21915g/L, glutathione 0.0005g/L, 
peptone 0.6g/L, phenol red 0.011g/L and D-Glucose 3g/L. A 500ml bottle of medium 
was supplemented with 10% (v/v) FBS (Fetal Bovine Serum, Invitrogen, Paisley, 
UK) and 2% of penicillin 5000 units.ml-1/streptomycin 5000μg.ml-1 solution (Sigma-
Aldrich, Cambridge, UK). Cells were cultured at 37°C with 5% CO2 in a humidified 
air incubator (Binder, New York, USA) and passaged every 2-4 days. Once 
confluent, cells were washed with 10 ml PBS (Phosphate Buffered Saline, PAA, 
Yeovil, UK) and incubated for 5-10 minutes with 5 ml 0.25% Trypsin-EDTA solution 
(PAA, Yeovil, UK) at 37°C with 5% CO2. Detached cells were re-suspended in 7-10 
ml of fresh cell culture medium and counted (see below). The desired number of 
cells was pipetted into a new flask. 
3.1.2 Cell Counting 
Trypsinised cells were re-suspended in 5-10 ml cell culture medium. Suspended 
cells (100 μl) were mixed with an equal volume of trypan blue (Sigma-Aldrich, 
Cambridge, UK) in a bijou (Greiner Bio-One, Stonehouse, UK). This cell suspension 
solution was then pipetted into a haemocytometer (Hawksley, Sussex, UK), enough 
to cover the counting grid in order to count viable cells. The 4 outer squares were 
counted and the following equation was used to calculate the cell number per ml of 
medium:  
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(counted cells ÷ 4) x 2 (dilution factor) x 104 = cells/ml in cell suspension 
3.1.3 Thawing of cryopreserved cells 
Prior to thawing, cryovials (Fisher Scientific, Loughborough, UK) containing HEC-1A 
cells were transferred from liquid nitrogen to a water bath (Grant Instruments, 
Cambridge, UK) at 37°C. Once thawed, cells were then transferred from the 
cryovials into 19 ml of pre-warmed (37°C) cell culture medium to allow dilution of the 
cryoprotector dimethyl sulfoxide (DMSO). The suspension was then centrifuged at 
177 x g (Sanyo Mistral MSE 3000, U.K) at 25°C for 5 minutes. The supernatant was 
removed and the cell pellet was re-suspended in fresh cell culture medium. Cells 
were then transferred to a 25 cm2 cell culture flask (Greiner Bio-One, Stonehouse, 
UK) and 7ml of medium was added. To increase cell density, confluent cells were 
then transferred to a larger 75 cm2 flask and 175 cm2 respectively. 
3.1.4 Freezing of HEC-1A cells 
Prior to storage in liquid nitrogen, the HEC-1A cells were split from a confluent cell 
layer grown in cell culture flask and detached from the flask using trypsinisation 
process as described and re-suspended in growth medium. Cells were counted as 
described and a cell suspension was produced with 1x106 cells in 500 μl of cell 
culture medium and prepared in a 5ml bijou. An equal volume of 10% (v/v) DMSO 
(Dimethyl Sulfoxide, Sigma-Aldrich, Cambridge, U.K) in cell culture medium was 
then carefully droplet pipetted to mix with the 500 μl of HEC-1A cell suspension to 
make a final suspension solution of 1x106 cells/ml of culture medium containing 5% 
DMSO. DMSO was used as a cryoprotective protective agent as gradual freezing 
leads to optimal viability of cryopreserved cells by minimising the formation of ice 
crystals both within and outside the cells undergoing cryopreservation. The 
suspensions were kept in cryovials marked for date and passage number and 
stored overnight at - 80°C freezer for slow cooling. On the following day, the 




3.2.1 Culturing Epithelial Cells on Transwells® 
The apical chambers of 12-well polycarbonate (PC) and polyester (PE) systems 
(Corning Costar Corp, Cambridge, UK) seeded with different densities of HEC-1A 
cells in 500 μl of medium. Following addition of 1500 μl culture medium to the 
basolateral chamber, cells were cultured for the desired number of days. The 
medium in the apical and basolateral chambers was changed every 48-72 hours. 














PC 0.4 1x108 1.12 Translucent 
PC 3.0 2x106 1.12 Translucent 
PE 0.4 4x106 1.12 Clear 
Table 3.1 Properties of the Transwells
®
 used in this study. 
3.2.2 Coating of semi-pearmeable Supports  
12-well Transwells® were coated with the major extracellular matrix membrane 
protein Laminin (Sigma-Aldrich, Cambridge, UK) or reconstituted basement 
membrane preparation Matrigel® (Corning Costar Corp, Cambridge, UK). Matrigel® 
is extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich 
in extracellular matrix proteins. This material, once isolated, is approximately 60% 
laminin, 30% collagen IV, and 8% entactin. Human Laminin, Mouse Laminin and 
Matrigel® were compared to investigate any effects on cell attachment and TEER. 
Various concentrations were prepared as recommended by the manufacturer’s 
instructions. All laminin and Matrigel® solutions were diluted in PBS or ice cold 
serum free cell culture media, respectively. Once coated, Transwell® permeable 
supports were left to air dry (lid off) for 16-24 hours in a laminar flow hood. Any 
remaining solution was aspirated from the inserts which were then washed once 
with either PBS or cell culture medium. 
3.3 Measurement of Transepithelial Electrical Resistance (TEER) 
The TEER of HEC-1A cell monolayers grown on permeable supports was measured 
with an Epithelial Voltohmmeter (EVOM2), (World Precicion Instruments, Sarasota, 
FL) which measured cell resistance. TEER reflects the ionic conductance of the 
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paracellular pathway in the epithelial monolayer. The STX2/”chopstick” electrode 
(WPI, Sarasota, FL) pair that are connected to the EVOM2 voltohmmeter were 
rinsed in 70% ethanol for sterilisation prior to taking measurements. Each stick of 
the electrode pair (4 mm wide and 1 mm thick) contains a silver/silver chloride pellet 
for measuring voltage and a silver electrode for passing current. All TEER 
measurements were made in a laminar flow hood and were made within 
approximately 3 minutes of removal of Transwells® from the incubator as TEER can 
fluctuate with temperature. For electrical measurements, two electrodes are used, 
with the shorter electrode immersed in the apical (upper) compartment and the 
longer electrode in the basolateral (lower) compartment and the electrodes are 
separated by the cellular layer. It was important to make sure the shorter tip did not 
contact cells growing on the membrane, with the longer tip gently touching the 
bottom of the basolateral chamber (Fig. 9).   
 
Figure 3.1 Measurement of TEER of HEC-1A cells using the EVOM
2
 voltohmmeter and 
STX2 electrodes. Electrodes are immersed into the medium of apical and basolateral 
compartments. The ionic conductance of the paracellular pathway in the epithelial 
monolayer is measured. Total electrical resistance includes; resistance of the cell layer 
(RTEER), resistance of the cell culture medium (RM), resistance of the semipermeable 
membrane insert (RI) and the resistance pf the electrode medium interface (REMI). 
Application of AC with a square waveform. 
The ohmic resistance is calculated based on Ohm's law as the ratio of the voltage 
and current. However, as direct current (DC) can damage both cells and the 
electrode tips, an alternating current (AC) with a square waveform is therefore 
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applied. An AC square wave at a frequency of 12.5 Hz is used to avoid any 
detrimental effects on the electrodes and the cell layer. The EVOM system has a 
measurement range of 1-9,999 Ω with a 1 Ω resolution [223]. 
The measurement procedure includes measuring the blank resistance (Rblank) of the 
semipermeable membrane only (without cells) and measuring the resistance across 
the cell layer on the semipermeable membrane (Rsample). The cell specific resistance 
(Rnet) is the corrected TEER value of the cell monolayer multiplied by the surface 
area of the permeable support to give a value in ohms(Ω) x cm2, can be calculated 
using the following equation:  
(Rsample(Ω) – RblankA = Rnet  
TEER was also used as method to determine cell viability in all assays. Toxicity 
would be indicated by a rapid and significant decrease in TEER reading. 
3.4 Disrupting tight junctions using the calcium chelator EDTA 
HEC-1A cells were cultured on transwells as described as described above. The 
Ca2+ chelator EDTA (Sigma-Aldrich, Cambridge, UK) was diluted in cell culture 
medium. After removal of medium, 500 μl of medium containing 2.5 mM EDTA was 
added to the apical chamber and 1500 μl of EDTA-free cell culture medium was 
added to the basolateral chamber. Cells were incubated at 37°C. TEER was 
monitored at various time points over a 90 minute period. At T=90, HEC-1A cell 
layers were then washed twice with HBSS and the medium in both chambers was 
replaced with fresh EDTA-free cell culture medium. HEC-1A cell layer recovery was 
allowed to proceed and TEER was measured at 150 minutes and 1440 minutes. 
3.5 Immunofluorescence  
3.5.1 Glass slides 
HEC-1A cells were seeded on 0.69 cm2 glass slides (BD Biosciences, Oxford, 
England) with a removable plastic chamber separator (8 chambers) and cultured in 
500μl of culture medium which was replaced every 2-3 days. Slides were washed 
with 2X with 100μl HBSS and cells were fixed with 100 μl of fixing agent 4% 
paraformaldehyde (Sigma-Aldrich, Cambridge, UK), (PFA- 4% v/v in 10X PBS) for 
15 minutes at 37 °C in 5% CO2. Fixed cells were washed 3X with 100 μl HBSS then 
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permeabilised by adding 100 μl Triton X-100 (Sigma-Aldrich, Cambridge, U.K), 
(0.2%, v/v for 15 minutes at 37 °C in 5% CO2). Triton X-100 was removed by 
washing 2X with HBSS, and any non-specific binding sites were blocked by adding 
100 μl of blocking agent (1X TBS Tris Buffered Saline, Severn Biotech, 
Kidderminster, UK) and Tween 20 (Sigma-Aldrich, Cambridge, UK)) supplemented 
with 3% BSA (Bovine Serum Albumin, Sigma-Aldrich, Cambridge, UK) for 30 
minutes at 37 °C in 5% CO2. Blocking solution was removed and cells were then 
incubated for 90 minutes with 100 μl of 2.5 μg/ml anti-ZO-1 monoclonal primary 
antibody (clone 1, BD Bioscience, Oxford, England) diluted in TBS-T/BSA. Omission 
of the primary antibody served as negative control as did an isotype-matched 
control anti-gp41 secondary antibody diluted 1:500. Cells were washed 3X with 100 
μl HBSS and incubated with FITC goat anti-mouse IgG conjugated secondary 
(Sigma-Aldrich, Cambridge, UK) 100 μl diluted 1:100 in TBS-T/BSA for 2 hours at 
room temperature in the dark. Slides were washed 3X with HBSS and the plastic 
separating chamber was removed. To each well 8 μl of Vectashield mounting 
medium (Vector Laboratories, Burlingame, USA) containing Dapi was then added 
and a microscope cover slip (Fisher Scientific, Loughborough, UK) was gently 
applied. Slides were analysed using an Olympus BX61 microscope that was 
equipped with an Olympus XM10 digital monochrome camera and images were 
observed by the Olympus Cell F imaging software. 
3.5.2 Transwell® membrane 
HEC-1A cells were seeded on insert membranes of clear PE Transwells® and 
cultured as described in above. After 7 days in culture HEC-1A cell layers were 
washed 2X with HBSS and cells were fixed with 150 μl of fixing agent 4% 
paraformaldehyde (Sigma-Aldrich, Cambridge, UK), (PFA- 4% v/v in 10X PBS) for 
15 minutes at 37 °C in 5% CO2. Fixed cells were washed 3X with 150μl HBSS then 
permeabilised by adding 150 μl Triton X-100 (Sigma-Aldrich, Cambridge, U.K), 
(0.2%, v/v for 15 minutes at 37 °C in 5% CO2). Triton X-100 was removed by 
washing 2X with HBSS, any non-specific binding sites were blocked by adding 150 
μl of blocking agent (1X TBS Tris Buffered Saline, Severn Biotech, Kidderminster, 
UK) and Tween 20 (Sigma-Aldrich, Cambridge, UK) supplemented with 3% Bovine 
Serum Albumin  (BSA) (Sigma-Aldrich, Cambridge, UK) for 30 minutes at 37 °C in 
5% CO2. Blocking solution was removed and cells were washed 3X with 100μl PBS. 
Cells were then incubated for 90 minutes with 150 μl of 2.5 μg/ml anti-ZO-1 
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monoclonal primary antibody (clone 1, BD Bioscience, Oxford, England) diluted in 
TBS-T/BSA. Omission of the second antibody served as negative control. Cells 
were washed with 3X 150 μl HBSS and incubated with FITC goat anti-mouse IgG 
conjugated secondary (Sigma-Aldrich, Cambridge, UK) 150 μl diluted 1:100 in TBS-
T/BSA for 2 hours at room temperature in the dark. Slides were washed 3X with 
HBSS and the plastic separating chamber was removed. The membranes of the 
Transwell inserts were cut out with a scalpel (Sigma-Aldrich, Cambridge, UK) and 
placed on a glass microscope slide (Sigma-Aldrich, Cambridge, UK). To each 
membrane 10 μl of Vectashield mounting medium (Vector Laboratories, Burlingame, 
USA) containing Dapi was then added and a microscope cover slip (Fisher 
Scientific, Loughborough, UK) was gently applied. A round cover glass was gently 
placed on top of the membrane and the edges were sealed with nail varnish. Slides 
were analysed using an Olympus BX61 microscope that was equipped with an 
Olympus XM10 digital monochrome camera and images were observed by the 
Olympus Cell F imaging software. 
3.6 Protein assays  
3.6.1 Protein extraction from cells 
1x106 HEC-1A cells were seeded in 6-well plates to obtain overnight confluency of 
70-80%, at 37 °C in 5% CO2. All sample lysis steps were carried out outside of the 
laminar hood and on ice unless otherwise stated. Following overnight incubation, 
the 6-well plate was placed on ice and the media was aspirated. Plate was washed 
2X with 500 μl ice-cold PBS and removed by aspiration. 250 μl ice-cold 0.5% NP40 
lysis buffer (Tris 2M, NP40, dH2O, NaCl), (Sigma-Aldrich, Cambridge, UK) with the 
addition of 1:100 protease inhibitor was added to each well. The wells were scraped 
with a cell scraper (Fisher Scientific, Loughborough, UK) and the lysate was 
transferred to a pre-chilled 1.5 ml Eppendorf tube. Lysates were incubated on ice for 
30 minutes then spun at full speed (~14,000 × g) in a microcentrifuge for 10 minutes 
at 4°C. Supernatant was transferred to a new tube and the pellet was discarded. 
The supernatant was aliquoted and stored at −80°C for long term storage and -20°C 




3.6.2 Protein extraction from tissue 
Human (provided by Imperial College London whom ethically obtained from the NIH 
repository [224]) and rat tissues (already sacrificed rats by qualified staff) were 
obtained. Tissue was washed with ice cold PBS to remove any blood and then cut 
and weighed. Tissue was placed into an Eppendorf tube containing 1.4mm lysing 
matrix beads (MP Biomedical, UK). 1% NP40 lysis buffer (500ul/10mg tissue) 
containing 1:100 protease inhibitor was added to each tube. Tissue was 
homogenised by Fastprep-24 (MP Biomedical, UK) with functions set to 4 m/s and 
ran for 40 seconds, this was repeated 3-4X. Lysate was transferred to an Eppendorf 
tube which was then spun down (~14,000 × g) in a microcentrifuge for 10 minutes at 
4°C. Supernatant was transferred to a new Eppendorf tube. 
3.6.3 Bicinchoninic (BCA) assay 
Total protein concentrations were determined using a BCA kit (Thermo Scientific). 
This biochemical assay is based on a reduction of Cu2+ ions from the copper 
sulphate to Cu+ in the BCA reagent. The amount of Cu2+ reduced is proportional to 
the amount of protein present. Two molecules of the bicinchoninic acid chelate with 
each Cu+ ion and is depicted by a colour change of the sample solution from green 
to purple, measurable at a wavelength of 562 nm. The amount of protein present is 
quantified by comparing the absorption with a protein solution of known 
concentration, which serves as the standard. 
For this assay, samples were diluted 1:12 in PBS and Bovine Serum Albumin (BSA) 
was used as the standard, with concentrations ranging between 31.25 and 2000 
μg/ml prepared. 25 μl of each standard and sample were mixed with 200 μl of BCA 
reagent. The absorbance of the plate was measured at 562 nm and the protein 
concentration in individual samples calculating using a standard curve. From this, 
proteins could be prepared to the appropriate amount for further studies.3.6.4  SDS-
PAGE (sodium dodecylsulphate polyacrylamide gel electrophoresis) 
This type of gel electrophoresis is used to analyse proteins. Proteins are denatured 
by an anionic detergent SDS and separated by size on a polyacrylamide gel. An 
electric current is applied; smaller proteins migrate faster through the gel matrix than 
larger proteins.  
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For Western blots described in this thesis, the NuPAGE® Novex Bis-Tris 
electrophoresis system (Invitrogen, Paisley, UK) was used. This is a neutral pH, 
discontinuous SDS-PAGE, pre-casted polyacrylamide [Bis-(2-hydroxethyl) imino-tris 
(hydroxymethyl) methane-HCL) mini-gel system made with a separating gel 
acrylamide concentration of 4-12% and a stacking gel acrylamide concentration of 
4% at a thickness of 1.0mm. Prior to running of the gel, denatured protein 
concentrations were prepared and 40 μg/ml of protein was prepared for each 
sample. Each sample contained NuPAGE® LDS sample buffer (lithium dodecyl 
sulfate pH 8.4, coomasie G250 and phenol red), NuPAGE® reducing agent (500mM 
dithiotreitol (DTT)) and added at volumes according to the manufacturer’s 
instructions. Once samples were prepared and added to Eppendorf tubes, tubes 
were spun and mixed by turning upside down. Samples were then boiled in a pre-
heated waterbath (Grant Instruments, Cambridge, UK) for 10 minutes at 70°C. 
Samples were then spun again for 2 minutes and placed on ice. The pre-casted gel 
was placed into a gel electrophoresis tank (BioRad, CA, USA) in the correct 
orientation and filled with 1X running buffer (NuPAGE MOPS, SDS Running Buffer, 
ddH20). 10-25μl of protein sample was then loaded into the wells of the pre casted 
gel in addition with 5μl of the ColorBurst™ (myosin-violet, BSA-red, GDH-blue, 
ADH-red, Carbonic Anhydrase-orange, Trypsin Inhibitor-blue, Lysozyme-red, 
Aprotinin-blue, 200 mM Tris, SDS and, formamide) electrophoresis marker. Gel was 
set to run for 2 hours at 100V.  
3.6.5 Western blot analysis 
Proteins that are separated on SDS can be transferred onto nitrocellulose 
membrane where they are detected by specific antibodies. The primary antibody 
directly binds to the protein of interest on the membrane and the secondary 
antibody is species-specific (e.g. mouse or rabbit) and detects the bound primary 
antibody. The secondary antibody is linked to a reporter enzyme, which catalyses 
the conversation of a peroxidase substrate contained in the enhanced 
chemiluminescence (ECL) solution. X-ray films are used to capture the light emitted 
during this reaction, creating an image on the film of the bound antibodies.  
Upon completion of gel electrophoresis, the gel was gently removed from the tank 
and placed on top of the nitrocellulose membrane (GE Healthcare Life Sciences, 
Bucks, UK) within a “sandwich” cassette (sponge>3x filter paper>gel>membrane>3x 
filter paper>sponge). The cassette was closed and placed into a transfer tank 
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(BioRad, CA, USA) which was filled with transfer buffer (running buffer, ddH20, 
methanol). A magnetic stirrer (Velp Scientifica, IT) and an ice pack were also added 
into the tank which was connected to a basic power supply (BioRad PowerPac). A 
constant of 400 mAmp and a voltage of 90V was set for 90 minutes.  
Once transfer was completed, the membrane was gently removed from the cassette 
and washed by incubating with washing solution (5% milk PBS/Tween20) for 30 
minutes on an orbital shaker at 60 revolutions per minute (RPM), (Astra Zeneca, 
DE, USA). Washing buffer was then removed and primary antibody was added at 
the required concentration (diluted in 3% milk PBS/Tween20) and incubated 
overnight at 4°C at 60 RPM. The membrane was then washed 3x with washing 
solution, 10 minutes each, at 60 RPM at room temperature. Secondary antibody 
conjugated to HRP (horseradish peroxidase) was diluted in 3% milk PBS/Tween20 
was added and left to incubate for 1 hour at room temperature. 3X washes were 
repeated and the membrane was placed inside a film developing cassette 
containing a clear plastic A4 cover sheet. 5 ml of Luminata Crescendo Substrate 
(Millipore, MA, USA) was added to the membrane a left to incubate for 2 minutes at 
room temperature. Excess substrate was removed, the cover sheet was applied 
over the membrane and the cassette was closed. In a dark room, X-ray film (SLS, 
Yorkshire, UK) was then exposed to the membrane for various time points to detect 
a chemiluminescent signal.                                                                                                                    
3.6.5.1 Antibody concentrations for Western blot analysis 
All primary and secondary antibodies were used at the following concentrations: 




Anti-MRP1 (ABCC1) ab24102 Mouse monoclonal IgG2a Isotype 1:1000 
Anti-MRP2 (ABCC2) ab3376 Mouse monoclonal IgG2a Isotype 1:500 
Anti-MRP3 (ABCC3) ab3376 Mouse monoclonal IgG2b Isotype 1:500 
Anti-MRP4 (ABCC4) ab15602 Rat monoclonal IgG2a Isotype 1:1000 
Anti-MRP5 (ABCC5) ab180724 Rat monoclonal IgG2a Isotype 1:1000 
Anti-ENT1 (SLC29A4) ab135756 Rabbit Polyclonal IgG 1:1000 
Anti-P-gp (ABCB1) ab168337 Rabbit monoclonal IgG 1:100 
OATP1B3 (SLCO1B3) ab122123 Rabbit polyclonal IgG 1:1000 
OATP4A1 (SLCO4A1) ab122123 Rabbit polyclonal IgG 1:100 




Table 3.2 Primary antibody information and their working concentrations. All primary 







Anti-Rat 31470 Goat anti-Rat IgG2a polyclonal- HRP 
conjugated 
1:20000 
Anti-Rabbit 65-6120 Goat anti-Rabbit IgG polyclonal- HRP 
conjugated 
1:20000 
Anti-Mouse 31450 Rabbit anti-mouse IgG polyclonal- 
HRP conjugated 
1:2500 
Table 3.3 Secondary antibody information and their working concentrations. Anti-Rat 
secondary was purchased from (Thermo Fisher Scientific, PA, USA), Anti-Rabbit and Anti-
Mouse secondary antibodies were purchased from Sigma-Aldrich, Cambridge, UK. 
3.7 mRNA analysis 
3.7.1 SYBRgreen® drug transporter primers 
Using the expression profiles of the cell lines, obtained using the TaqMan® 96-well 
Drug Transporter Array plates, and cervicovaginal tissue data, a panel of 2 
endogenous controls, 9 ABC efflux transporters and 11 SLC uptake transporters 
were selected as a focus for validation of expression and for stimulation 
experiments. 
3.7.1.1 Design and reconstitution of primers 
The first goal to generating this new condensed panel of primers for targeting the 
two endogenous controls and 20 drug transporters was to ensure proper design that 
were specific to the target of interest. All primer sets were designed in that at least 
one of each pair of primers would span an exon-exon boundary to prevent the 
amplification of genomic DNA. The Roche universal probe library assay design 
centre software was used to design all primer pairs (https://lifescience.roche.com/). 
The software generated a list of potential primer sets for each target that were all 
designed to generate primers with optimal annealing temperatures ≈ 60˚C. All 
primer sets were then checked for specificity to their target gene, including all 
transcript variants, using the NCBI nucleotide BLAST software 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). All primer sets had to pass these three main 
criteria (exon-exon spanning, annealing temperature ≈ 60˚C, specific to target gene 




Drug Transporter Forward Sequence 5’>3’ Reverse Sequence 5’>3’ 
HPRT1 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 
RPLP0 TCCAGGCTTTAGGTATCACCAC TTGATCAGCTGCACATCACTC 
P-gp CTTCATCGAGTCACTGCCTAATAA GCTATGGCAATGCGTTGTT 
BCRP TGGCTTAGACTCAAGCACAGC TCGTCCCTGCTTAGACATCC 
MRP1 CCTGTTCAACGTCATTGGTG AGGAAGCCACGTAGAACCTCT 
MRP2 CTGGATCACCTCCAACAGGT AGAAGACAGTCAGGTTCCCAAC 
MRP3 AATGTCGACCCTAACCCCTAC GGGTCAGGGTTTAGCAGCTT 
MRP4 GCGCCTGGAATCTACAACTC CTTTGTATGCCCGGATGGT 
MRP5 CAGCGACCTGACGGAGAT GGGCAAGGCTGATCCTCT 
MRP6 CGGGAAGGATTGCATCAC GGCACCGTGAGGTTTATTCT 
MRP7 GCCCTCAATGATGACCTCAG CCTCCGCTAAGGGTGACA 
ENT1 TCACCAGCCTCAGGACAGAT GAGTGGCCGTCATGAAAAA 
ENT2 GCTGAGCTCCTCCAGTCTGA GGCTCATCTGGCTCTGATTC 
CNT3 CTGAACTCCACGCCATCA CAAGTGGGAGGATGGAACC 
OCT1 CTCGCCCAACTACATGTCC CGAGCCAACAAATTCTGTGAT 
OCT3 CACCATCGTCAGCGAGTTT CAGGATGGCTTGGGTGAG 
OATPD TGTTCCCTATGGAAACAGCA CAGGTAGGTGATGCCATCTG 
OATPE AGCTGCCACCTTGTTTGG GCCTGAGCTTGTTCACAAAGA 
OATP8 TCAAGTGGTATTAAAAAGCATACAGTG TTCACCCAAGTGTGCTGAGT 
Table 3.4 Primer sequences for use with SYBRgreen® RT-qPCR experiments. Primer sets were optimised to find the ideal dilutions using the 




3.7.1.2 Optimisation of primers 
The optimal primer concentration for each target was investigated until acceptable 
assay efficiencies of 90-110% were obtained. To determine primer efficiencies 
standard curves were generated for each primer set by performing a series of 1/10 
dilutions of cervicovaginal cell line cDNA template from 50 ng down to 5 pg. Due to 
the lack of P-gp expression within the four cervicovaginal cell lines, cDNA obtained 
from Caco-2 cells, which express P-gp, was used to optimise this primer set. A 
value of -3.32 generated from the slope of the standard curve signifies 100% 
efficiency from the primer set, with slopes between -3.1 and -3.6 signifying 
acceptable primer efficiencies of 90-110%. All primers sets were originally tested at 
a concentration of 10 pmol/µl, however many of the primer sets did not generate 
acceptable efficiencies (90-110%) with this concentration, mainly due to primer-
dimer formation, confirmed by the generation of a second peak detected at a lower 
temperature than the melting temperature (Tm) of the amplified product. A major 
cause of primer dimer formation is excessive primer concentration which leads to 
hybridisation of the primer pairs and unwanted amplification. Therefore a range of 
reduced primer pair concentrations were investigated down to 4 pmol/μl until 
acceptable efficiencies were obtained for each primer pair. These ranged between 
4-10 pmol/µl with efficiencies between 94.54-107.57% obtained. Dissociation curves 
were also performed to ensure no, or minimal, primer-dimer and non-specific 
amplification was generated from the primer pairs at their optimised concentrations. 
Primer sets were validated by comparing the expression levels with those generated 











Table 3.5 The optimised primer concentrations for all individual assays designed for 
use with SYBRgreen
®
. Slope values are given, obtained from standard curve plots, in 
addition to the calculated efficiencies for all primer sets.  
3.7.1.3 SYBRgreen® RT-qPCR 
SYBRgreen® PrecisionTM 2X qPCR Mastermix with ROX quencher (Primer 
Design, Southampton, UK) was used for all individual assay RT-qPCR experiments. 
Standard curves were generated to determine primers set efficiency using cDNA 






Slope Efficiency (%) 
HPRT1 6 -3.24 103.63 
RPLP0 6 -3.33 99.79 
P-gp 10 -3.30 100.75 
BCRP 6 -3.20 105.49 
MRP1 10 -3.36 98.48 
MRP2 10 -3.23 103.98 
MRP3 4 -3.15 107.57 
MRP4 10 -3.31 100.50 
MRP5 6 -3.18 106.10 
MRP6 4 -3.26 102.83 
MRP7 4 -3.19 105.77 
ENT1 10 -3.38 97.63 
ENT2 10 -3.28 101.78 
CNT3 4 -3.27 102.21 
OCT1 4 -3.17 106.57 
OCT3 4 -3.27 102.21 
OATPD 4 -3.43 95.68 
OATPE 10 -3.46 94.54 
OATP8 6 -3.36 98.44 
PEPT1 10 -3.25 99.01 
PEPT2 6 -3.18 104.03 




diluted to 10 ng/μl and then serially (1/10) using nuclease free water to give final 
cDNA template concentrations of 1x10-2-1x10-6 µg/µl. To duplicate wells of 96-well 
MicroAmp® Fast Optical 96-Well Reaction Plates (Life Technologies, Paisley, UK) 
5µl of diluted cDNA was plated to give final concentrations of 5x10-2-5x10-6 µg. To 
these wells 15 μl of Master Mix consisting of SYBGgreen® and primers was added 
to give a final volume of 20µl per well. Primers were diluted to workable 
concentrations (10 pmol/µl) from stock concentrations using nuclease-free water. 
Material Volume (μl) 
SYBRgreen® PrecisionTM Mastermix 10 
Forward Primer (10pmol/µl) 1 
Reverse Primer (10pmol/µl) 1 
Nuclease-free Water 3 
Total Volume 15 
Table 3.6 Mastermix for SYBGgreen® RT-qPCR 
The plate was then covered using MicroAmp® Optical Adhesive Film and 
centrifuged at 1000 RPM for 1 minute to ensure that the reaction mix was pooled at 
the bottom of the wells. The plate was then transferred to the Applied Biosystems® 
7900HT Fast Real-Time PCR system and the PCR run using SDS 2.4 software. The 
cycling conditions used were an enzyme activation step at 95˚C for 5 minutes, 
followed by 40 cycles of denaturation at 95˚C for 10 seconds, annealing at 60˚C for 
10 seconds and extension at 72˚C for 10 seconds. A melting curve was also 
performed to detect the presence of primer-dimers and non-specific binding. R2 
values were generated from the standard curves generated. The optimal R2 value 
that indicates 100% efficiency is -3.32, however values of -3.1-3.6 (80-110%) are 
widely accepted. To generate the optimal primer set efficiency (80-110%), the 
primer concentrations were reduced, where necessary, in a stepwise fashion from 
10 pmol/µl to 8, 6 and 4 pmol/µl until primer-dimers and non-specific binding were 
eliminated, if present, to improve primer set efficiency. 
3.7.2 Gene expression calculations 
Target gene ratios were generated by calculating the combined mean Ct value of 
the triplicate repeats of the three selected housekeeper genes and dividing by the 




Housekeeper (HK) 1 = (Ct repeat 1 + Ct repeat 2 + Ct repeat 3)/3 = HK1mean 
Housekeeper (HK) 2 = (Ct repeat 1 + Ct repeat 2 + Ct repeat 3) /3 = HK2mean 
Housekeeper (HK) 3 = (Ct repeat 1 + Ct repeat 2 + Ct repeat 3) /3 = HK3mean 
HKcombined = (HK1mean + HK2mean + HK3mean)/3 
Target Gene (TG)combined = (Ct repeat 1 + Ct repeat 2 + Ct repeat 3)/3 
Ratio (TG expression) = HKcombined/TGcombined 
3.8. P-gp cDNA production and transfection into HEC-1A 
3.8.1 Production of P-gp expression plasmid 
Plasmid pcDNA3.1 Zeo was digested with EcoR5 and the linearised vector was 
purified by preparative agarose gel electrophoresis. Linearised vector was 
combined with 5’-phosphorylated amplification products (P-gp) at 3-fold molar 
excess and ligated by incubation with T4 DNA ligase for 2h at 25°C. Ligation 
mixture was desalted and used to transform E. coli XL1Blue electrocompetent cells. 
Plasmids DNA obtained from transformants were used as template for PCR 
amplification using primers flanking the site of insertion of DNA encoding the P-gp 
sequence (Table 3.7). Amplification products were analysed by agarose gel 
electrophoresis. Transformants that showed DNA bands corresponding to the 
expected size of the inserted DNA were sent for sequencing. The following 
procedures described below were undertaken for the production of the P-gp 
expressing plasmid. 
 P-gp primers 
PGP amp F [Phos]GACATGGATGGATCTTGAAGGGGACCGCAATGGA 
PGP amp R [Phos]TCACTGGCGCTTTGTTCCAGCCTGGAC 




3.8.1.1 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) was carried out using 10ng of plasmid DNA, in 
50 μl of PCR mixture {dNTPs (deoxyribonucleotides: dATP, dCTP, dGTP and dTTP 
each at 0.2 mM); 2.5 mM MgCl2 (Promega, Southampton, UK); 10X reaction buffer 
[200 mM Tris-HCl (pH 8.8 at 25°C), 100 mM (NH4)2SO4, 100 mM KCl, 1% (v/v) 
Triton X-100, 1 mg/mL BSA]; 2.5U PfuUltra™ HF DNA polymerase (Stratagene, La 
Jolla, CA, USA); 10 pmol of 5’ phosphorylated sense and antisense oligonucleotide 
(Sigma-Aldrich, Dorset, UK)}. Following initial template denaturation (2 min at 95°C), 
PCR proceed through 12-30 denaturation-annealing-extension cycles. Finally, 
reactions were incubated for 1 min at the annealing temperature and for 5 min at 72 
°C for final annealing and extension. Extension time was evaluated according to the 
DNA polymerase speed as well as the target length. Annealing conditions were 
optimized based on the oligonucleotide sequences. 
3.8.1.2 Digestion of DNA 
Restriction enzymes were all from New England Biolabs and were used according 
to the manufacturer’s instructions. Generally 10-20 U of restriction enzyme were 
used to digest 1 μg of plasmid DNA in the presence of the buffer supplied. Mixtures 
were incubated at 37 °C for a minimum of 60 minutes. Enzyme inactivation, when 
necessary, was carried out after digestion by heating the reaction for the time and 
temperature required for each enzyme according to the manufacturer’s instructions. 
DNA digestion was verified by agarose gel electrophoresis. 
3.8.1.3  Preparative agarose gel electrophoresis for purification of DNA 
fragments 
3.8.1.3.1 DNA agarose gel electrophoresis 
DNA plasmids/fragments were analysed by agarose gel electrophoresis. Gels were 
prepared by dissolving electrophoresis grade agarose [(0.8-2% w/v) Sigma-Aldrich, 
Dorset, UK] in TAE buffer (0.004 M Tris-acetate, pH 8.0; 1 mM EDTA). 6-10 μl of 
GelRed (Biotium, Hayward, CA, USA) were added to the solution after it was cooled 
down to 55-60 °C. Solution pouring into a gel cast containing combs followed. 




bromide consisting of two ethidium subunits bridged by a linear spacer. It is 
noncytotoxic, nonmutagenic and non-hazardous at concentrations well above the 
working concentrations used in gel staining and more sensitive than ethidium 
bromide. DNA samples were mixed with loading buffer [0.04% (w/v) bromophenol 
blue; 0.04% (w/v) xylene cyanol; 5% glycerol] and loaded into wells at the end of the 
gel closer to the cathode. A voltage of 80-120 V was applied allowing for DNA 
migration to the positive terminal (anode). Bromophenol blue and xylene cyanol 
served ad as tracking dyes migrating at about the same rate as a 500 and 4000 
base pair DNA fragment respectively. DNA molecular weight markers (1 kb DNA 
ladder, 100 bp DNA ladder; New England Biolabs, Ispwich, MA, USA) were run in 
parallel with the DNA samples as a reference for DNA fragment size. DNA 
fragments were visualised by UV light exposure. Pictures were taken by using a gel 
documentation system (Syngene). 
3.8.1.3.2 Purification of DNA fragments 
To maximise the efficiency of ligation into vectors, digested plasmid and inserts 
werere solved on agarose gel and bands of interests were excised and purified. 
Agarose gels were prepared as described in Section 3.8.1.3.1, using autoclaved 1 x 
TAE buffer. With the exception of the chamber lid, all the equipment used for 
electrophoresis (chamber, gel cast and combs) was pre-washed with 10% SDS and 
rinsed with autoclaved distilled water in order to minimise nuclease activity. DNA (1-
5 μg) in 20-60 μl was applied to the gel wells. Electrophoresis was run at 80 volts for 
4-5 hours for optimal separation. DNA was visualised by brief (5-10 seconds) 
exposure to long wavelength UV to reduce the likelihood of phosphodiester bond 
cleavage (DNA nicking). DNA bands corresponding to inserts and linearised vectors 
were excised with sterile blades and purified using the QIAquick Gel Extraction Kit 
(QIAGEN) following the manufacturer’s instructions. This system is based on DNA 
selective absorption by a silica membrane. Agarose gel slices were solubilized 
using a guanidine thiocyanate-containing buffer which also provided the high-salt 
concentration conditions required for DNA binding to the silica membrane. Following 
adsorption to silica and washing with 70% ethanol, DNA was eluted in 15-30 μl of 




3.8.1.4 Determination of DNA concentration 
The concentration of DNA was determined using the Nanodrop 2000 
(LabtechInternational Ltd, East Sussex, UK). DNA preparations with an OD 260/OD 
280 ratio in the range 1.8-2.0 were suitable for further use. 
3.8.1.5 Ligation of DNA 
Purified linearised vectors (approximately 100 ng) were combined with a 3-fold 
molar excess of insert DNA in the presence of the supplied ATP-containing ligase 
buffer (30 mM TRIS-HCl pH 7.8, 10 mM MgCl2, 10 mM DTT and 1 mM ATP) and 10 
U (1 μl) of the T4 DNA ligase. The reaction was incubated for 2 hours at 25 °C, 
temperature at which the enzyme has optimal activity. Control reactions in which i) 
no insert was added, ii) no polymerase was added; were also set to check for false 
positives. ATP (Adenosine triphosphate) is a nucleoside triphosphate composed of 
an adenine ring, a ribose sugar and three phosphate groups. This molecule is 
crucial for DNA ligation as once it is hydrolysed to Adenosine monophosphate 
(AMP) the DNA ligase transfers it to the 5' phosphate (pyrophosphate bond). Then, 
the AMP-phosphate bond is attached by the 3’-OH, forming the covalent bond and 
releasing AMP. The formula used to calculate the 3-fold molar excess of insert DNA 
is shown below: 3 x {[amount of vector (ng) x length of insert (bp)]/ length of vector 
(bp)} 
3.8.1.6 Transformation of E.coli by Electroporation 
DNA was desalted to reduce the likelihood of sample arcing using the QIAquick 
PCR purification Kit (QIAGEN) according to the manufacturer’s instructions and was 
eluted in deionized water. Electrocompetent E.coli cells were thawed on ice 15 min 
before transformation. Cells (45 μl) were transferred to an ice-cold electroporation 
cuvette (gap width 0.1 cm) (Biorad CA, USA) and gently mixed with the desalted 
DNA (1-10 ng in a maximum of 10 μl). Electroporation was carried out using the 
Gene-Pulser (Biorad) set to discharge a 25 μF capacitor, charged to 2.5 kV in 
parallel with a 200 Ω resistor giving time constants ranging between 4.5 and 5 ms. 
SOC medium (950 μl) was added immediately after electroporation. The cell 




for expression of the antibiotic resistance gene. Cells were then plated on LB 
agarose plates supplemented with carbenicillin (50 μg/ml). 
3.8.1.7 Sequencing of DNA 
DNA sequencing analysis was carried out by Eurofins MWG Operon (Ebersberg, 
Germany). The DNA of interest (1.3 μg) was mixed in aqueous solution of a final 
volume of 50 μl with a primer (13 ρmol) annealing at least 50 bp upstream the 
fragment. Samples were run on a DNA sequencer and high quality sequence data 
on 500-700 bp fragments was generally obtained. 
 P-gp primers 
PGP F1 seq TCCAAGTCTTCCACCCCATTG 
PGP F2 seq TGCCTATGGAGACAACAGCC 
Table 3.8 Oligonucleotides used for P-gp DNA sequencing. 
3.9 PAMP stimulation of cells 
Toll-like receptors (TLRs) are pattern recognition receptors that recognise various 
microbial and viral molecules known as pathogen-associated molecular patterns 
(PAMPs). When cells are stimulated with various PAMPS, immune responses are 
activated to protect the host from infection and intracellular signalling proteins 
(cytokines) are released.   
Cells were stimulated with different PAMPS (Pam 3CSK4, LTA, Poly I:C, E. coli LPS, 
FSL-1, Flagellin, Imiquimoid, Zymosan),  (InvivoGen, CA, USA)  diluted in serum 
free cell culture media and left to incubate at 37°C in 5% CO2 for 24 hours. Blank 
samples contained media only. After 24 hours, supernatant was collected and 
















LPS E.coli TLR4 5 5 1:1000 
Poly I:C TLR3 1 25 1:40 
Pam 3CSK4 TLR1/2 1 1 1:1000 
Zymosan TLR2/4 10 50 1:200 
LTA TLR2 1 10 1:100 
FSL-1 TLR2/6 0.1 1 1:100 
Flagellin TLR5 0.1 5 1:20 
Imiquimoid TLR7/8 1 5 1:200 
Table 3.9 PAMP properties. Including stock concentrations and recognition receptors.  
3.9.1 Cytokine detection assay 
Cytokine levels were determined using a Magnetic Luminex® Performance Assay kit 
(R&D Systems, MN, USA) following the manufacturer’s instructions. Analyte-specific 
antibodies were used, which were pre-coated onto colour-coded microparticles. All 
microparticles, standards were prepared. 50 μl of microparticle cocktail was added 
to each well of a 96-well plate. 50 μl of Standard and samples were then all pipetted 
into wells of the 96-well plate and left to incubate at room temperature on a plate 
shaker set at 800 RPM. The immobilised antibodies bind the analytes of interest. 
The plate is then placed on a magnetic platewasher and wells are washed with 100 
μl washing buffer. After wash, any unbound substances are removed, and 50 μl of a 
biotinylated antibody cocktail specific to the analytes of interest is added to ach well. 
Following another wash, any unbound biotinylated antibody was removed. 50 μl of 
streptavidin-phycoerythrin conjugate is added to each well and left to incubate a 
room temperature for 30 minutes on a plate shaker set at 800 RPM, which binds to 
the biotinylated antibody. After a final wash, microparticles are resuspended in 100 
μl of washing buffer and left to shake for 2 minutes at 800 RPM. Measurements are 
made using a Luminex 100 machine according to the manufacturer’s protocol. 
Lasers in the machine determine the magnitude of the phycoerythrin-derived signal, 
which is proportional to the amount of the analyte bound. 
3.10 In vitro drug permeability studies 
3.10.1 Drug permeability studies using the HEC-1A model 
All transport experiments  were undertaken over a 2 hour period (unless stated) at 




UK) at pH 7.4 as reported [225]. HBSS was used to prevent drug from binding to 
albumin found in cell culture media. All solutions were warmed to 37 °C and 
experiments were performed on a heated orbital shaker set at 50 RPM. Two HBSS 
based transport solutions were prepared: a donor solution containing drugs 
generally solubilised in HBSS + 1% HEPES +/- DMSO (0.01-1 %) to final dug 
concentrations of 0.1-100 μM, depending on the drug being investigated, and a 
receiver solution containing HBSS + 1% HEPES +/- poloxamer 407 (0.2% w/v), 
(Sigma-Aldrich, Cambridge, UK). Prior to the initiation of the drug transport 
experiments TEER was measured. Cell layers were then washed twice with pre-
warmed HBSS+1%HEPES transport buffer and equilibrated in the same solution for 
30 minutes at 37 °C. In all permeability assays, donor solutions were spiked with 
approximately 4000 Becquerel (Bq) of either radioactive [14C]mannitol or 
[3H]mannitol. The experiment was initiated when either 520 μl or 1520 μl of donor 
solution was added to the donor compartment and either 520 μl or 1520 μl of 
receiver solution was added to the receiver compartment, subject to the direction of 
transport being measured. A timer was started as soon as the donor solution was 
added and 20 μl samples were taken from donor and receiver compartments, 
termed T=0 (for assessment of initial concentration and background radioactivity, 
respectively). Transwells® were then placed on an orbital shaker set at 50 RPM. 
Samples, either 200 μl or 600 μl depending on the receiver compartment, were 
taken from the receiver compartments at time points T=30, T=60, T=90 and T=120 
(to obtain cumulative amount of drug in the receiver side versus time) and added to 
polyethylene liquid scintillation vials. Samples were taken in triplicate and replaced 
with equivalent volumes of the receiver solution. After final sampling, TEER was 
measured to confirm that there was no disruption to the epithelial barrier during the 
experimental procedure. Radioactive samples were mixed with 4 ml of scintillation 
fluid (Fisher Scientific, USA) prior to being analysed using a liquid scintillation 
counter (Beckman Coulter, CA, USA). Additionally, with the use of a scalpel, the 
semipermeable membranes of the Tanswell® inserts were cut and also placed into 










to-basolateral (A-B) and basolateral-to-apical (B-A) directions. 
Apparent permeability (Papp) was calculated using the following equation: 
Papp (cm/s) = (∆Q/∆t)/(AC0V) 
Where /  is the gradient of the (linear) slope of the cumulative amount of drug 
in the receiver given as disintegrations per minute (DPM) vs time, A is the surface 
area of the Transwell® membrane, Co denotes the initial loading concentration in the 
donor chamber at T=0 and V is the volume of the initial receiver sample taken at 
T=0. 
3.10.2 Drug permeability studies using the Epivaginal™ model 
Upon receipt, EpiVaginal™ tissues were placed in a refrigerator (2-8°C) until assay 
medium (Mattek Corp, MA, USA) was warmed to 37°C. 900 μl pre-warmed assay 
medium was added to each well of a Nunc® 6-well plate (MatTek Corp, MA, USA). 
Under sterile conditions open, sterile forceps were used to remove the inserts 
containing the tissues from the agarose they were packaged in, making sure the 
plate was at refrigerator temperature allows smooth removal of the insert from the 
agarose. Each insert was placed into each well of the 6 well plates and incubated at 
37°C 5% CO2 overnight- allowing for tissue recovery. 
On the following day, inserts were transferred to new Nunc® 24-well plates and 
transport experiments were undertaken at 37°C in HBSS supplemented with 1% 
HEPES buffer at pH 7.4. All solutions were warmed to 37°C and experiments were 
performed on a heated orbital shaker set at 50 RPM. Two HBSS based transport 
solutions were prepared: a donor solution containing drugs generally solubilised in 
HBSS + 1% HEPES +/- DMSO (0-0.01%) to final dug concentrations of 10 μM, and 




twice with pre-warmed HBSS + 1% HEPES transport buffer and equilibrated in the 
same solution for 30 minutes at 37°C. In all permeability assays, donor solutions 
were spiked with approximately 4000 Becquerel (Bq) of either radioactive 
[14C]mannitol or [3H]mannitol. The experiment was initiated when either 270 μl or 
320μl of donor solution was added to the donor compartment and either 270 μl or 
320 μl of receiver solution was added to the receiver compartment, subject to the 
direction of transport being measured. A timer was started as soon as the donor 
solution was added and 20 μl samples were taken from donor and receiver 
compartments, termed T=0 (for assessment of initial concentration and background 
radioactivity, respectively). Transwells® were then placed on an orbital shaker set at 
50 RPM. Samples, either 100 μl or 120 μl depending on the receiver compartment, 
were taken from the receiver compartments at time points T=30, T=60, T=90 and 
T=120 minutes and added to polyethylene liquid scintillation vials. Samples were 
taken in triplicate and replaced with equivalent volumes of the receiver solution. 
Radioactive samples were mixed with 4 ml of scintillation fluid prior to being 
analysed by a liquid scintillation counter. Additionally, with the use of a scalpel, the 
semipermeable membranes of the Nunc® inserts were cut out and also placed into 
scintillation vials for mass balance measurements. 
3.10.3 Drugs used in this study 
3.10.3.1 Radiolabelled Drugs and concentrations 
Drug Isotope location Stock conc Conc MBq/ml 
DRV carbonyl-14C 2 mCi in 20 ml 3.7 
DPV pyrimidine-2-14C 2 mCi in 20 ml 3.7 
TFV adenine-8-14C 0.05 mCi in 0.5ml 3.7 
Digoxin [3H(G)] 0.25 mCi in 0.25ml 3.7 
D-mannitol 1-3H(N) 1 mCi in 1ml 37 
D-mannitol 1-14C(N) 0.25 mCi in 2.5ml 37 
 














DRV (carbonyl-14C), 2 mCi in 20ml (Moravek Biochemicals Inc, CA, USA) 
DPV (pyrimidine-2-14C) 2 mCi in 20ml (Moravek Biochemicals Inc, CA, USA) 
TFV (adenine-8-14C) 50 μCi in 0.5ml (Moravek Biochemicals Inc, CA, USA) 
*1 mCi = 37 MBq 
Mannitol D-[1-3H(N)] 37 MBq (Perkin-Elmer, MA, USA) 
Mannitol D-[1-14C (N)] 37 MBq (Perkin-Elmer, MA, USA) 





Table 3.11 Volumes of radiolabelled drug prepared for each drug for a permeability assay. As each condition was generally undertaken in 


























Vol of stock required for 
experiment (μl) 
Apical          
14C DRV 260 3 780 1000 4000 15384.62 3700000 0.00416 4.16 
14C  TFV 260 3 780 1000 4000 15384.62 3700000 0.00416 4.16 
14C DPV 260 3 780 1000 4000 15384.62 3700000 0.00416 4.16 
14C  Mannitol 260 3 780 1000 4000 15384.62 37000000 0.00042 0.42 
3H Mannitol 260 3 780 1000 4000 15384.62 37000000 0.00042 0.42 
14C  Digoxin 260 3 780 1000 4000 15384.62 3700000 0.00416 4.16 
Basolateral          
14C  DRV 760 3 2280 2500 4000 13157.89 3700000 0.00356 3.56 
14C  TFV 760 3 2280 2500 4000 13157.89 3700000 0.00356 3.56 
14C  DPV 760 3 2280 2500 4000 13157.89 3700000 0.00356 3.56 
14C  Mannitol 760 3 2280 2500 4000 13157.89 37000000 0.00036 0.36 
3H  Mannitol 760 3 2280 2500 4000 13157.89 37000000 0.00036 0.36 




3.10.3.2 Unlabelled drugs and concentrations 
Drugs were weighed on a μg scale and transferred to a bijou. Solubilising solution 
was added and drug solution was vortexed. TFV (Johnson and Johns, NJ, USA) 
solubilised freely in HBSS.   
DRV and DPV (Gilead Sci, CA, USA), DPV (Selleckchem, Stractech Sci, Suffolk, 
UK) and Digoxin (Sigma-Aldrich, Cambridge, UK) required pre-warmed (37 °C) 
solubilising solutions and extended vortex periods prior to becoming completely 
solubilised. Stock and working concentrations of each of the drugs are shown 
below: 
TFV 
- 0.01 gm + 3.48ml HBSS = 10000 μM (Stock) 
             → 100 μl + 9900 μl = 100 μM 
                      → 1000 μl + 9000μl = 10 μM        
DPV 
- 0.015 gm + 5 ml DMSO = 9000 μM @ 100 % DMSO (Stock) 
          → 50μl + 9950μl HBSS = 45 μM @ 0.5 % DMSO 
                  → 2222μl + 90 μl DMSO + 7690 μl HBSS = 10 μM @ 1 % DMSO 
DRV 
- 0.02 gm + 0.5ml DMSO = 70000 μM @ 100% DMSO (Stock) 
             → 25 μl + 9975 μl HBSS = 175 μM @ 0.25 % DMSO                
                        → 571 μl + 9429μl HBSS = 10μM @ 0.01% DMSO  
 
- 0.02 gm + 0.5ml DMSO = 70000 μM @ 100% DMSO  (Stock) 
                     → 14.3μl + 9985.7 μl 1X Krebs = 100 μM @ 0.14% DMSO 
Digoxin 
- 1 gm in 12.8 ml DMSO = 100000μM @ 100% DMSO (Stock) 
              →1 0 μl + 9990 μl HBSS = 100 μM @ 0.1% DMSO 




3.11 Ex vivo drug permeability studies 
3.11.1 Rat cervicovaginal tissue preparation 
Excised tissue segments were from adult female Wistar rats that had been 
sacrificed as part of separate studies. Tissue from the genital tract was carefully 
washed with cold Krebs solution containing NaCl, NaHCO3, MgSO4, KCL, NaH2PO4, 
HEPES, ddH2O (Sigma-Aldrich, Cambridge, UK) solution and transferred to a 
beaker with oxygenated (95%O2/ 5%CO2) ice cold Kreb’s buffer. All segments were 
cut along their mesenteric border and the muscularis externa was removed using 
blunt dissection. The stripped cervicovaginal mucosa was mounted in modified 
Ussing Chambers containing oxygenated 37˚C transport buffer solutions and tissue 
was allowed to recover for 30 minutes. The effective exposed area of the tissues 
was 0.2 cm2.  
 
Figure 3.3 Excised rat genital tract. Uterus, cervix, cervicovaginal tissue and muscularis 
externa are labelled. 
2.11.2 Macaque tissue preparation 
Excised tissue segments from adult female NHP M. fascicularis were used. Excision 
of vaginal tissue was performed by scientists at the CEA. On receipt, tissue was 
washed with cold Krebs solution and transferred to a beaker with oxygenated 95% 
O2/ 5% CO2) ice cold Kreb’s buffer. All cervicovaginal segments were cut along their 
mesenteric border and the muscularis externa was removed using blunt dissection. 




containing oxygenated 37˚C transport buffer solutions and tissue was allowed to 
recover for 30 minutes. The effective exposed area of the tissues was 0.2 cm2.  
 
Figure 3.4 Excised macaque cericovaginal tissue. Cervix, cervicovaginal tissue, 
muscularis externa and vulva are labelled.  
3.11.3 Drug permeability studies using animal cervicovaginal tissue 
Before an experiment Ussing Chambers (Harvard Apparatus, Cambridge, UK) were 
assembled. Were possible, the low permeability compound [3H]mannitol was 
included in every chamber as an integrity marker. The diffusion cells were 
composed of two glass chambers (apical and basolateral) and separated by the 
mounted tissue. For mammalian physiological buffers, the gas is carbogen (95% O2 
and 5% CO2) which oxygenates solutions to high levels was necessary to overcome 
the lack of haemoglobin delivery by the blood. A flow through system was used to 
continuously supply tissue via tubing that leads to each half of the chamber. Once 
the tissue is mounted and relevant tubes are connected, drug test solutions to each 
chamber half depending on the direction of permeability were ready for the 
experimental procedure. The entire system was maintained at vaginal temperature 
of approximately 37°C and was achieved by the continuous circulation of pre-
warmed water pumped through a heat block. The Papp for all compounds was 
determined in three independent studies. The tissue was allowed to recover for 30 
minutes, bathed bilaterally with 0.35 ml of Krebs at pH 7.4 and continuously gassed 




solution containing 100μM DRV +/- [14C]DRV solubilised in Krebs + 0.1% DMSO 
and a receiver solution containing Krebs solution only. 
The experiments were initiated by removal of Krebs buffer solution from both sides 
(donor and receiver chambers). Donor solution containing drug was then applied to 
the donor side and receiver solution was added to the receiver side. 20 μl samples 
from both donor and receiver side of each chamber were taken and termed as time 
zero (T=0), (for assessment of initial concentration and background radioactivity, 
respectively). At 15 minute intervals over a 1 hour period, 100 μl samples were 
taken from the receiver side and replaced with fresh receiver solution over a 60 
minute period. At the end of the experiment, 100 μl samples were again taken from 
both the donor and receiver chambers. All samples were collected in labelled 
scintillation vials, mixed with 4 ml of scintillation fluid and analysed a Beckman 
Coulter LS6000TA (Beckman Coulter™, Bucks, UK). Additionally, if no radiolabelled 
drug was used, samples were collected in labelled Eppendorf tubes for drug 
analysis by liquid chromatography mass spectrometry (LC-MS) carried out at the 
institute of pharmaceutical sciences (King’s College London, UK). 
3.12 Liquid scintillation counting  
Liquid scintillation counting is an analytical technique which is defined by the 
incorporation of the radiolabeled analyte into uniform distribution with a liquid 
chemical medium capable of converting the kinetic energy of nuclear emissions into 
light energy. Beta particles are emitted in a radioactive decay. To assure efficient 
transfer of energy between the beta particle and the solution, the solution is a 
solvent for the sample material. A beta particle will take only a few nanoseconds to 
dissipate all its kinetic energy. The energy is absorbed by the liquid scintillation 
counter in 3 forms: heat, ionization and excitation. Some of the beta energy is 
absorbed by solvent molecules making them excited (not ionized). Energy of the 
excited solvent is emitted as UV light and the solvent molecule returns to ground 
state. The excited solvent molecules can transfer energy to each other and to the 
solute. The solute is a fluor- an excited solvent molecule which passes its energy to 
a solute molecule disturbing the orbital electron cloud of the solute, raising it to a 
state of excitation. As the excited orbital electrons of the solute molecule return to 
the ground state, a radiation results, in this case a photon of UV light. The UV light 




state. This is subsequently detected by the scintillation counter and read out as 
DPM (disintegrations per minute). 
3.13 Statistical analysis 
Where statistical data is given for analysis of three or more datasets, one-way 
ANOVA tests were performed and post-hoc comparisons were conducted according 
to the Tukey method. For datasets comparing two samples, an unpaired two-tailed 
t-test was performed. All values are represented as means ± SD. Differences were 
considered statistically significant when P < 0.05. Statistical analyses were 














>Chapter 4 Optimisation of an in vitro model for drug 
transport studies 
4.1 Aim 
To optimise an in vitro model of the vaginal epithelium for measurement of drug 
permeability. To develop a model of in vitro inflammation and assess effects on drug 
permeability. 
4.2 Introduction 
The aim of work described in this chapter was to optimise an in vitro model of the 
vaginal epithelium for measurement of drug permeability. Previous studies have 
described formation of an in vitro barrier epithelium by the human endometrial 
adenocarcinoma cell line HEC-1A [199, 226-230] and use of this model to measure 
drug permeability in the apical to basolateral (A-B) direction [136]. However, this 
model was designed also to investigate HIV transmission through vaginal epithelium 
using both cell-associated and cell free virus and therefore cells were cultured on 
membranes with pore sizes (3 μm, 6 μm) that allowed transmigration of cells in the 
dual chamber Transwell® culture system [222]. In addition, no studies of bi-
directional drug transport were reported. 
The findings that HEC-1A cells form a barrier epithelium when cultured in the dual 
chamber system (Figure 4.1) [177, 185-189] provided the basis for the studies 
described in this chapter. Microbicides against HIV that are based on the reverse 
transcription inhibitors DPV and TFV or the protease inhibitor DRV target 
intracellular events in HIV replication. In vitro models of barrier epithelium provide a 
means of investigating factors that influence permeability of such ARVs across the 
epithelium - an essential requirement for the ARVs to access the sub-mucosal T 
cells that form the initial targets for infection. Models based on culture of continuous 
cell lines such as the Caco-2 model of gastrointestinal epithelium [231-233] and the 
16HBE14o [234] model of the respiratory epithelium has provided invaluable data 
on drug transport in other systems. The Caco-2 system is considered as the “gold 
standard” of in vitro models and has been extensively used for high throughput drug 




28 days [233, 235] in Transwells® differentiate to form a confluent epithelial cell 
monolayer consisting of columnar and polarised cells interconnected by tight 
junctions. As well as developing microvilli on their apical membranes, Caco-2 cells 
naturally express a variety of drug transporters (i.e. P-gp) and metabolising 
enzymes. Such characteristics are typical of the human jejunum. In contrast, Calu-3 
cells are primarily used for assessing the permeability of nasal/inhaled and 
pulmonary drug delivery and can be air-liquid interphase cultured or liquid-covered 
cultured depending on the drug delivery route being tested. After 2-3 weeks in 
culture these cells form monolayers that express drug transporters and efficiently 
secrete mucus, typical characteristics of the human lung epithelia [236]. Key 
requirements for such models is the formation of tight junctions, resulting in both 
polarisation of the cell and barrier function, and adherence of cells to the semi-
permeable membrane of the Transwell® insert. A further desirable property is that 
the profile of drug transporter expression resembles that of the corresponding 
human tissue. When cultured in inserts, epithelial cell layers separate two liquid 
compartments. The polarisation of these cells differentiates the apical (donor) and 
basolateral (receiver) liquid compartments, which are in direct contact with the 
respective domain of the cells. The drug concentration, when sampled from the 
receiver compartment, must be lower than that of the donor compartment drug 
concentration per time interval. This maintenance is defined as the “sink condition” 
of the receiver. Additionally, impaired “sink conditions” can be avoided by applying 
suitable liquid volumes in each of the compartments or by using bio-enhancers to 
improve hydrophilic drug permeability. 
 
Figure 4.1 A schematic representation of a Transwell
®
 chamber. The microporous 




transport studies and separates the well into two compartments (apical and basolateral). 
Image adapted from [237]. 
Movement of a paracellular tracer (mannitol) between the two compartments is a 
result of paracellular diffusion and is a quantitative routine control to assess barrier 
integrity. The flux of such tracers (expressed as permeability coefficient) indicates 
the paracellular water flow, as well as the pore size of the tight junctions [238]. 
Typically, this mode of transport displays a linear cumulative rate of transport as 
well as symmetry between the rate of transport in the apical-to-basolateral (A-B) 
and basolateral-to-apical (B-A) direction. Rate of transport can be calculated by the 
apparent permeability coefficient (Papp, unit: cm/s) and is determined from the 
amount of compound that is transported per time (as described in chapter 3). An 
additional control to monitor barrier formation and integrity, involves the qualitative 
measurement of TEER.   
4.2.1 Expression of drug transporters in HEC-1A cells 
Comparative analyses of drug transporter expression in human vaginal and cervical 
tissue and in HEC-1A cells have been reported. The mRNA profile of efflux 
transporters in HEC-1A and human tissue showed reasonable correlation [206]. 
BCRP was not expressed and expression of P-gp was lower in HEC-1A cells 
compared with human tissue where expression of both was high. In contrast, MRP3 
and MRP4 were highly expressed in HEC-1A cells but at lower levels in human 
tissue. Expression of uptake transporters showed some overlap but in contrast to 
human tissue, OCT3, CNT2 and CNT3 were not expressed in HEC-1A cells. 
Additionally, transporters OAT1-3 have also shown no expression in HEC-1A cells 
but the less well-characterised OAT4 and OAT6 showed low to moderate 
expression, respectively [214]. Protein expression of P-gp, BCRP and MRP2 was 
also undetected in HEC-1A cells when compared to positive expression from 
vaginal and endocervical tissue of premenopausal women [134] 
4.2.2 Tight junctions 
Epithelial and endothelial cells form morphologically distinct seals connecting the 
membranes of adjacent cells. These apically located junctional complexes of the 
lateral membrane consist of three components: tight junctions, adherens junctions 




epithelium [215]. Tight junctions contribute to the formation of polarised epithelial 
barriers by forming a paracellular diffusion barrier, or gate, that regulates epithelial 
permeability, and an intra-membrane diffusion barrier, or fence, which restricts the 
apical-to-basolateral diffusion of membrane components [216]. These junctions are 
composed of transmembrane and cytosolic proteins that interact with each other as 
well as with components of the cytoskeleton. Tight junctions are formed by 
association of tetra spanning membrane proteins occludin, tricellulin and the 
claudins as well as the single-pass membrane proteins, the junctional adhesion 
molecules (JAMs), (Fig. 4.2). 
 
Figure 4.2 Schematic representation of the tight junction, adherens junction and 
desmosome of between epithelial cells. Magnification of the tight junction protein and its 
physiological components. 
Occludin was the first trans-membrane tight junction protein discovered [239] and its 
function in the tight junction remains to be fully understood. It is, however, an 
important structural element to the complex as over expression has shown to 
increase electrical resistance, phenotypically implying a tight apical-basolateral 
intra-membrane lipid diffusion barrier [240]. The occludin-related protein tricellulin is 
involved in tight junction composition and shares a conserved domain with occludin 
mediating the binding to zona occludens-1 (ZO-1) [241]. It is concentrated at 
regions where three cells form a contact or at the tricellular tight junction, hence the 
name tricellulin. Like occludin [242, 243], tricellulin knockdown interferes with tight 
junction assembly and enhances solute diffusion across cultured epithelial 
monolayers [244], while tricellulin overexpression enhances barrier function [245]. 




paracellular pathway. All claudins (except claudin-12) end in a carboxyl terminal 
(PSD59-D1gA-ZO-1) PDZ binding motif [246] and interact with several PDZ 
domains of the tight junction scaffolding proteins. Claudin interaction involves 
binding with the first three PDZ domains ZO-1, ZO-2 and ZO-3 [246] of the tight 
junction proteins. Claudin interaction with the other PDZ domain-containing proteins 
has also been reported, these include MPDZ (MUPP1, Multi PDZ domain protein 1) 
[247] and Pat J (protein associated with tight junctions) [248], however they remain 
to be fully investigated. The ZO’s appear to be fundamental for tight junction 
formation, particularly ZO-1 and ZO-2 as these scaffolding proteins are required to 
create claudin-based junctional strands in the mouse breast epithelial cell line Eph4 
[249]. The cytoplasmic C-terminus of occludins also binds to the tight junction 
associated proteins ZO-1, ZO-2 and ZO-3 via PDZ binding motifs and therefore 
provides a link between the extracellular domains. Removal of claudin proteins have 
shown disrupted barrier-specific phenotypes as deletion of claudin-1 in mice 
compromises the epidermal barrier causing wrinkled skin and is lethal within 1 day 
of birth due to excessive water loss [239].  
The JAMs are a group of proteins that are sub-divided as JAM-A, JAM-B, JAM-C. 
Of these JAM family members, several studies have implicated JAM-A in the 
regulation of barrier function and the inflammatory response. This single-pass 
transmembrane protein is expressed in several cell types but is particularly 
abundant in epithelial and endothelial cells, where it accumulates at tight junctions. 
JAM-A has been reported to influence various cellular processes, including 
regulation of paracellular permeability, cell polarity, cell adhesion, cell migration, 
angiogenesis, and leukocyte migration [250-254]. JAM-A knockout mice display 
increased polymorphonuclear leukocyte infiltration increasing mucosal permeability 
[255] which is consistent with an in vitro study that showed that JAM-A is crucial for 
epithelial cell polarity [250].  
Linkage of the cytoplasmic domain of tight junctions to the actin cytoskeleton is 
mediated by the ZO proteins which bind actin directly and interact with actin binding 
proteins (reviewed in [246]). Extracellular Ca2+ has shown importance in the 
physiology and maintenance of tight junctions [256-258] . Depletion of Ca2+ in cell 
cultures resulting in a decrease in TEER that is reversible on replacement of Ca2+ 




mechanisms of tight junction disassembly are complex and involve differential 
inhibition of protein kinase c isoforms [258] as well as actin remodelling with 
clathrin-mediated endocytosis of junctional proteins [260] and a variety of 
intracellular signalling pathways [261].  
The tight junction is composed of at least two functionally distinct pathways, this 
includes a high-capacity, charge selective pore pathway that mediates the 
movement of small ions and uncharged molecules, and a low-capacity leak pathway 
that allows the free movement of larger ions and macromolecules, regardless of 
charge. TEER measures the flux of all ions across confluent monolayers (measured 
with AC current), and is indicative of transepithelial ionic permeability as electrical 
currents are carried by ions in aqueous solution using Ohms law to calculate the 
resistance to current flow [262]. The most common ions in physiological solutions 
are Na+ and Cl- which carry the electrical currents; TEER therefore reflects tight 
junction permeability depending on the conductance of these ions. If ion 
conductance across the tight junction is far greater than across the apical and 
basolateral domains, then this is indicated by low TEER readings and signifies 
‘leaky’ epithelia. If ion conductance across the tight junction is far less than across 
the apical and basolateral domains then this is indicated by higher TEER readings 
and signifies ‘tight’ epithelia [263].  
4.2.3 Cell attachment to dual chamber porous membrane 
Physiologically, the basolateral surface of the epithelium is associated with an 
extracellular matrix protein complex termed the basement membrane as reviewed in 
[264]. Major components of the basement membrane include type IV collagen and 
laminin, that self-assemble to form a polymeric scaffold, as well as entactin which 
interacts with both components. To model extracellular matrix and promote cell 
attachment, several studies including those using HEC-1A cells have reported 
coating of the chamber surface with laminin [222, 229, 230] or Matrigel® [265], a 
reconstituted murine basement membrane preparation that is approximately 60% 
laminin, 30% collagen IV, and 8% entactin [265-267]. While this may be beneficial 
for some cell lines, others such as the intestinal cell lines Caco-2/15, HT29 and T84 




In the study described in this chapter, a variety of conditions including nature of the 
support membrane, seeding cell density, length of culture and requirement for 
coating with extracellular matrix proteins were investigated for optimising the barrier 
properties of HEC-1A cells in dual chamber cultures. Formation of tight junctions 
was monitored by measurement of TEER and the permeability of the paracellular 
marker mannitol as well as by immunofluorescent staining. In addition, expression 
of selected drug transporters at the protein level was investigated by Western 
blotting. 
4.3 Results 
4.3.1 Determination of optimal culture protocols 
Optimal conditions for establishing a permeability barrier in HEC-1A cell cultures 
using the Transwell® dual chamber system were investigated in a step by step 
process by comparison with the procedures published previously [222, 230]. Barrier 
properties were estimated by measurement of TEER. 
4.3.1.1 Effect of pore size 
In previous studies where HEC-1A model epithelial barriers were used to model HIV 
transmission by cell-free and cell-associated virus, a pore size of 3.0 μm in the 
semi-permeable membrane of the Transwell® insert was used to allow 
transmigration of cells [222]. Since transmigration is not required in drug 
permeability assays, the barrier properties of HEC-1A cells cultured on membranes 
containing pore sizes of 3.0 μm or 0.4 μm were compared using the Transwell® 
culture system. 1x105 cells were seeded in Transwell® inserts and cultured for 10 
days. TEER values were measured in the cultures daily. As shown in Figure 4.3, 
TEER values reached a plateau on day 6 of culture in inserts containing 0.4 μm 
pore size membranes and day 8 for inserts containing the 3.0 μm pore size 
membranes. No significant difference (P ≥ 0.05, two-tailed t test) was evident in the 
maximal TEER values of 90±20 Ωxcm2 (0.4 μm pore size) and 100±20 Ωxcm2 (3.0 





Figure 4.3 Effect of pore size on TEER. The time-course of increasing TEER of HEC-1A 
cells cultured in inserts with 3.0 μm and 0.4 μm filter pore sizes is shown. TEER values were 
measured daily over 10 days and corrected by subtracting the blank value (115 Ω) obtained 
from inserts containing culture media only and expressed as ohms Ω×cm2. Cells were 
seeded at a density of 1x105/1.12cm2 in each Transwell® insert. Data represent mean ± 
S.D., n = 2 (6 technical repeats). 
4.3.1.2 Effect of seeding cell density 
The effect of seeding the Transwell® inserts at cell densities/insert surface area 
(1.12cm2) of 1x105, 2x105 and 4x105 on development of TEER was investigated 
over the period of culture. For these experiments, inserts with the larger pore size 
were also included. As shown in Figure 4.4, in the inserts with the 0.4 μm pore size 
membrane, the size of the seeding density did not affect the maximum TEER value 
but at higher seeding density the maximum value was reached more quickly. 
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Figure 4.4 Effect of seeding cell density on TEER. The time-courses are shown of TEER 
increase in HEC-1A cell cultures in inserts containing 0.4 μm (A) and 3.0 μm (B) membrane 
pore sizes at three different seeding densities. Data represent mean ± S.D., n = 2 (6 
technical repeats). 
For the inserts containing 3.0 μm pore size membranes, TEER increased with cell 
density. At the higher densities, values between days 4 and 7 plateaued but then 
appeared to increase. For the lower densities, TEER values increased more slowly 
beginning to plateau between days 8 to 10. In these Transwells®, partial passage or 
migration of cells through the larger pores may contribute to the apparent increase 
in TEER following the initial plateau. The inserts containing 3.0 μm pore size 
membranes were not considered further for culture of a HEC-1A cell-based model 
epithelium for drug permeability studies. 
4.3.1.3 Comparison of Polycarbonate (PC) and Polyester (PE) Semi-Permeable 
Membranes 
Transwell® inserts containing a polyester (PE) supporting semi-permeable 
membranes have the advantage of being optically transparent compared with the 
translucent polycarbonate (PC) membranes used in the experiments described 
above. Cells cultured in PE Transwells® can therefore be visualised directly by 
microscopy. 
Barrier properties of HEC-1A cell cultures on both surfaces were compared as 
before by measuring TEER development over time. For these experiments, inserts 
were seeded with 2x105 cells/1.12cm2 each. As shown in Figure 4.5, TEER values 
for the cultures in PE Transwells® were significantly higher (P < 0.05, ANOVA) than 
those in PC Transwells® with maximum values of 228±20 Ωxcm2 and 91 Ωxcm2 (p≤ 
0.05, two-tailed t test), respectively. As before, blank values (TEER for membrane 
alone) were subtracted. Thus PE semi-permeable membranes may provide an 






Figure 4.5 Effect of chemical nature of semi-permeable membrane. The time-course of 
increasing TEER in HEC-1A cells cultures on PC and PE Transwells® (0.4 μm pore size) is 
shown. Cells were seeded at a density of 2x105/1.12 cm2 on each Transwell®. (*, P < 0.05). 
Data represent mean ± S.D., n = 2 (6 technical repeats).  
4.3.1.4  Effect of coating Transwell® insert membrane with extracellular matrix 
proteins 
As described above, prior coating of the Transwell® insert membrane with 
extracellular matrix proteins that form the basal membrane may improve adherence 
and barrier formation by some cell types. Individual Transwell® insert membranes 
(both PE and PC) were coated with human or mouse laminin by applying 0.25ml of 
solutions at different concentration and left to air-dry overnight in a laminar flow 
hood. In these experiments, PC inserts were seeded with 2x105 cells. As shown in 
Figure 4.6A and Figure 4.6B, coating with the higher concentrations of (5 μg/cm2 or 
10 μg/cm2) of human or mouse laminin resulted in small but significant (P ≤ 0.05, 
ANOVA) increases in the maximum TEER value. In PC Transwell® cultures 
increased TEER readings of 110-120 Ωxcm2 were observed compared with 70-80 
Ωxcm2 in cultures with no coating. Coating of PE Transwells® with mouse or human 
laminin at 5μg/cm2 also resulted in a minor increase in the plateau TEER value 






A                                                                   B                                            
   
C 
 
Figure 4.6 Time-dependent development of TEER by HEC-1A cells cultured in 
Transwells
®
 coated with Human or Mouse laminin. (A) 2x105 HEC-1A cells cultured on 
PC insert membranes coated with varying concentrations of human laminin. (B) 2x105 HEC-
1A cells cultured on PC insert membranes coated with varying concentrations of mouse 
laminin. (C) 2x105 HEC-1A cells cultured on PE membranes inserts coated with either 
mouse or human laminin at a concentration of 5 μg/ml. Uncoated Transwells® were used as 
a control. Data represent mean ± S.D., n = 2 (6 technical repeats). 
The effect of coating with Matrigel® was investigated in PE Transwells® only as 
shown in Figure 4.7. There was no difference in the plateau TEER values between 
uncoated membranes of the Transwell® inserts and any of the Matrigel® coated 























































































Figure 4.7 Time-dependent development of TEER by HEC-1A cells cultured in 
Transwells
®
 coated with Matrigel
®
. 2x105 HEC-1A cells were cultured on PE inserts 
coated with varying concentrations of Matrigel®. Uncoated inserts were used as a control. 
Data represent mean ± S.D., n = 2 (6 technical repeats). 
Overall, these results indicate that optimum conditions for culture of HEC-1A cells in 
the dual chamber system to produce a barrier epithelium for drug transport assays 
is to seed 0.4 μm PE Transwell® with 2x105 cells and to culture for 6-10 days. The 
effect of coating with either laminin or Matrigel® is relatively minor. 
4.3.1.5 Extended assessment of barrier properties of HEC-1A culture over 21 
days 
The time to reach plateau values of TEER in HEC-1A cultures is considerably 
shorter than that required for some other cell lines, notably the human colon-derived 
cell line Caco-2 that is approved by the FDA as a model for measuring drug 
transport  [233, 271]. To confirm the time frame of when HEC-1A cell layers are at 
their most stable in regards to barrier integrity, HEC-1A cells were cultured in 
Transwells® over a 21 day period. Barrier properties were assessed by both; 
measurement of TEER and by measurement of permeability of radiolabelled 
[14C]mannitol which is used a bi-directional marker for paracellular transport. 
As shown in Figure 4.8 TEER values increased to a maximum value of 250 Ωxcm2 
while Papp values decreased to a minimum of 1.50x10
-6 cm/s on day 6. TEER values 


































and Papp increased more rapidly. These data confirm the window between days 6 
and 10 of culture as optimum for drug transport assays. Paracellular [14C]mannitol 
fluxes across the HEC-1A cells displayed bi-directional permeation as calculated 
absorptive A-B permeability and secretory B-A. Maximum TEER values (in excess 
of 190 Ωxcm2) were achieved between days 6 and 10 by cells seeded at 2x105 cells 
per Transwell®, after which the TEER value decreased from day 10 onwards. 
Measurement of bi-directional Papp of [
14C]mannitol through cells cultured under the 
optimised culture conditions indicated that mannitol permeability declined with time 
in culture as the cell layers developed a concomitant increase in TEER (Figure 4.8). 
From day 6 the bi-directional Papp of [
14C]mannitol was reduced  to 1-3x10-6 cm/s 
and remained in this region until day 10. 
 
Figure 4.8 Stability of HEC-1A model barrier epithelium over time. 2×105 HEC-1A cells 
were seeded and cultured on uncoated 0.4 μm PE transwells over a 21 day period. Data 
represent mean ± S.D., n = 3-6 (9-18 technical repeats). 
4.3.2 Investigation of tight junction formation 
Formation of tight junctions by HEC-1A cells was investigated by measuring the 
effect of calcium depletion on TEER values in the Transwell® system and by 
























































4.3.2.1 Calcium depletion 
The Ca2+ chelator EDTA disrupts tight junctions [256] by a process that modulates 
activity of protein kinase c family members and involves actin remodelling with 
clathrin-mediated endocytosis of junctional proteins [258, 260]. The effect is 
reversible and tight junctions reform when re-exposed to a solution containing Ca2+ 
[256]. The effect of EDTA on Transwell® cultures was investigated by measurement 
of TEER during and after 90 minutes exposure to cell culture medium containing 5 
mM EDTA. Following the addition of 5 mM EDTA TEER values decreased by 45% 
at 90 minutes (Fig. 4.9). Cell culture medium containing EDTA was removed and 
replaced with EDTA -free cell culture medium. After 2 hours TEER values were 82% 
of pre-exposure levels and by 24 hours culture in EDTA-free media, TEER values 
returned to pre-exposure levels. In control cells maintained in EDTA-free cell culture 
media there was no decrease in TEER. 
 
Figure 4.9 Disruption of tight junction functions by EDTA. HEC-1A cells were exposed 
to 5 mM EDTA diluted in normal cell culture media. HEC-1A cells were cultured on 0.4 
μm PE Transwells® at a seeding density of 2x105. TEER measurements gradually 
decreased over a 90 minute period when exposed to the Ca2+ chelator EDTA. TEER values 
returned to pre-exposure levels on re-incubation in EDTA-free cell culture medium. Data 





 4.3.2.2 Immunofluorescent analyses of tight junctions in HEC-1A cultures 
To further investigate the formation of tight junctions, HEC-1A cells were cultured on 
glass slides and stained for the cytoplasmic adaptor protein ZO-1 using an FITC-
conjugated anti-ZO-1 monoclonal antibody which was visualised by fluorescence 
microscopy. Intense bands of fluorescence surrounding the periphery appeared as 
a series of apparent fusions or “kissing points” between HEC-1A cells confirming the 
expression and localisation of ZO-1 (Fig. 4.10, panel 2B). In contrast, no 
fluorescence was detected in cell layers exposed to the isotype-matched control 
anti-gp41 monoclonal antibody produced no fluorescence (Fig. 4.10, panel 1B).  
 
Figure 4.10 Immunofluorescence staining of ZO-1 expression in HEC-1A cells five 
days after seeding on small glass culture slides. ZO-1 expression was visualised using a 
mouse IgG1 FITC-conjugated monoclonal antibody to the ZO-1 tight junction protein (green), 
panel (2B). In contrast no ZO-1 expression was visualised when using a control mouse IgG1 
anti-gp41 monoclonal antibody, panel (1B). In both cases cell nuclei were stained with Dapi 
(blue), panels (1A) and (2A). A merge image was produced of cell nuclei and tight junction 
staining at 10X and 60X magnifications, panels (2C) and (2D).  
Tight junction formation was also determined in cultures of HEC-1A cells on the 
transparent membrane of a PE Transwell®. In agreement with results from cells 
cultured on glass slides, intense bands of fluorescence were detected surrounding 
the periphery of the cells (Figure 4.11A). Confocal microscopy also indicated that 
the confluent barrier, was not formed by a simple monolayer but that several multi-
layered ‘cell clumps’ were formed (Figure 4.11A). The Z-stack image of the PE 
Transwell® (Figure 4.11B) confirmed that HEC-1A cells formed an irregular 1-4 cell 




imaging of HEC-1A on Transwells® [222]. Green fluorescence ZO-1 staining can 
also be observed at areas of cell to cell contact. 
 
Figure 4.11 Confocal microscopy of HEC-1A cell layers cultured for 7 days on PE 
Transwells
®. (A) HEC-1 cells exhibit areas of clump-like formations as they grow on top of 
each other. ZO-1 expression was visualised using a mouse IgG1 FITC-conjugated 
monoclonal antibody to the ZO-1 tight junction protein (green). Cell nuclei were stained with 
Dapi (blue). (B) Z-stack image produced a sliced view of HEC-1A cells attached to the PE 
transwell. Cell multilayers ranged from a 1-4 cell thickness, and maintained tight junction 
formation (green) at cell to cell contact.  
4.3.3 Expression of drug transporters in HEC-1A cells 
Expression of drug transporters in HEC-1A cells lines and in human cervico-vaginal 
tissues has been investigated by quantitative analyses of mRNA using PCR arrays 
[206]. Efflux transporters, which affect the uptake of ARVs including DRV and TFV, 
including MRP1 (ABCC1), MRP3 (ABCC3), MRP4 (ABCC4) and MRP5 (ABCC5) 
were reported to be highly expressed in HEC-1A cells while P-gp (ABCB1) and 
MRP2 (ABCC2) showed lower expression. Some differences were noted with 
expression of efflux transporters in vaginal tissue where P-gp, MRP1 and MRP5 
were highly expressed while no expression of MRP2, MRP3 or MRP4 was evident. 
Uptake transporters including organic anion transporters and nucleotide 
transporters that may also influence ARV uptake were also identified. To investigate 
the correlation between these findings and protein expression of transporters, 
lysates of HEC-1A cells were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes for Western blot analyses of specific transporters (Figure 




Western blotting (Figure 4.13). Lysates were also prepared from the well 
characterised human colon cell line Caco-2 and used as controls for expression of 
some transporters. 
 
Figure 4.12 Expression of ABC and SLC transporters in HEC-1A cells and Caco-2 
cells. Cell lysates were prepared, samples (40 μg total protein in each well) were loaded 
and separated by SDS-PAGE. Proteins were transferred electrophoretically to nitrocellulose 
membranes and probed with specific antibodies to individual drug transporters. Lane’s a-f 
and h-j: Western blotting of HEC-1A lysates for ABC and SLC transporter expression 
respectively. Lanel g: Western blotting of Caco-2 lysate as a control.  
Probing blotted lysates with anti-MRP4 antibody showed a diffuse band 
corresponding to the expected molecular weight of 159kDa (Figure 4.12, lane d). 
MRP4 has 7 sites for N-linked glycosylation and the diffuse nature of the band may 
reflect the presence of differentially glycosylated isoforms. Expression of MRP1 
(Figure 4.12, lane a) was indicated by a single band of approximate molecular 
weight 55 kDa, much lower than the expected value of approximately 172 kDa, and 
assumed to represent a product of proteolysis. No bands were observed on probing 
with antibodies recognising MRP2, MRP3 or P-gp (Figure 4.12, lanes b, c and f) 
consistent with lack of expression of these transporters. Additionally, MRP5 was 
undetected at protein level (Figure 4.12, lane e) but has reported to show relatively 
high expression at mRNA level [206]. Expression of the uptake transporters 
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OATP1B3 (SLCO1B3) and OATP4A1 (SLC4OA1) was indicated by bands albeit of 
higher molecular weight than expected value of 77 kDa for each (Figure 4.12, lanes 
i and j). Bands of higher molecular weight (approximately 200 kDa) may represent 
oligomers formed by association of the extensive hydrophobic regions in the multi-
membrane spanning molecules that are not disrupted by heating in SDS prior to 
electrophoresis. In contrast, the additional band of lower molecular weight observed 
for OATP1B3 may be a proteolytic product. Similarly the bands evident on probing 
with antibody against ENT1 (SLC29A4), (Figure 4.12, lane h) are considerably 
higher than the expected value of 55 kDa and likely to be oligomers. The doublet 
may be the result of proteolysis or differential glycosylation or both. These blots 
were repeated 2-3 times and similar patterns of bands were observed on each 
occasion. For each experiment, control blots where the first antibody was omitted, 
no bands were visible.  
Figure 4.13 Expression of P-gp and MRP4 transporters in human endocervix and 
ectocervix tissue, HEC-1A cells and Caco-2 cells. Tissue and cell lysates were prepared, 
samples (40 ug total protein in each well) were loaded and separated by SDS-PAGE. 
Proteins were transferred electrophoretically to nitrocellulose membranes and probed with 
specific antibodies to individual drug transporters. Panel a: Western blotting of tissue and 
cell lysates for P-gp expression. Panel b: Western blotting of tissue and cell lysates for 
MRP4 expression. 
Blotted ectocervical and endocervical tissue lysates probed with anti-P-gp antibody 
showed bands corresponding to a molecular weight of approximately 141 kDa 
(Figure 4.13, Panel a), also with some diffuse bands. Expression of MRP4 was also 




presenting expected molecular weights of approximately 159 kDa. HEC-1A and 
Caco-2 cell lysates were used as controls, additionally the housekeeping gene anti-
β actin was used as a protein concentration loading control and produced bands at 
42kDa (Figure 4.13). 
4.3.4 Modelling of inflammation 
In many cases, particularly when users of topical microbicides suffer from bacterial 
vaginosis or sexually transmitted diseases, topical microbicides may be 
administered to inflamed genital mucosae. To develop an in vitro model of vaginal 
inflammation, HEC-1A cells were screened against a panel of 8 PAMPs that 
stimulate different TLRs to identify those that most potently stimulated production of 
pro-inflammatory cytokines. Cytokine production was measured by Multiplex bead 
based immunoassay. Consistent with reports that TLR3 is expressed by this cell 
line, the TLR3 agonist Poly I:C was the most potent stimulator of TNF-α, GM-CSF, 
IL-1α, IL-6 and IL-8 (Figure  4.14).  
 
Figure 4.14 PAMP stimulation of pro-inflammatory cytokines in HEC-1A cells. Cultures 




production of selected cytokines was determined by Multiplex bead immunoassay. n=1 (2 
technical repeats). 
Dose response analyses indicated that Poly I:C stimulation was most potent at a 
concentration of 25 μg/ml (Figure 4.15). Poly I:C stimulation at 25 μg/ml produced 
the highest concentrations for all cytokines apart from IL-6, where 50 μg/ml 
marginally produced the highest concentration. Based on the effects on the 
stimulation of the other cytokines as well as the effect on IL-6, 25 μg/ml was 
selected as the final dose concentration for the permeability studies (discussed in 
chapter 5).  
 
Figure 4.15 Dose-response of pro-inflammatory cytokines in HEC-1A cells with 
different concentrations of Poly I:C. Cultures of HEC-1A cells were stimulated with 




cytokines was determined by Multiplex bead immunoassay. The dose that stimulated the 
highest concentrations of cytokines was selected the final dose concentration. n=1 (2 
technical repeats). 
4.4 Discussion 
The results presented above confirm findings reported previously [222] that HEC-1A 
cells form a permeability barrier when cultured in the dual chamber system. Barrier 
properties of this model epithelium were demonstrated by measurement of TEER 
and by restricted permeability of mannitol, a low molecular weight polar compound 
that is excluded from the cell and penetrates by the paracellular route. In repeated 
experiments, TEER reached a maximum value around day 6 of culture and 
remained at that level until around day 10. Consistent with these findings, 
permeability of mannitol reached a minimum and remained low within the same 
timeframe. These conditions provide a convenient window for drug permeability 
assays. The maximum TEER values of HEC-1A cultures were approximately 10-fold 
lower than those of Caco-2 cells cultured in parallel and reported previously, 
although for the latter, a longer period of culture (21-28 days) is required to reach 
maximum TEER [233]. These differences may reflect different physiological 
requirements for the corresponding epithelia. Caco-2 TEER readings of 1500-2000 
Ωxcm2 and Papp values for mannitol of 1-2×10
−7 cm/s [233] reflect a ‘tight’ barrier 
formation. In contrast, HEC-1A TEER readings of 150-250 Ωxcm2 and Papp values 
for mannitol of 1-2x10-6 cm/s reflect an ‘intermediate’ barrier. Tight epithelia have a 
deep complex network of junctional strands, while ‘leaky’ epithelia have shallower 
junctions composed of fewer junctional strands. Epithelia with ‘intermediate’ 
permeability generally have junctional strands with intermediate or variable 
morphology. The 10 fold increase in TEER between Caco-2 and HEC-1A cells is 
proportional to the 10 fold difference in mannitol permeability. 
Increases in TEER readings over time provided evidence of tight junction and 
barrier formation. Nonetheless, to confirm tight junction formation, abundant 
expression of the tight junction protein ZO-1 at contact regions of cells cultured on 
glass slides or in PE Transwells® was demonstrated by immunofluorescence. 
Confocal microscopy also indicated that HEC-1A cells in culture formed an irregular 
multilayer possibly more reflective of the multi-layered epithelium of the vaginal and 
ectocervix surfaces of the FGT. The abrupt decrease in TEER following removal of 
Ca2+ from HEC-1A cultures as well as the recovery in TEER after replacement of 
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Ca2+ provided further evidence for formation of tight junctions. Moreover, scanning 
electron microscopy (SEM) shows apical and basolateral polarised phenotype 
displayed by HEC-1A [272].  
Topical microbicides may be administered under conditions of vaginal inflammation 
that result from conditions such as bacterial vaginosis or sexually transmitted 
diseases (STDs). Pro-inflammatory cytokines have been shown to increase 
epithelial permeability in a variety of systems by reducing tight junction activity 
(reviewed in [273]). Mechanisms of tight junction inhibition include downregulation 
and relocalisation of tight junction proteins. In this chapter, the potential for 
modelling inflammation was investigated by stimulation of HEC-1A cells with ligands 
for TLR-3 and TLR-5. Induction of TNF-α and IL-6, as reported here, reduce tight 
junction activity by downregulation and relocalisation of ZO-1, respectively [274]. 
Levels of IL-8 were higher than those reported previously to be associated with 
occludin redistribution and corresponding tight junction inhibition [275].  
Expression of selected drug transporters was investigated in HEC-1A cells and in 
human endocervix and ectocervix tissue by Western blotting. Expression of 3 
uptake transporters (ENT1, SLCO1B3, SLCO4A1) and two efflux drug transporters 
(MRP1, MRP4) was demonstrated in HEC-1A cells. MRP4 and P-gp expression 
was detected in human ectocevrix and endocervix tissue. ENT1, MRP1 and MRP4 
protein expression validates our findings with recently published HEC-1A mRNA 
expression data for these drug transporters. The ARV drugs Atazunauvir, Ritonavir, 
Lopinavir, Saquinavir and Emtricitabine have been identified as substrates for 
MRP1 and TFV and Zidovudine are substrates for MRP4 [138]. No expression of P-
gp, MRP2, MRP3 or MRP5 was detected by Western blotting. These findings were 
not consistent with quantitative analyses of mRNA encoding these transporters 
[148]. Lack of correlation between mRNA concentrations and protein expression 
may be due to several factors such as instability and turnover of mRNA or because 
levels of endogenous proteins were too low to be detected by Western blotting. 
Patterns of drug transporter expression vary along the FGT [151] and the 
endometrial epithelium-derived HEC-1A cell line may not reflect the pattern of 
expression of some transporters in vaginal or cervical epithelia. Expression of 
specific transporters by transfection of HEC-1A cells to improve the physiological 




The finding that pre-coating with either laminin or Matrigel® had little effect on barrier 
formation in HEC-1A cultures as determined by measurement of TEER has also 
been reported in other models [276, 277] and may reflect intrinsic production of 
extracellular matrix proteins [268]. Direct culture of HEC-1A cells on PE membranes 
with no addition of such proteins may provide a more standardised system to 
measure drug transport. 
The findings reported here that, HEC-1A cells in dual chamber cultures consistently 
form tight junctions to provide a barrier epithelium in a relatively short time 
(compared with the Caco-2 model), provide a rationale for its use as a model for bi-
directional drug transport studies. The ability to induce secretion of pro-inflammatory 
cytokines by TLR ligands and the pattern of transporter expression that 
approximates to that of the FGT further support the physiological relevance of this 
model. 
4.4.1 Limitations 
Interpretation of data from western blotting analyses of drug transporter expression 
was limited by the lack of positive controls. While the presence of bands in HEC-1A 
lysates probed with specific anti-drug transporter antibodies together with data from 
quantitative mRNA analyses is indicative of expression, absence of bands does not 
exclude expression. For P-gp, Caco-2 cell lysates provided a positive control and 
the lack of detectable protein in the HEC-1A lysate together with the lack of 
associated transporter function (described in Chapter 5) suggests strongly that P-gp 
is not expressed at significant levels in HEC-1A cells. Cells transfected with MRP2, 
MRP3 or MRP5 and lysates or membrane preparations are commercially available 
and would be appropriate controls for this study. 
The PAMP stimulation assays undertaken in this chapter provided preliminary data. 
While pro-inflammatory cytokines by TLR ligands were activated, further biological 
replicates would need to be completed to confirm the reliability of this particular 
dataset. Levels of cytokines that were induced in these studies, with the exception 
of IL-8 and IL-6, were significantly lower than those measured in vaginal fluid from 




Chapter 5 Determination of Tenofovir (TFV), Darunavir (DRV) 
and Dapivirine (DPV) transport across HEC-1A cell 
layers 
5.1 Aim 
To investigate the permeability properties of three ARV drugs in the HEC-1A dual 
chamber models described in Chapter 4. 
5.2 Introduction 
This chapter describes an investigation of the permeability properties of three ARV 
drugs in the HEC-1A dual chamber model described in Chapter 4. The study was 
performed as part of a collaborative project aimed at developing topically applied 
microbicides against HIV. Specific objectives of the project were to correlate in vitro 
and in vivo studies of drug distribution at vaginal and rectal mucosae and to develop 
formulations to optimise drug uptake at mucosal surfaces. The ARVs chosen for 
study in this project were those which had been most advanced along the 
development pathway as topical microbicides. TFV was selected because, at the 
time, it was the only ARV to have demonstrated efficacy in a clinical trial (as 
reviewed in Chapter 2). DPV had been extensively tested in both gel and 
intravaginal ring formulations in several phase I trials and plans for testing in phase 
III efficacy trials were well advanced. DPV has since shown significant efficacy in 
the ASPIRE and RING trials (also reviewed in Chapter 2). Protease inhibitors have 
not been investigated as extensively as other ARV classes for use as microbicides, 
in part, because they act post-integration. However macaque transmission studies 
have suggested that establishment of infection is dependent upon “broadcasting” of 
initial isolated mucosal foci of infection to disseminating lymph nodes and beyond 
[111]. Protease inhibitors may be ideally suited to prevent such secondary 
“broadcasting” leading to an aborted infection. DRV is a potent protease inhibitor 
with a high genetic barrier to resistance [279] and has recently been tested in a 
vaginal gel co-formulation with DPV in a phase I trial.  
In vitro drug permeability assays are useful methods to determine the PK properties 
of drugs. The assays can be optimised for the routine assessment of interactions 
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with drug transporters as well as barrier penetration. To measure the bi-directional 
permeability of the various ARV drugs, the optimised HEC-1A dual chamber model 
was used. The distribution of drug between the two compartments of the Transwell® 
system is a result of passive transcellular diffusion, paracellular diffusion, 
transporter-mediated absorption or transporter mediated secretion. While 
paracellular diffusion displays a linear rate of transport and symmetrical A-B/B-A 
permeability, transporter mediated transport is detected by asymmetry between the 
rate of transport in the A-B and B-A direction. 
Bi-directional drug transport assays across polarised epithelial cells are useful for 
detecting drug transporter activity, especially drug efflux. Drug efflux transporter 
activity can be identified by the detection of bi-directional differences in drug 
permeability. This method also provides drug accumulation analysis for each of the 
tested drugs. Based on data obtained in Chapter 4 and the general FDA/nature 
protocol guidelines [7, 233], the conditions shown in Table 5.1 were adopted for all 
drug permeability assays in this study. 
Table 5.1 Experimental data acceptance criteria. 
*Conditions based on our findings
**FDA and Nature protocol [7, 233]
HEC-1A seeded Transwells® with TEER values below 150 Ωxcm2 were not used for 
experiments. All drug transport experiments were undertaken with mannitol, this 
paracellular tracer molecule serves as a routine control for paracellular diffusion as 
well as a quantitative routine marker to assess barrier integrity (as described in 
Chapter 4). Therefore, Transwell® inserts in which mannitol permeability values 
exceeded 4x10-6 cm/s were not considered in any data analysis. Similarly, analyses 
were considered invalid if post TEER values deviated by more than 20% from pre 
A-B/B-A
Minimum TEER value (Ω x cm2) 150* 
TEER value as % deviation of initial 100±20** 
Cumulative flux linearity (r2) > 0.980**
Mannitol Papp (cm/s) < 4x10
-6* 
Solute recovery (%) 100 ± 15** 
122 
experiment value, flux linearity was less than an r2 value of 0.98 and total drug 
recovered was outside the range of 90-110% of the original quantity added to the 
donor chamber. All transport experiments were undertaken when HEC-1A cell 
layers had been cultured for a period of 6-10 days. All drug concentrations used in 
this study were within or above the EC50 values of each drug and did not exert a 
cytotoxic effect in vitro. 
5.2.1 Tenofovir, Darunavir and Dapivirine drug permeability across HEC-1A 
cell layers 
Previous drug formulation studies have used the HEC-1A model to measure the 
permeability and trans-cellular accumulation of TFV, DRV and DPV in the 
absorptive A-B direction only [136]. The permeation profiles of each drug were 
determined after 1 hour incubation when formulated in acidified HBSS (pH 4.2) 
diluted with vaginal fluid simulant (VFS) as the solvent in the apical compartment. 
DPV showed highest permeation with 20.8% detected in the receiver compartment, 
followed by permeation fractions of 10.1% for DRV and 1.85% for TFV suggesting 
that the more lipophilic drugs (DRV and DPV) permeated faster than the hydrophilic 
drug (TFV). Additionally, intracellular fractions were measured at <1% TFV, 3% 
DRV and 56% for DPV. 
5.2.2 Tenofovir, Darunavir and Dapivirine drug interactions with transporters 
expressed by HEC-1A and P-gp 
Of the three ARV drugs, analyses of drug transporter interactions with transporters 
expressed by HEC-1A have been reported only for TFV and DRV [177, 214]. 
Increased TFV accumulation was detected in MRP4-overexpressing MDCK cells in 
the presence of the MRP4 inhibitor MK571. TFV was selectively taken up by 
membrane vesicles prepared from insect cells transfected with MRP4. DRV was 
effluxed by the P-gp transporter when permeability was assessed across Caco-2 
monolayers. After 6 hours, approximately 20% of DRV from the donor compartment 
in the A-B absorptive direction was present in the basolateral compartment while in 
the B-A direction, 43% of donor DRV was detected in the apical compartment. P-gp 
inhibitors enhanced the A-B transport of DRV in Caco-2 cells providing further 
evidence that P-gp mediates efflux transport of DRV in the apical membranes of 
Caco-2 cells. 
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5.2.3 Drug-drug interactions 
As discussed in Chapter 2, development of microbicides combining more than one 
ARV may improve efficacy and present a higher barrier to the development of 
resistant strains of HIV. Drug interaction studies are fundamental for determining the 
PK of a particular drug when formulated as a combination or co-administered with 
other drugs. Drug-drug interactions can alter the PK properties of drugs or their 
metabolites. For the purpose of this study, which focuses on the pre-clinical 
assessment of topically applied microbicides that may include ARV co-formulations, 
it is essential to determine the PK interactions between each of the drugs. 
Alterations in metabolism or transport can completely change the safety and 
efficacy of a drug. Changes in parameters such as area under the curve (AUC), 
maximum blood plasma concentration (Cmax) and minimum blood plasma 
concentration (Cmin) can have detrimental effects on the body. Drug databases such 
as [280] provide useful information on HIV drug interactions. Currently no drug-drug 
interactions have been identified between TFV, DRV and DPV. 
5.3 Results 
5.3.1 Permeability of TFV in the dual chamber HEC-1A cell culture model 
Permeability of the hydrophilic ARV drug TFV was assessed in the HEC-1A barrier 
epithelium model described in Chapter 4. All assays were performed between days 
6-10 of culture corresponding to the period when TEER values remained at a
maximum. TEER values were measured before and after each assay and 
[3H]mannitol was included as a marker for the HEC-1A barrier integrity. Experiments 
were repeated at least 2 times and data represents all experiments. Bi-directional 
Papp values determined for [
14C]TFV concentrations ranging from 0.1-100 μM 
(prepared in HBBS+1%HEPES) across HEC-1A cell layers are shown in Figure 
5.1A. No significant differences (P ≥ 0.05, ANOVA) were evident in Papp values 
determined for A-B or B-A directions. In addition, Papp values (1-2x10
-6 cm/s) were 
similar at each concentration of TFV. Furthermore, the low rate of [14C]TFV 
movement across HEC-1A cell layers was similar to that measured for the 
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Figure 5.1 A-B/B-A permeability of different TFV concentrations and the percentage 
distribution of various TFV concentrations in the A-B direction. (A) A-B/B-A Papp TFV 
(B) A-B/B-A Papp mannitol (C) A-B TFV distribution in each compartment of the Transwell
®. 
Data represent mean ± S.D., n = 2-3 (4-6 technical repeats). 
The distribution of TFV at the end of the assay was determined in the absorptive (A-
B) direction within the apical, basolateral and intracellular compartments of the 





































































most drug was in the apical compartment (approximately 97%), 2-3% was detected 
in the basolateral compartment and less than 0.5% was detected intracellularly. The 
low permeability coefficient of 1-2x10-6 cm/s across the HEC-1A layers for TFV and 
extremely low intracellular accumulation is consistent with the transport 
characteristics of a molecule permeating via the paracellular pathway. Additionally, 
the efflux ratio value of approximately 0.8 for each concentration (shown in Table 







Table 5.2 Efflux ratio for each TFV concentration. Data represent mean ± S.D., n = 2-3 
(4-6 technical repeats). 
5.3.2 Permeability of DRV through HEC-1A model epithelium 
Permeability of DRV was also assessed in the HEC-1A model system. DRV is 
poorly soluble in aqueous buffer and 0.01% DMSO was included for solubilisation. 
Experiments were repeated at least 2 times and data represents all experiments. No 
effect of DMSO on TEER or permeability of mannitol was evident in these assays. 
Apparent permeability (Papp) values for [
14C]DRV (1-20 μM prepared in 
HBBS+1%HEPES+0.01% DMSO) are shown in Figure 5.2A. As for TFV, there were 
no significant differences (P ≥ 0.05, ANOVA) in Papp values determined for A-B or B-
A directions. Papp values (8-12x10
-6 cm/s) were again independent of DRV 
concentration. However, the rate of [14C]DRV permeation across HEC-1A cell layers 
was 9-10-fold higher than that measured for the paracellular tracer molecule 
[3H]mannitol (Figure 5.2B) and correspondingly higher than that of TFV.  
 Papp (x10
-6 cm/s) 
 A-B B-A 
Efflux ratio 
Papp (B-A)/Papp (A-B) 
TFV (0.1μM) 1.76 (0.15) 1.46 (0.15) 0.83 
TFV (1μM) 1.86 (0.15) 1.55 (0.07) 0.83 
TFV (10μM) 1.99 (0.16) 1.64 (0.11) 0.82 














Figure 5.2 A-B/B-A permeability of different DRV concentrations and the percentage 
distribution of various DRV concentrations in the A-B direction. (A) A-B/B-A Papp DRV 
(B) A-B/B-A Papp mannitol (C) A-B DRV distribution in each compartment of the Transwell
®. 
Data represent mean ± S.D., n = 2-3 (4-6 technical repeats). 
The distribution of DRV at the end of the assay was determined in the absorptive 
(A-B) direction transport within the apical, basolateral and intracellular 
compartments of the Transwell® system as shown in Figure 5.2C. For each of the 
DRV concentrations, the level of drug was highest in the apical compartment 






































































was detected intracellularly. The higher permeability coefficient of 8-10x10-6 cm/s for 
DRV when compared to that of [14C]mannitol and [14C]TFV, and higher 
accumulation in the basolateral compartment is consistent with the transport 
characteristics of a molecule permeating via the passive transcellular pathway. 
Additionally, the efflux ratio value of approximately 0.8-1 for each concentration 
(Table 5.3.) confirmed the transporter-independent permeability of DRV through 
HEC-1A cell layers. 
Table 5.3 Efflux ratio for each DRV concentration. Data represent mean (± S.D), n = 2-3 
(4-6 technical repeats). 
5.3.3 Permeability of DPV through HEC-1A model epithelium 
Permeability of the highly hydrophobic ARV drug DPV was also determined in the 
HEC-1A cell dual chamber model. Experiments were repeated at least 2 times and 
data represents all experiments. For solubilisation of DPV, DMSO (1% v/v) was 
included in the transport assay buffer. In preliminary experiments, the effect of 
DMSO on HEC-1A dual chamber cultures was investigated by determination of 
TEER and [3H]mannitol permeability. DPV at concentrations ranging from 1-20μM 





Papp (B-A)/Papp (A-B) 
DRV (1μM) 10.8 (1.21) 9.34 (0.50) 0.86 
DRV (5μM) 9.66 (0.91) 9.42 (0.39) 0.98 
DRV (10μM) 10.4 (0.43) 8.59 (0.55) 0.82 
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Figure 5.3 A-B/B-A permeability of different DPV concentrations and the percentage 
distribution of various DPV concentrations in the A-B direction. (A) A-B/B-A Papp DPV 
(***, P < 0.05) (B) A-B/B-A Papp mannitol (C) A-B DPV distribution in each compartment of 
the Transwell®. Data represent mean ± S.D., n = 2-3 (4-6 technical repeats). 
Figure 5.3A shows the effect of the 1% DMSO + DPV test solutions on HEC-1A cell 
layer integrity, by the measurement of Papp [
3H]mannitol. Following application of 
DMSO/DPV solutions in the apical chamber, Papp values for [
3H]mannitol 



















































epithelium. In contrast, application of the same solutions to the basolateral chamber 
resulted in statistically significant (P ≤ 0.05, ANOVA) increased secretory mannitol 
flux indicating some loss of barrier integrity. This was confirmed by the substantial 
decrease in post experimental TEER readings which showed a reduction of 60-70% 
when compared to the pre (initial) experimental TEER readings (Table 5.4). 
Consistent with mannitol permeability, application of 1% DMSO in the apical 
compartment did not affect TEER values post-assay which remained within 
100±15% of the initial TEER measurements. [14C]DPV absorptive permeability (A-B) 
was determined with Papp of 1-2x10
-6 cm/s irrespective of DPV concentration (Figure 
5.3B). The distribution of [14C]DPV in the absorptive direction was determined in 
each compartment. As shown in Figure 5.3C, for all concentrations, approximately 
80% of [14C]DPV was shown to accumulate intracellularly, while 15% remained in 
the apical compartment and 2% was in the basolateral compartment. This 2% 
accumulation in the basolateral compartment was similar to that detected for TFV, 
however unlike TFV, DPV partitions into the cell membranes. This is consistent with 
the characteristics of an extremely lipophilic molecule.   
 
Table 5.4 A-B/B-A [
3
H]mannitol Papp values and % of initial TEER in the presence of 
test solution containing various concentrations of 1% DMSO + DPV. In the A-B 
direction HEC-1A barrier integrity is stable. In contrast, loss of barrier integrity is detected in 
the B-A direction. Data represent mean ± S.D., n 2-3 (4-6 technical repeats). 
Since DPV could not be dissolved in solutions containing <1% DMSO further 
analyses of secretory permeability of the drug were not performed. Addition of 
amphiphilic compounds such as the surfactant poloxamer 407 in the receiver 
compartment increases flux of lipophilic compounds across model epithelium [281]. 















0.1μM DPV+HBSS+1%HEPES+1%DMSO 2.42±0.0 95-105  5.88±0.5 25-40 
1μM DPV+HBSS+1%HEPES+1%DMSO 2.38±0.0 96-103  6.14±0.7 30-42 
5μM DPV+HBSS+1%HEPES+1%DMSO 2.38±0.2 93-105  5.31±0.7 27-38 




Such compounds may partially mimic drug interactions with components on the 
basolateral side of the epithelium and improve transfer of lipophilic drugs. 










Figure 5.4 A-B permeability of different DPV concentrations and the percentage 
distribution of various DPV concentrations in the A-B direction. (A) A-B Papp DPV with 
poloxamer 407 in the receiver compartment (B) A-B Papp mannitol (C) A-B DPV distribution 
in each compartment of the Transwell®. Data represent mean ± S.D., n = 2-3 (4-6 technical 
repeats). 
Poloxamer 407 (0.2% w/v) was added to the basal chamber and absorptive 
permeability (A-B) of [14C]DPV was determined.  Under these conditions, higher Papp 






































































poloxamer (Figure 5.4A). No significant difference (P ≥ 0.05, ANOVA) in absorptive 
permeability was observed between the various DPV concentrations (addition of 
poloxamer 407 had no effect on permeability of the polar paracellular marker 
mannitol), (Figure 5.4B). 
The increased Papp correlated with the data shown in Figure 5.4C as poloxamer 407 
enhanced [14C]DPV permeability by an additional 10% into the basolateral 
compartment, reducing the amount of DPV in the cells to approximately 70%. 
Residual [14C]DPV in the apical (donor) chamber remained at 16%. Since DPV may 
absorb to the surfaces of the culture chambers, a series of permeability assays 
were performed with poloxamer 407 added to the basolateral compartment of 
Transwells® with and without HEC-1A cell cultures and the distribution of drug was 
determined as shown in Table 5.5. 
A-B DPV (HBSS+1%HEPES+1%DMSO) PE Transwell® Intracellular/Transwell® membrane 
DPV accumulation (%) 
With cells - poloxamer 407 in basolateral compartment 80 
With cells + poloxamer 407 in basolateral compartment 70 
Without cells + poloxamer 407 in basolateral compartment 10-20 
  
Table 5.5 Percentage of DPV that absorbs to the PE membrane material of the 
Transwell
® 
insert.  Data represent mean ± S.D., n = 2-3 (4-6 technical repeats). 
Table 5.5 indicates that of the 70-80% of [14C]DPV described as “intracellular” DPV 
accumulation, above, a significant proportion (10-20% of total) [14C]DPV is absorbed 
to the PE membrane material of the Transwell® insert. Thus of the 70% 
“intracellular” [14C]DPV recovered, approximately 50-60% is cell associated, 
presumably partitioned into cell membranes. 
5.3.4 Permeability of double drug combinations in the HEC-1A model system 
Microbicides comprising two or more ARVs may be more effective than those based 
on a single drug as discussed previously. An important requirement for combination 
microbicides is that there should be no detrimental binding competition between 
drugs to enter the cells ie. drug-drug interactions. The effects of drug combinations 




described below, a fixed concentration of 10 μM was used in test solutions for each 
drug. Permeability coefficients were determined for the double combinations. For all 
TFV+DRV combinations A-B/B-A transport was assessed and for DRV+DPV and 
TFV+DPV combinations A-B transport was assessed only.       
5.3.4.1  Permeability of 10μM [14C]TFV and combinations with DRV or DPV in 
the HEC-1A model 
To determine any drug-drug interactions between TFV and either DRV and DPV, 
the permeability of 10 μM [14C]TFV in the presence of varying concentrations of 
DRV and DPV was evaluated.  Drug transport assays were performed as described 
above but in the presence of unlabelled DRV or DPV (Figure 5.5A and 5.5B, 
respectively). Addionally, all combinations with DPV contained poloxamer 407 
(0.2% w/v) in all receiver (basolateral) compartments. 
The effect of the addition of DRV 0-10 μM or DPV 0-10 μM in double combinations 
with TFV was assessed. The double combinations of either [14C]TFV+DRV or 
[14C]TFV+DPV had no effect on [14C]TFV transport as there were no significant 
differences (P ≥ 0.05, ANOVA) in Papp coefficients (1-2x10
-6 cm/s) between drug 
combinations and controls of TFV alone. Additionally, HEC-1A exposure to test 
solutions containing TFV+DRV and TFV+DPV combinations had no effect on the 
barrier integrity, as mannitol permeability was consistent with maintenance of a 
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Figure 5.5 A-B and/or B-A permeability of 10μM [
14
C]TFV in the presence of various
DRV and DPV concentrations. (A) A-B/B-A Papp 10 μM [
14C]TFV in the presence of 0-10
μM DRV (B) A-B/B-A Papp [
3H]mannitol in the presence of 0-10 μM DRV (C) A-B/B-A Papp 10
μM [14C]TFV in the presence of 0-10 μM DPV (D) A-B/B-A Papp [
3H]mannitol in the presence
of 0-10 μM DPV. Data represent mean ± S.D., n = 2-3 (4-6 technical repeats). 
5.3.4.2 Permeability of 10μM [14C]DRV and combinations with TFV or DPV in 
the HEC-1A model 
To determine drug-drug interactions between DRV and either TFV and DPV, the 
permeability of 10 μM [14C]DRV in the presence of varying concentrations of 
unlabelled TFV or DPV was evaluated (Figures 5.6A and 5.6B). All combinations 





























































































C                                                                       D   
          
Figure 5.6 A-B and/or B-A permeability of 10μM [
14
C]DRV in the presence of various 
TFV and DPV concentrations. (A) A-B/B-A Papp 10μM [
14C]DRV in the presence of 0-100 
μM TFV (B) A-B/B-A Papp [
3H]mannitol in the presence of 0-100 μM TFV (C) A-B/B-A Papp 10 
μM [14C]DRV in the presence of 0-10 μM DPV (D) A-B/B-A Papp [
3H]mannitol in the presence 
of 0-10 μM DPV. Data represent mean ± S.D., n = 2-3 (4-6 technical repeats). 
The effect of including TFV 0-100 μM or DPV 0-10 μM in double combinations with 
DRV was assessed. The double combinations of either [14C]DRV+TFV or [14C]DRV 
+DPV had no effect on [14C]DRV transport as a Papp coefficients of 8-12x10
-6 cm/s 
were not significantly  different (P ≥ 0.05, ANOVA) in all combinations and in the 
control test solutions in which TFV and DPV were not present. Mannitol permeability 




























































































5.3.4.3 Permeability of 10 μM [14C]DPV and combinations with DRV or TFV in 
the HEC-1A model 
To evaluate drug-drug interactions between DPV and either TFV or DRV, the 
permeability of 10 μM [14C]DPV in the presence of varying concentrations of 
unlabelled TFV and DRV was evaluated (Figures 5.7A and 5.7B).  








C                                                               D 
                                                                 
Figure 5.7 A-B permeability of 10μM [
14
C]DPV in the presence of various TFV and DPV 
concentrations. (A) A-B Papp 10 μM [
14C]DPV in the presence of 0-100 μM TFV (B) A-B 
Papp [
3H]mannitol in the presence of 0-100 μM TFV (C) A-B Papp 10 μM [
14C]DPV in the 
presence of 0-10 μM DRV (D) A-B Papp [
3H]mannitol in the presence of 0-10 μM DRV. Data 


























































































The effect of including DRV (0-10 μM) or TFV (0-100 μM) in double combinations 
with DPV was assessed. The double combinations of either [14C]DPV+DRV or 
[14C]DPV+TFV had no effect on [14C]DPV transport as a Papp coefficients of 10-
14x10-6 cm/s were similar in all combinations as well as the control test solutions in 
which DRV and TFV were not present. Small increases in DPV Papp coefficients 
were obtained in these assays compared with those reported above, however, the 
values for the control test solutions were also raised confirming that this was not 
influenced by the presence of either DRV or TFV. Mannitol permeability again 
remained consistent in both combination test solutions with Papp values in the range 
of 2-3x10-6 cm/s. 
5.3.5 Transfection and transient expression of P-gp in HEC-1A cells 
DRV is a substrate for the P-gp efflux transporter [214] which is expressed in the 
FGT [145, 146, 149] although expression could not be detected in HEC-1A cells. To 
improve the physiological relevance of this model to assess permeability across 
cervicovaginal epithelium, transient expression of P-gp was investigated by 
transfection of HEC-1A cells with the plasmid pcDNA-Pgp encoding the entire P-gp 
protein. In preliminary experiments, HEC-1A cells were transfected, pooled and 
used to seed Transwell® cultures. After 6 days, when TEER values reached a 
maximum, cells were harvested and lysed for analysis of P-gp expression by 
Western blotting. 
Lysates of HEC-1A cells (transfected and non-transfected) and from Caco-2 cells 
(which express P-gp constitutively) were resolved by SDS-PAGE, transferred to 
nitrocellulose filters and probed with anti-P-gp antibody. As shown in Figure 5.8, 
diffuse bands corresponding to the expected molecular weight of 141 KDa were 
evident in lysates from Caco-2 cells and transfected HEC-1A cells but not in lysates 
from non-transfected HEC-1A cells. The total protein loaded on the gel was 
equivalent for all lysates (40 μg) thus the level of P-gp expression in transfected 
HEC-1A cells appears to be similar to that in Caco-2 cells. P-gp has three 
glycosylated isoforms and so the diffuse nature of the band may reflect these. In 





Figure 5.8 Expression of P-gp in transfected HEC-1A cells and Caco-2 cells. Cell 
lysates were prepared, samples (40 μg total protein in each well) were loaded and separated 
by SDS-PAGE. Proteins were transferred electrophoretically to nitrocellulose membranes 
and probed with an anti-P-gp specific antibody to the P-gp drug transporter. Diffuse bands 
were detected in two samples of transfected HEC-1A cells (HEC-1A/P-gp). Caco-2 cell 
lysates served as a positive control. In contrast, non-transfected HEC-1A cells served as a 
negative control.   
5.3.6 Permeability of the P-gp substrate 10 μM [3H]digoxin the HEC-1A/P-gp 
model 
Activity of the P-gp transporter expressed in HEC-1A cells was investigated by 
performing permeability assays in parallel cultures with 10 μM digoxin, a well-
characterised substrate for P-gp [214]. As shown in Figure 5.9A, Papp values for 
[3H]digoxin were similar for both absorptive and efflux permeation and no effect of 
P-gp transport was evident. Formation of tight junctions was demonstrated both by 
TEER and the limited permeability to [14C]mannitol (Figure 5.9B). Transport assays 
were performed with Caco-2 Transwell® cultures in parallel where P-gp activity was 
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Figure 5.9 A-B/B-A permeability of the P-gp substrate 10 μM [
3
H]digoxin across non-
transfected and transfected HEC-1A cell layers. A-B/B-A permeability of [14C]mannitol. 
No differece in digoxin permeability was determined between transfected and non-
transfected HEC-1A cells. Data represent mean ± S.D., n=1 (3 technical repeats). 
5.3.7 Modelling inflammation in HEC-1A Transwell® cultures and effect on TFV 
and DRV drug perembaility. 
HEC-1A cells cultured in Transwells® were stimulated at the apical surface with the 
TLR 3 agonist Poly I:C for 18-24h as described in Chapter 4. Aliquots of culture 
media from both apical and basolateral compartments were analysed for production 
of inflammatory cytokines as also described in Chapter 4. As shown in Figure 5.10, 
high levels of IL-8 and IL-6 were secreted together with high concentrations of TNF-
α and GM-CSF and lower concentrations of IL-1α. IL-1β was not detected. Levels of 
cytokines were consistent with those published previously in studies of in vitro 
cytokine production from immune cells [282]. Low levels of TNF-α and GM-CSF 
were measured in unstimulated HEC-1A cell cultures but no other cytokines were 
detected in these cultures. For all cytokines except IL-8, secretion appeared to be 









































Figure 5.10 Stimulation of HEC-1A cultures in Transwells
®
 by Poly I:C. Patterns of IL-
1α, IL-1β, IL-6, GM-CSF, TNF-α and IL-8 release into A-apical and B-basolateral 
compartments containing culture supernatants of HEC-1A epithelial cells cultured in 
Transwell® inserts and treated for 24 hours with 25 μg/ml of Poly I:C. Cytokines were 
determined by Multiplex bead immunoassay. Mean secretion-blank are shown n=1 (3 
technical repeats).  
The effects of Poly I:C stimulation on permeability of TFV and DRV were assessed 
in the same cultures. Apparent pereability values for 10 μM [14C]TFV and [14C]10 μM 
DRV are shown. Figure 5.11A indicates that there were no significant differences (P 
≥ 0.05, ANOVA) in Papp values determined for A-B or B-A directions for TFV and 
DRV when compared to the permeability across unstimulated HEC-1A cell layers. 
The Papp values for TFV were approximately 1x10
-6 cm/s when cells were 
unstimulated and 1.4x10-6 cm/s when cells were stimulated. Additionally DRV Papp 
was approximately 8x10-6 cm/s for both, when cells were stimulated and 
unstimulated. The paracellular tracer molecule mannitol further confirmed that there 
were no significant (P ≥ 0.05, ANOVA) effects of Poly I:C stimulation on barrier 
integrity as [3H]mannitol Papp values for stimulated cells were 1.5-1.9x10
-6 cm/s and 






































H]mannitol permeability across Poly I:C
stimulated and unstimulated HEC-1A cell layers. (A) A-B/B-A [14C]TFV and [14C]DRV 
permeability across HEC-1A stimulated and unstimulated HEC-1A cell layers, with no 
significant differences (P ≥ 0.05) of Papp values. (B) A-B/B-A [
14C]mannitol permeability
across HEC-1A stimulated and unstimulated HEC-1A cell layers, again with no significant 
differences (P ≥ 0.05, ANOVA) of Papp values. n=2, data represent mean ± S.D., from 1 
experiment (3 technical repeats). 
5.4 Discussion 
The major findings from this part of the work are that permeation of each drug 
across the HEC-1A model epithelium is transporter-independent. TFV permeates 
across HEC-1A cell layers by paracellular diffusion, while DRV and DPV both 
permeate by diffusion across the transcellular route. Intracellular accumulation was 
highest for DPV as reported previously [136] whereas intracellular accumulation 
was substantially lower for DRV and TFV. Bi-directional permeability of single drugs 
was compared with double drug combinations and no drug-drug interactions were 
detected.  
For the studies reported here, permeability was determined in both absorptive and 











































indicate the effects of drug transporters. In contrast, previous studies have reported 
TFV permeability in the absorptive (A-B) direction only [136, 199, 283]. The Papp 
values for TFV in both directions determined in this study (1-2x10-6 cm/s) are in 
good agreement with those reported previously for TFV permeability through HEC-
1A dual chamber cultures [136] and through human ectocervical explants [283] 
pointing to the consistency and physiological relevance of this model. Bi-directional 
permeability was also demonstrated in the human ectocervical polarised explant 
model by a functional assay in which basolateral application of TFV prevented 
infection of the tissue following apical challenge with HIV [199]. 
The distribution of TFV between donor, intracellular and receptor compartments 
reported here is also consistent with those reported previously [136] of 
approximately 2% in the basolateral (acceptor) compartment and negligible 
quantities in the intracellular compartment. Drug concentrations in tissue were not 
reported for permeability studies of 1% TFV gel formulations using ectocervical 
explants but TFV recovered in the basolateral compartment was estimated to be 
approximately 2-5% or 5-10% (with different formulations) of the input dose [199]. 
The TFV gel formulation that resulted in 2-5% permeation was that used in the 
CAPRISA 004 trial [2] but extrapolation to in vivo administration of TFV gel may also 
require estimation of drug loss due to discharge of vaginal fluid. Vaginal tissue 
concentrations of TFV 24 hours after dosing with the vaginal gel (total dose of 40 
mg TFV) following the CAPRISA 004 trial regime, were reported to be in the range 
of 103 - 104 ng/g or approximately 3.5-35 μM [284] compared with the in vitro tissue 
EC50 of 0.2-8.5 μM [195, 198-200]. 
The efflux ratio for TFV was close to 1 and both absorptive and efflux Papp values for 
TFV were similar to those of the paracellular marker, mannitol, consistent with 
transfer across the epithelium by paracellular diffusion. No efflux of TFV mediated 
by MRP4 was evident. In a connected study, within the collaborative project, 
permeability of TFV was also assessed in the Caco-2 Transwell® system and again 
no effect of MRP4 was evident [Swedrowska et al, personal communication; 
manuscript submitted for publication). Additionally, activity of uptake and efflux 
transporters expressed in the cervicovaginal epithelium is yet to be reported. 
DRV displays a bi-directional Papp coefficient in the range of 8-12x10
-6 cm/s and an 




independent. While DRV has been reported to be a substrate for P-gp [214], HEC-
1A cells do not naturally express P-gp (as identified in Chapter 4). DRV exhibits low 
A-B HEC-1A intracellular accumulation of 1-2% and basolateral accumulation of 
15% of drug from the donor compartment. With a log P of 1.80, DRV has low 
solubility in aqueous buffers but does not show the properties of a highly lipophilic 
drug as evident from its low intracellular HEC-1A accumulation. The data here 
suggests that DRV freely permeates through HEC-1A cell layers via passive 
diffusion without binding to lipids within cell membranes. In areas of the vagina with 
low, inactive or no expression of P-gp, DRV may freely permeate into the sub-
epithelium. In contrast, although DPV shares a similar basolateral accumulation 
value to DRV (in the presence of poloxamer 407), the much higher intracellular 
accumulation (50%) reflects the difference in lipophilicity between the two drugs. 
The low absorptive Papp of DPV is consistent with partition and accumulation of 
(uncharged drug) at high levels in the membrane compartment of epithelial cells. 
Such accumulation has also been shown in vaginal epithelial tissue following 
vaginal administration in rabbit and macaque models [100].  
Drug permeability in this study was assessed at pH 7.4 whereas healthy vaginal pH 
is 3.5-4.5 [102]. Further work should include repeating the assays at lower pH. In 
preliminary experiments, exposure of the HEC-1A dual chamber cultures to low pH 
led to significant reductions in TEER (data not shown) and has also shown to 
reduce TEER in Caco-2 cells [146]. Furthermore the correspondence between the 
findings reported here and those described previously [136] where assays were 
performed at pH 4.2, indicate that the transporter-independent permeation shown by 
these drugs is not altered within this pH range. The more lipophilic drugs DRV and 












) in this pH range. 
When formulated in double combinations, TFV, DRV and DPV do not show 
evidence of incompatibility with regard to solubility although solubilising excipients 
such as DMSO are required for both DPV and DRV. The presence of the surfactant 
poloxamer 407 in all combination test solutions which contained DPV did not have 




identified, as Papp coefficients for each of the drugs showed similar values when 
compared as single and double formulations.  
To investigate the effects of inflammation on drug permeability, HEC-1A cell layers 
were stimulated with the TLR ligand Poly I:C. Levels of pro-inflammatory cytokines 
were comparable to those previously reported to reduce maintenance of tight 
junctions (as discussed in Chapter 4) although no reduction in TEER or increase in 
mannitol permeability was evident in these studies. In future work, longer term 
stimulation may be necessary. Studies of the effects of inflammation on expression 
of drug transporters generally focus on intestinal, hepatic, or placental transporters 
and data for the female reproductive tract are not available. In inflamed tissue of 
duodenal biopsies from patients with ulcerative colitis, the expression of P-gp and 
BCRP efflux transporters is reduced as compared to non-affected mucosa or normal 
controls [285]. In colon biopsies from patients with ulcerative colitis, mRNA levels of 
the nucleoside transporters ENT1, ENT2 (SLC29 family), and CNT2 (SLC28) were 
significantly increased as were mRNA levels of the organic anion transporters 
OATP2B1, OATPE (SLCO), and OCTN1 (SLC22) [286]. The net effect of these 
changes has not been determined although reduction in efflux transporters could 
lead to higher tissue levels of topically applied drugs. 
In any case, inflammation may not have detrimental effects on uptake of the drugs 
studied here. Any reduction of tight junction function may lead to increased 
permeability of TFV. In addition, permeability of DPV and DRV requires partition into 
lipophilic compartments and may not be compromised in an inflammatory 
environment. 
In studies involving heterologous overexpression of the efflux transporter MRP4 in 
mammalian or insect cell lines, TFV was identified as a substrate for MRP4 [177]. 
As above, no effect of MRP4 was evident either in the HEC-1A model or in Caco-2 
Transwell® cultures. This may simply reflect low intracellular uptake of TFV since 
organic anion transporters OAT1 and OAT3 identified as uptake transporters for 
TFV [287] are not expressed in HEC-1A cells [206]. To model more closely 
transporter expression of the FGT, transient expression of P-gp in HEC-1A cells 
was investigated. Expression of P-gp in transfected HEC-1A cells was comparable 
to that in constitutively-expressing Caco-2 cells, however, in contrast to Caco-2, no 
P-gp transport activity could be detected in transfected HEC-1A cells. The simplest 
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explanation is that P-gp was not correctly folded, however, this result may also 
reflect differences in the nature of intestinal and cervicovaginal epithelial cells. 
Several tissue dependent post-translational modifications of transporter proteins 
may be critical for transporter activity [288]. Moreover, the vaginal epithelium, in 
contrast to the intestinal mucosa, is not regularly exposed to xenobiotics, especially 
in the form of ingested drugs. The continuous efflux activity of these transporters 
that prevent the absorption of foreign material into the bloodstream may result in a 
state of higher activation of transporters in intestinal derived cells such as Caco-2 
and MDCK lines compared with HEC-1A.  
The findings from the work described here have some implications for vaginal 
administration of ARV-based microbicides. TFV can readily access sub-epithelial 
cells by paracellular diffusion. Although the proportion that diffuses is relatively low 
(approximately 2% of total input in these studies), a higher sub-epithelium dose can 
be achieved simply by increasing the dose of TFV with no requirement to include 
inhibitors of specific efflux transporters. Moreover, potential “loss” of drug in the 
epithelium does not occur as the proportion of TFV that enters epithelial cells is very 
low. For DRV, transcellular diffusion is relatively efficient again with low levels of 
drug remaining in the intracellular compartment. For higher doses solubilising 
excipients may be required although inclusion of such excipients has been shown to 
decrease permeability by increasing the affinity of the drug for the donor 
compartment [136]. DPV is readily taken up by the model epithelium but remains 
cell associated. Physiologically, it may transfer to sub-epithelial cells that make 
close contact at the basolateral surface or be transferred as a complex with proteins 
or other solubilising moieties. DPV may also partition directly into the HIV 
membrane during transmission through the mucosal epithelium. The results of the 
RING and ASPIRE phase III trials of DPV formulated as intravaginal rings confirm 
that effective levels of drug permeate the epithelium to access sub-epithelial cells 
[6]. 
5.4.1 Limitations 
Cytotoxicity assays were not undertaken to determine cell viability in the drug 
permeability assays although TEER values were recorded to assess the barrier 
properties of the cell cultures. Various studies have demonstrated strong correlation 
of TEER with cell viability [289-291] with some suggesting that TEER may be a 
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more sensitive measure of cell cytoxicity than conventional assays [292]. 
Nonetheless, in future work some determination of cellular cytotoxicity in parallel to 
TEER measurement should be performed. 
No effect of PAMP stimulation of HEC-1A cells on drug permeability was evident. In 
view of the relatively low levels of inflammatory cytokines and chemokines (as 
discussed in Chapter 4), direct addition of cytokines and chemokines at higher 
concentrations should be considered in further work. In addition, since the effects of 
IL-8 may be indirect and mediated by activated macrophages or dendritic cells, co-
culture with these cell types should be investigated. 
Expression of P-gp following transfection of HEC-1A cells was demonstrated by 
western blotting, however, P-gp activity was not detected in transport studies. 
Transfection of other cells (both epithelial and non-epithelial) should be performed 
to investigate whether activity is influenced by the cellular environment.  
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Chapter 6 Investigation of alternative cellular and tissue-
based models for drug permeability analysis 
6.1 Aim 
To compare drug permeability in different models including ex vivo epithelial tissue. 
6.2 Introduction 
HEC-1A cell layers provide a useful model to determine drug transport across the 
cervicovaginal epithelium as discussed in Chapters 4 and 5. Nonetheless, 
alternative approaches have been used to determine drug permeability across 
tissue. In vitro models have been developed that mimic the vaginal epithelium 
including three-dimensional (3D) organotypic tissue and ex vivo (animal or human) 
excised mucosae.  
The work described in this chapter assesses drug permeability using one in vitro 
model and one ex vivo model. The EpiVaginal™ model developed by MatTek 
Corporation (Ashland, MA, USA), is an organotypic 3D vaginal tissue model formed 
by culture of primary epithelial cells with or without fibroblasts from women 
undergoing hysterectomy [293]. The second model is to use excised vaginal tissue 
from adult rats and macaques. Tissues are mounted on custom-made Ussing 
diffusion chambers (Figure 6.2).  
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Figure 6.1 Histology of the vaginal epithelium. Comparison of the morphological 
characteristics of the vaginal epithelium between (A) Human (B) Macaque (C) Rat (D) 
MatTek Epivagina™. All tissue types represent an epithelial layer resting on a submucosal 
lamina propria. Images (A,B,D) [294] and image (C) [295]. 
6.2.1 The MatTek EpiVaginal™ tissue model 
Although this primary cell-based model was initially developed for vaginal irritation 
assays and vaginal pathogen transmission assays such as HIV transmission, 
various reports have described the use of the EpiVaginal™ tissues for assessing 
drug permeability [296, 297]. The EpiVaginal™ models investigated in this study 
were the VEC-100-PT (partial thickness), containing epithelial cells only and the 
VEC-100-FT (full thickness) that also includes primary fibroblasts as well as the 
primary epithelial cells. Previous studies reported the use of the VEC model for 
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permeability studies [296, 297]), presumably due to the morphological similarities to 
the epithelial layer of the cervicovaginal epithelium. The VEC Epivaginal™ model is 
formed by culture of primary ectocervical epithelial cells in a process that involves 
exposure at the air-liquid interface to produce a non-keratinised, multi-layered 
epithelium that can be used in a dual chamber system [293, 298]. 
6.2.2 Ex vivo models and Ussing diffusion chambers 
An alternative approach to determine drug permeability, involves the use of mucosal 
tissues excised from animals which may better represent in vivo tissue by 
preserving native tissue architecture and normal healthy tissue processes. Typical 
permeability experiments involve mounting of the excised cervicovaginal tissue 
between two Ussing chambers (Figure 6.2) which is especially designed to provide 
exposure to a small area of the animal tissue (0.2 cm2). The rate of permeability will 
be directly correlated to the surface area of tissue exposed to media. The diffusion 
system is composed of two glass chambers (apical and basolateral) that are 
separated by the mounted tissue. A continuous supply of oxygen and carbon 
dioxide is supplied to the tissue. Drug test solutions are added to the donor chamber 
and samples are taken for both chambers subsequently. After the final time point 
sampling, the tissue can be collected to determine tissue accumulation of drug. 
Similar to the permeability studies in Chapter 5, the data acceptance criteria for 
these experiments were: flux linearity r2 must be >0.98 and total drug recovery must 
be within the range of 80-120% of the original quantity added to the donor chamber. 
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Figure 6.2 Schematic representation of a small piece of tissue mounted between 
Ussing chambers. The Ussing chamber system includes a heat block in which the 
chambers are mounted on as well as tubing connectors for the O2 and CO2 supply into the 
test solution and across the tissue.   
6.2.3 Drug transporter expression in tissue-based models 
Ideally, in vitro models for drug permeability should be well characterised with 
regard to expression of drug transporters. No studies that characterise drug 
transporters in the rat vagina appear to have been reported. In macaques, 
expression of the efflux transporters P-gp, MRP4 and BCRP has been 
demonstrated by quantitative PCR and by immunohistochemistry in endocervical, 
ectocervical and vaginal tissues [151]. A more systematic study of drug transporter 
expression in the macaque was performed as part of the collaborative MOTIF 
project and demonstrated a similar pattern of expression compared with human 
cervicovaginal tissue although some differences including expression of CNT2 and 
ENT2 in macaque but not human tissue (K. Hijazi, personal communication, 
unpublished data). Since the data from Chapter 5 demonstrate that permeability of 
the drugs investigated in this thesis, in vaginal tissue may be transporter-
independent, full characterisation of transporters in the models used here may be of 
less importance. Nonetheless, characterisation of transporter expression in the 
Epivaginal™ models was performed as were permeability assays in rat and 





6.3.1 Quantitative mRNA analyses of expression of transporters in the 
EpiVaginal™ model 
Permeability of DRV and TFV was measured in the Epivaginal™ model. Before 
these studies, expression of drug transporters was investigated in the VEC-100-PT 
and VEC-100-FT primary cell-based models for comparison with expression profiles 
of HEC-1A cells and human vaginal tissue. Total RNA from each model was 
converted to cDNA and levels of mRNA encoding 9 ABC efflux transporters and 11 
uptake drug transporters were assessed by quantitative PCR using the TaqMan 
PCR Array Human Drug Transporters system. The data presented in Table 6.1 are 
compared with data from previous studies of expression in HEC-1A cells and 
human vaginal tissue [206]. Expression profiles in VEC-100-PT and VEC-100-FT 
were similar apart from lower expression of OATP-D in the VEC-100-PT model. 
Expression of ABC and SLC transporters in both EpiVaginal™ models was also 
similar to that in HEC-1A cells [206] with 15 transporters in common. Three 
transporters (BCRP, PEPT1, and CNT3) were expressed in Epivaginal™ models 
but not in HEC-1A cells. Conversely, three transporters (MRP6, OATP8, and OCT1) 
were expressed only in HEC-1A cells.  
Comparison with the data from human vaginal tissue indicates that for both models 
there are a few significant differences in transporter expression compared with 
human cervicovaginal tissue. Epivaginal™ cultures of primary cells more closely 
resemble human tissue with regard to expression of BCRP, PEPT1 and CNT3 and 
similar levels of expression of MRP3, MRP4 and MCT1. In contrast, the HEC-1A 
model is more suitable for assessing permeability of drugs that are substrates for 








 Gene expression level 
 Cell-based models  Tissues 
Transporter 
HEC-1A 
[206]       










P-gp + + +  ++ + ++ 
BCRP - + +  ++ + ++ 
MRP1 ++ ++ ++  ++ + ++ 
MRP2 + + +  + - - 
MRP3 ++ + +  + + - 
MRP4 ++ + +  + + - 
MRP5 ++ ++ ++  ++ ++ ++ 
MRP6 + - -  + - - 
MRP7 + ++ ++  + + ++ 
OATPD + + ++  + + ++ 
OATPE ++ ++ ++  + + ++ 
OATP8 + - -  + + - 
ENT1 ++ + ++  ++ ++ ++ 
ENT2 ++ + +  + - - 
OCT1 +  - -  + - - 
OCT3 + + +  ++ + ++ 
PEPT1 - ++ ++  + + ++ 
PEPT2 + ++ ++  + ++ - 
CNT3 - ++ ++  + + - 
MCT1 + ++ ++  ++ + + 
Table 6.1 Expression of drug transporter genes. ABC and SLC drug transporters in VEC-
100 partial (PT) and full thickness (FT) MatTek Epivaginal™ models and as reported 
previously [206] for the HEC-1A cell line and human vaginal tissue. Data were calculated as 
Ct(control gene)/Ct(target gene). Values obtained correspond to ratio ranges of <0.65 as -; 
0.65-0.80 as +, 0.81-1 as ++ and >1 as +++. n=1 (3 technical repeats). 
6.3.2 MatTek Epivaginal™ barrier properties  
Drug permeability was measured in the EpiVaginal™ VEC-100-PT model of vaginal 
epithelium only. All assays were performed on the day after receiving the tissue, 
allowing for overnight recovery by incubation in recovery culture medium (supplied 
by MatTek) at 37°C. The barrier properties of the model epithelium were assessed 
by bi-directional permeability of the paracellular tracer [3H]mannitol as described in 
Chapter 4. As shown in Figure 6.3. paracellular [3H]mannitol fluxes across the 
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EpiVaginal™ were similar in both absorptive and secretory directions with Papp 
values of 3-5x10-6 cm/s. In control inserts with no cells, Papp values were 10.8x10
-6 
cm/s (data not shown). Thus the EpiVaginal™ model has some barrier function 
although the Papp values for mannitol in the A-B direction were 4-5x10
-6 cm/s which 
were higher than those observed in the HEC-1A model (2-4x10-6), (Chapter 4), 
indicating a more leaky barrier epithelium.  
Figure 6.3 Bi-directional permeability of [
3
H]mannitol across the MatTek Epivaginal™
primary cell-based model. Assays were conducted at 37°C over a 2 hour period. Data 
represent mean ± S.D. n=1 (3 technical repeats).  
6.3.3 Effect of PAMP stimulation in the EpiVagina™ model 
To investigate the potential for modelling inflammation in the EpiVaginal™ model, 
cultures were screened against a panel of 5 PAMPs that stimulate different TLRs to 
identify those that most potently stimulated production of pro-inflammatory 
cytokines. Medium from both apical and basolateral compartments was collected 
and analysed by Multiplex bead based immunoassay to determine the 
concentrations of 6 pro-inflammatory cytokines (Figure 6.4). Strikingly, in 
unstimulated Epivaginal™ cultures, high levels of IL-1α, IL-1β and IL-8 were 
measured in the culture medium. The concentration of IL-8 was comparable to that 
of Poly I:C stimulated HEC-1A cultures as reported in Chapter 5 while the 
concentrations of IL-1α and IL-1β were much higher than those of Poly I:C 
stimulated HEC-1A cultures. The high concentrations of these cytokines may 
account for reduced barrier function of the Epivaginal™ model compared with HEC-
1A dual chamber cultures. Stimulation with the TLR5 agonist, flagellin (FLA) and the 























TNF-α. A small increase in IL-6 production was also evident following stimulation 
with FSL-1 but these values are at least 10 fold lower than those of stimulated HEC-
1A cultures. LPS, LTA and imiquimod were not screened; nonetheless when 
exposed to HEC-1A cell layers they did not stimulate any TLRs (Chapter 4.3.4). 
 
Figure 6.4 PAMP stimulation of pro-inflammatory cytokines in the Epivaginal™ model. 
Epivaginal™ tissues were stimulated with each PAMP at a single concentration (50 μg/ml) 
and production of selected cytokines was determined by Multiplex bead immunoassay. n=1. 
(2 technical repeats). 
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6.3.4 Bi-directional permeability of Tenofovir (TFV) through MatTek 
Epivaginal™ model epithelium 
Permeability of the hydrophilic ARV drug TFV was assessed in the Epivaginal™ 
model over a 2 hour period. [3H]mannitol was included as a marker for integrity of 
the epithelial barrier. Bi-directional apparent permeability (Papp) values determined 
for 10 μM [14C]TFV across the EpiVagina™ are shown in Figure 6.5A. Papp values 
(2-4x10-6 cm/s) were similar in both A-B and B-A directions. The rate of [14C]TFV flux 
across the EpiVaginal™ was slightly lower than that measured for the paracellular 
tracer molecule [3H]mannitol 3-5x10-6 cm/s (Figure 6.3) which was measured in 
parallel in the same experiment.  
A  B 
Figure 6.5 TFV permeability and distribution in the EpiVaginal™ model. (A) A-B and B-
A apparent permeability (Papp) of TFV across the EpiVagina™. (B) % distribution of TFV in 
each compartment of the EpiVagina™ “transwell” system. Data represent mean ± S.D. n=1 
(3 technical repeats). 
The distribution of TFV at the end of the assay was determined in the A-B direction 
within the apical, basolateral and intracellular compartments of the “‘transwell’ and is 
shown in Figure 6.5B. The highest proportion of the drug was present in the apical 
compartment (approximately 94%), 4% was detected in the basolateral 
compartment and 1-2% was detected intracellularly. Additionally, the ER value of 
approximately 0.8 (Table 6.2) for TFV confirmed the transporter-independent 

















































Table 6.2 Efflux ratio (ER) of TFV. Data represent mean ± (S.D.), n=1 (3 technical 
repeats). 
6.3.5 Bi-directional permeability of Darunavir (DRV) through MatTek 
Epivaginal™ model epithelium 
Permeability of DRV was also assessed in the EpiVaginal™ model. DRV was 
solubilised in the transport buffer containing 0.01% (v/v) DMSO. Apparent 
permeability (Papp) values for [
14C]DRV 10 μM are shown in Figure 6.6A. As for TFV, 
there were no significant (P ≥ 0.05, ANOVA) differences in Papp values determined 
for A-B and B-A directions. Average Papp values were in the range 2-4x10
-6 cm/s and 
were comparable to those for mannitol. These values were lower than those 
determined in the HEC-1A system as reported in Chapter 5. The Papp [
3H]mannitol 
(3-5x10-6) was measured in parallel in the same experiment (Figure 6.3). 
A                                                          B 
            
Figure 6.6 Figure 6.6 DRV permeability and distribution in the EpiVaginal™ model. (A) 
A-B and B-A apparent permeability (Papp) of DRV across the EpiVagina™. (B) % distribution 
of DRV in each compartment of the EpiVagina™ “transwell” system. Data represent mean ± 
S.D. n=1 (3 technical repeats). 
The distribution of DRV was determined in the absorptive (A-B) direction of 











































    
  Papp (x10
-6 cm/s)  Efflux ratio 
 A-B B-A  Papp (B-A)/Papp (A-B) 
TFV (10μM) 3.28 (1.21) 2.72 (0.50)  0.83 
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EpiVagina™ “transwell” system. The highest amount of DRV was in the apical 
(donor) compartment (approximately 84%), 3% was detected in the basolateral 
compartment and 13% was detected intracellularly.  
Table 6.3 Efflux ratio (ER) of DRV. Data represent mean ± (S.D.), n=1 (3 technical 
repeats). 
Moreover, the efflux ratio value of approximately 1.20 (Table 6.3) for DRV also 
confirmed the transporter-independent permeability of DRV through EpiVaginal™ 
tissue. 
6.3.6 Permeability of Darunavir (DRV) through Rat cervicovaginal tissue 
Permeability of DRV was also assessed in ex vivo rat tissue. Because quantities of 
tissue were limited, these studies could be performed with one drug only. DRV was 
selected due to its reported affinity for the efflux transporter P-gp, as observed in the 
Caco-2 model (discussed in Chapter 5). Bi-directional permeability of DRV was 
assessed across rat cervicovaginal epithelium. Excised vaginal tissues from two 
adult female rats were used as tissue-based models to determine DRV permeability. 
Excised tissue was stripped of any muscle layers prior to placement between the 
apical (donor) and receiver glass chambers of the Ussing system. Tissue from a 
single rat was sufficient for 4 sets of chambers. This allowed analyses in duplicate 
of both A-B and B-permeability. Samples were taken over a 1 hour period at 37°C. 
Tables 6.4 and 6.5 show the A-B and B-A permeability of DRV through individual 
segments of cervicovaginal tissue from 2 rats. 
There was considerable variability in the data. [3H]mannitol Papp values ranged 
between 2-8x10-6 cm/s (Tables 6.4 and 6.5) in tissues from the same or different 
animals. Results are shown as individual data rather than grouping and averaging 
data from each animal. Increased [3H]mannitol Papp provided a correlation with 
Papp (x10
-6 cm/s) Efflux ratio 
A-B B-A Papp (B-A)/Papp (A-B) 
DRV (10μM) 2.74 (0.14) 3.28 (1.67) 1.20 
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[14C]DRV Papp, as [
14C]DRV Papp also increased. This was observed in rat 1 tissues 
2 and 3 (Table 6.4) and rat 2 tissues 1, 3 and 4 (Table 6.5).  
Rat 1 A-B Drug distribution (%) 
Tissue 1 Tissue 2 Tissue 1 Tissue 2 
Papp Mannitol 3.80 7.95 Apical 97.40 94.15 
Basolateral 0.80 3.61 
Tissue 1.80 2.24 
Papp DRV 2.14 10.01 Apical 91.76 88.89 
Basolateral 2.33 5.36 
Tissue 5.90 5.75 
Papp B-A % Drug distribution 
Tissue 3 Tissue 4 Tissue 3 Tissue 4 
Papp Mannitol 7.63 - Apical 3.05 - 
Basolateral 95.10 - 
Tissue 1.85 - 
Papp DRV 8.10 - Apical 3.37 - 
Basolateral 90.38 - 
Tissue 6.25 -
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Table 6.4 DRV permeability across rat cervicovaginal tissue (Rat 1). A-B/B-A Papp for 
Mannitol and DRV as well as drug distribution is presented. Tissues 1 and 2 were used to 
assess A-B permeability and tissue 3 was used for B-A permeability. Tissue 4 data did not 
comply with data acceptance criteria as drug recovery was <80%. Assay conducted at 37°C 
over a 1 hour period. Data represent n=1 (2 technical repeats). 
Rat 2 A-B Drug distribution (%) 
Tissue 1 Tissue 2 Tissue 1 Tissue 2 
Papp Mannitol 5.54 2.19 Apical 95.59 98.45 
Basolateral 2.22 0.75 
Tissue 2.19 0.80 
Papp DRV 6.34 1.86 Apical 92.16 96.49 
Basolateral 1.79 0.52 
Tissue 6.05 2.98 
B-A % Drug distribution 
Tissue 3 Tissue 4 Tissue 3 Tissue 4 
Papp Mannitol 5.10 7.99 Apical 1.66 2.66 
Basolateral 97.68 96.68 
Tissue 0.66 0.66 
Papp DRV 4.45 7.61 Apical 1.92 3.52 
Basolateral 95.03 94.03 
Tissue 3.05 2.45 
Table 6.5  DRV permeability across rat cervicovaginal tissue (Rat 2).  A-B/B-A Papp for 
[3H]mannitol and [14C]DRV as well as drug distribution is shown. Tissues 1 and 2 were used 
to assess A-B permeability and tissues 3 and 4 were used for B-A permeability. Assay 
conducted at 37°C over a 1 hour period. Data represent n=1 (2 technical repeats). 
In these tissues the epithelia presented a leaky barrier as [3H]mannitol Papp values 
were in the ranges of 5-7x10-6 cm/s and likely resulted in an increased rate of 
[14C]DRV flux (4-10x10-6 cm/s). In rat 1 tissue 1 and rat 2 tissue 2 (Table 6.4), 
mannitol flux was more restricted as [3H]mannitol Papp values ranged between 2-
4x10-6 cm/s, and [14C]DRV flux was slower with Papp values of 1-2x10
-6 cm/s. The 
distribution of DRV in the A-B and B-A directions was determined in each of the 
compartments of the individual Ussing chambers (Tables 6.4 and 6.5). For the A-B 
direction approximately 88-92% of DRV remained in the apical side of the chamber, 
0.5-5% permeated into the basolateral side and 3-6% accumulated within the tissue. 
For the B-A direction approximately 90-95% remained in the basolateral side, 1.5-
3.5% permeated into the apical and 2-6% accumulated within the tissue. DRV tissue 




6.3.7 Darunavir (DRV) accumulation in Macaque cervicovaginal tissue 
DRV permeability was also assessed in ex vivo macaque cervicovaginal epithelium 
using the Ussing system. This work was performed at the Commissariat à l'énergie 
atomique et aux énergies alternatives, Fontenay-aux-roses, France. Cervicovaginal 
tissue was separated, segmented and stripped of any muscle layers prior to 
placement between the apical and basolateral glass chambers of the Ussing 
system. Tissue from a single macaque was sufficient for 6 sets of chambers 
allowing triplicate determinations of both A-B and B-Apermeability. Two independent 
experiments were performed with tissues from 2 animals. Samples were taken at 
T=0 and T=1 hour from the donor compartments and at 15 minute intervals over 1 
hour from the receiver compartments. Radiolabelled drug could not be used for 
these experiments and drug concentrations were determined by LC-MS. Levels of 
drug in the receiver compartments have yet to be quantified. The decrease (%) in 
total drug over the 1 hour period of the assay in the donor compartments is shown 
in Table 6.6 together with the level of drug (% of total) in tissue. 
Experiment A-B  B-A 
 *Donor 
Decrease      
(%) 





Decrease      
(%) 
**Tissue         
(%) 
1 7.1 + 0.44 2.6 + 0.3  17.0 + 2.8 0.95 + 0.35 
2 16.6 + 2.4 2.4 + 0.4  35.6 + 0.5 0.83 + 0.5 
 
Table 6.6 Permeability of DRV across macaque cervical vaginal tissue. 
*Decrease in total drug (% + SD) in donor chamber over 1 hour  
**Total drug in tissue at 1 hour (% + SD) n=1 (2 technical repeats). 
Although there is considerable variation in the quantity of drug leaving the donor 
chamber between the experiments, in both experiments the quantity of drug 
transferred from the basal donor chamber is 2 fold higher than the quantity 
transferred from the apical donor chamber. Together with the differences between 
the level of tissue associated drug, these data suggest that DRV may be effluxed at 
the apical surface of macaque vaginal epithelium. 
6.4 Discussion 
The main findings from the experiments described above are that TFV and DRV 




transporter-independent-manner, similar to observations in the HEC-1A model (as 
described in Chapter 5). TFV permeates across the EpiVagina™ via paracellular 
diffusion, while DRV permeates by transcellular diffusion. Quantitative mRNA 
analyses indicated that the expression profile of major drug transporters, including 
BCRP, in the Epivaginal™ model was similar to that of human cervicovaginal tissue. 
This model may therefore be of use in measuring permeability of drugs that are 
substrates for the transporters identified here. As discussed in Chapter 5, mRNA 
analyses may not correlate absolutely with functional protein expression and further 
experiments are required to confirm expression in the Epivaginal™ model. 
Papp values for mannitol in the Epivaginal™ system were consistently higher than 
those observed in HEC-1A dual compartment cultures and at least in the A-B 
direction were higher than 4 x 10-6 cm/s. Similarly, permeability of TFV was slightly 
higher in this system than in the HEC-1A model and the proportion of drug in the 
receiver compartment following the assays was higher (4% compared with 2-3%). 
The geometry of the Epivaginal™ insert did not allow measurement of TEER with 
the available electrode. Nonetheless, these findings together with observations of 
cell detachment in some of the Epivaginal™ cultures suggest that the epithelial 
barrier in this model is leakier than that of the HEC-1A model. In contrast to the 
findings for TFV, the bi-directional Papp coefficient of 2-3.5x10
-6 cm/s for DRV is 2-3 
fold less than that observed in HEC-1A. However, A-B intracellular accumulation of 
DRV was higher (approximately 13%) and basolateral accumulation lower (3%) 
compared with HEC-1A cultures. Thus, DRV does not permeate as freely as in the 
HEC-1A model. The EpiVagina™ presents a thicker, multi-layered epithelial 
morphology (approximately 20 cells thick) compared to the HEC-1A cell layers (1-4 
cells thick) as identified in chapter 4. Therefore, DRV may partition and accumulate 
within the thicker epithelial layer of the EpiVagina™.  
Experiments to model inflammation in Epivaginal™ cultures, by stimulation with 
PAMPS, indicated that unstimulated cultures produced levels of IL-8 that were 10-
fold higher than those reported to disrupt tight junctions in a human colonic cell line 
model [275]. This may be at least a partial explanation for the relatively high 
permeability of mannitol. Although other cytokines were also detected in the 
unstimulated cultures, the concentrations were significantly lower than those 




Permeability studies of DRV across rat vaginal tissue were performed to investigate 
correlation between cell-based models and tissue. Papp values for mannitol varied in 
the range 2-8x10-6 cm/s suggesting some disruption in barrier function. Out of 8 
tissue segments excised from 2 different rats, 7 tissues provided acceptable drug 
recovery values and Papp values for mannitol were below 4x10
-6 cm/s in 2 tissues. 
However, there are currently no reported Papp values for mannitol across vaginal 
tissue to compare with the results reported here. Accumulation of DRV within tissue 
is consistent with transcellular diffusion. Although the range is wide, the average 
Papp values for DRV lie between those determined in the HEC-1A and Epivaginal™ 
models. Further repeats with increased consistency of tissue handling are required 
to provide a more accurate measurement of permeability. 
Similar permeability assays were performed with macaque vaginal tissue. In these 
experiments, radiolabelled DRV could not be used and analyses of drug 
concentrations in receiver chambers are incomplete. Differences in the levels of 
drug remaining in apical and basolateral chambers, however, suggest that DRV 
may be effluxed at the apical surface in these tissues. 
The data presented in this chapter suggests that primary cell-based and tissue-
based models can provide an alternative screening method for drug permeability. 
Preliminary analyses of the data from macaque tissue suggest that DRV may be 
effluxed at the apical surface. Similar activity in humans could potentially limit 
uptake of DRV. This activity was not evident in the Epivaginal™ and HEC-1A 
models. However, a clear drawback of this approach is the limited availability of 
tissue. Additionally, the stripping of the muscle layer from the animal tissue is both 
extremely challenging and time consuming, adding to the possibility of physically 
disrupting the tissue integrity when mounted on the Ussing chamber.   
The attraction of the Epivaginal™ model is that primary cells are cultured which may 
more closely resemble normal epithelium. However, at least in the cultures 
examined in this study, the barrier properties of the epithelium appear to be sub-
optimal. This together with the expense and inconvenience of relying on external 





The main limitations here involve the low number of repeat experiments undertaken 
with rat and macaque tissue. While data presented here is preliminary, repeated 
permeability studies need to be undertaken. Lack of animal availability (especially 
Macaque) was the main reason for the low experimental repeats. However, 
although repeats with Macaques would be difficult, repeated experiments with rats 
would be achievable. Variability in TFV and DRV permeability data between rat 
vaginal tissue segments from the same animal under the same conditions was also 
observed when determining TFV and DRV permeability. This discrepancy in values 
may be due to the difficulty involved with stripping the muscle layer from epithelium, 
















Chapter 7 Final Discussion 
7.1 Study Outcomes 
The main outcomes from this study were: 
1. Development and optimisation of a reproducible in vitro model of vaginal 
barrier epithelium, using the HEC-1A cell line, to investigate drug 
permeability. 
2. Determination of the drug transporter-independent permeability properties of 
3 ARVs, namely, TFV, DRV and DPV. 
3. Demonstration of the potential for in vitro modelling of inflammation in dual 
chamber cultures of HEC-1A cells. 
4. Comparison of the HEC-1A model with the commercially available 
Epivaginal™ model epithelium and ex vivo tissue models. 
 
7.1.2 The HEC-1A model of the vaginal epithelium 
The study described in chapter 4 builds on previous work showing that HEC-1A, in 
contrast to several other cervicovaginal epithelial cell lines, forms a barrier 
epithelium in dual chamber cultures. The barrier results from the formation of 
intercellular tight junctions and is demonstrated by high TEER values [222]. Tight 
junction formation by epithelial cells is fundamental for drug permeability, as it 
discriminates the paracellular and transcellular diffusion pathways. HEC-1A cells 
reproducibly form a barrier epithelium after 6 days in culture that remains stable until 
day 10, providing a 4 day experimental window. The relatively short period to reach 
the maximum TEER compares favourably with the 21-28 day culture period 
necessary for the Caco-2 intestinal model epithelium [233]. The maximum TEER 
value for the HEC-1A model epithelium (approximately 250 Ωxcm2) is noticeably 
lower than the reported maximum for Caco-2 cells (1000 Ωxcm2) [236]. Additionally, 
the lowest mannitol apparent permeability coefficient for HEC-1A (2x10-6 cm/s) is 
considerably higher (10-fold) compared to that reported for Caco-2 (1.2 ± 0.5x10-7 
cm/s) [233], indicating that Caco-2 cells form a tighter epithelial cell layer. This 
tightness may reflect the functional differences in epithelia as the intestine is 
continuously involved in nutrient absorption and rigorously controls movement of 
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molecules across the intestine. Importantly, drug transporter expression in HEC-1A 
cultures resembles that of human vaginal tissue and therefore this model may be 
regarded as physiologically relevant for the investigation of drug permeability. The 
main difference from human tissue is the lack of expression of the efflux 
transporters P-gp and BCRP in HEC-1A cells. Although expression of P-gp was 
indicated by mRNA analyses [148], P-gp could not be detected by Western blotting 
and no effects were evident on the transport of the P-gp substrate digoxin across 
HEC-1A layers. Attempts were made by transfection to express P-gp in HEC-1A 
cells. Although P-gp expression was demonstrated in transfected cells by Western 
blotting, at a level similar to the endogenous expression in Caco-2 cells, no efflux 
activity was demonstrated by HEC-1A for the P-gp substrate digoxin. Lack of P-gp 
activity may again be related to the functional differences in epithelia as the 
cervicovaginal epithelia, in contrast to the intestinal epithelia, is not regularly 
exposed to xenobiotics. Cell lines such as Caco-2 that are derived from intestine 
may reflect the increased transporter activity of this tissue.  
Further development of this model as a useful screening tool for vaginal drug 
permeability studies could include determination of the requirements for functional 
expression of P-gp. Culture conditions may be altered to increase P-gp activity. 
Thus in vitro studies with tumour cells show that P-gp activity was increased (more 
than 2-fold) at acidic pH (pH 6.6) with no increase in P-gp expression [300, 301]. P-
gp activity was also increased in 3-dimensional cultures of a human prostate cancer 
cell line by incubation at elevated temperature (42 °C) by a mechanism that involves 
activation of p38 mitogen activated protein kinase [302]. Similarly, expression and 
activation of other transporters including BCRP warrants further investigation. 
The permeability studies described in this thesis were performed at neutral pH 
initially, to determine the transporter activity of HEC-1A in the optimum culture 
conditions that they are maintained and cultured in. The healthy vaginal pH is 4.0 + 
0.5 due largely to production of lactic acid by lactobacilli [303]. Further permeability 
studies should therefore be performed at this pH in the apical compartment, 





7.1.3 Permeability properties of TFV, DRV and DPV 
TFV, DRV and DPV showed transporter-independent permeability in the models 
used in this study (as described in Chapters 5 and 6). Apparent permeability values 
and drug intracellular accumulation for each drug reflected the physiochemical 
properties of each drug. TFV, a negatively charged hydrophilic molecule slowly 
permeates via the paracellular route through pores of the tight junctions with 
negligible intracellular accumulation. In contrast, DPV is a highly hydrophobic, 
lipophilic molecule that rapidly permeates via transcellular passive diffusion with 
high intracellular accumulation. DRV is less lipophilic and efficiently permeates via 
transcellular passive diffusion with low intracellular accumulation.  
Further work to increase TFV permeability across HEC-1A cell layers may involve 
increasing initial loading concentrations. DRV permeability is generally efficient in 
the presence of cells that are either not expressing P-gp or contain inactivated P-gp. 
For DPV, solubilising excipients may be used in the basolateral compartment in 
attempts to further draw across intracellularly bound DPV. Excipients that increase 
solubility of DPV may however decrease permeability when present in the donor 
compartment by reducing partitioning of the drug into cell membrane compartments 
[136]. Although highly lipophilic drugs may be substrates for transporters, the effect 
may be limited as drug uptake or efflux is likely to be dominated by transcellular 
diffusion. Screening of other drugs in this model would be useful to determine if the 
drug transporters (described in Chapter 4) can influence drug disposition.       
7.1.4 Modelling of vaginal inflammation 
The stimulation of HEC-1A with PAMPS provided a model to investigate drug 
permeability under conditions reflective of an inflammatory response (as described 
in Chapter 5). The use of PAMPS here provided a “more physiological” 
representation compared to the direct application of inflammatory cytokines to HEC-
1A cell layers. Stimulation by this method may better mimic the expression of 
inflammatory molecules in conditions such as bacterial vaginosis or STDs. 
Stimulation of HEC-1A with the TLR 3 ligand Poly I:C and the TLR 5 ligand 
Flagellin, induced production of some inflammatory cytokines. In particular, IL-8 and 
IL-6 were detected at concentrations comparable to those reported as sufficient for 




concentrations lower than those required for tight junction disruption [274]. In this 
study, PAMP stimulation had no effect on TEER and Papp values for mannitol, TFV 
and DRV were unaffected. Further experiments should involve direct addition and 
titration of pro-inflammatory cytokines to investigate effects on TEER. Increasing the 
length of exposure to PAMPs may also provide a more pro-inflammatory 
environment.  
7.1.5 Epivaginal™ model 
Analyses of drug transporter expression in the Epivaginal™ primary cell-based 
model by mRNA quantitation indicated that the expression profile more closely 
resembled that of human tissue when compared with HEC-1A. A major difference in 
both models was lack of BCRP expression. TFV permeated across the 
EpiVaginal™ model with Papp values lower than mannitol and negligible intracellular 
drug accumulation. In comparison to HEC-1A, TFV and mannitol permeability was 
elevated, indicative of a leakier barrier. Nonetheless, the permeability was similar 
with regard to diffusion via the paracellular pathway and transporter-independency. 
In contrast, Papp values for DRV permeation across the EpiVaginal™ were lower and 
intracellular accumulation was elevated when compared to HEC-1A. The low Papp 
value for DRV was similar to that of TFV and mannitol, but may reflect higher DRV 
intracellular accumulation rather than paracellular diffusion. This may be due to the 
thicker cell layer of the EpiVaginal™ model compared to the thinner cell layer of the 
HEC-1A model. Nonetheless, to further determine the reliability of these results, the 
data reported should be repeated due to the limited number of replicates.  
The main concern with the Epivaginal™ model is that the barrier properties of the 
culture were sub-optimal compared with the HEC-1A model as evidenced by 
increased Papp values for mannitol. Significant levels of IL-8 were also detected in 
unstimulated cultures which could compromise the integrity of the tight junctions. In 
contrast to the Epivaginal™ model, dual chamber cultures of HEC-1A cells provided 
a reproducible, convenient and relatively cost-effective alternative. 
7.1.6 Ex vivo tissue models for drug permeability studies 
Models involving mounted animal tissue in between Ussing chambers may mimic 




vaginal tissue a few challenges were encountered. Removing the underlying rigid 
muscle layer prior to all experiments was difficult and time consuming. Tissue was 
maintained in ice cold Krebs solution however some proteolysis may still occur. 
Initial ex vivo experiments included the use of rat tissue; the limited availability of rat 
tissue allowed only preliminary studies to be performed. Permeability of DRV and 
mannitol only was investigated. DRV is a substrate for P-gp [214] and was therefore 
selected as a means of investigating activity of this transporter in tissue. DRV 
permeability was transporter-independent with fluctuating Papp values. This 
fluctuation was a result of unstable individual tissue barrier integrities reflected in 
variable and high mannitol Papp values. Low mannitol permeability resulted in low 
DRV permeability and high mannitol permeability resulted in high DRV permeability. 
DRV accumulation was also detected intracellularly. The lower permeability rate of 
DRV was similar to that observed in the EpiVagina™ and may be due to thicker 
tissue which restricts the permeability of drug to the basolateral compartment.  
DRV permeability was also investigated using macaque vaginal tissues. The 
analyses of drug concentrations in the receiver compartment have not been 
completed but initial results suggest increased flow of drug in the basolateral to 
apical direction compared to the flow in the apical to basolateral direction. This may 
indicate efflux of DRV at the apical surface. The limitation of this work is that 
macaque tissue is less available than rat. 
Ex vivo animal tissues are significantly different in anatomy and physiology from 
human tissues. The rat vaginal epithelium is constituted by pluristratified squamous 
cells which undergo prominent changes throughout the estrous cycle which results 
in the regular transitioning of thin and thick epithelial layers. These morphological 
changes have shown to impair the hydrophilic drug absorption during ovulation 
[304, 305]. Additionally, the pH of the rat vaginal epithelium is neutral [306]. 
Macaque vaginal physiology is more similar to human exhibiting epithelial thickness 
within the same ranges mentioned previously. One notable difference is that the 
vaginal pH in macaques is also near neutral, and may be due to the smaller 
colonization of lactobacilli [307]. Due to the physiological differences and limitations 
encountered by each of these models, the drug permeability assessments 




model. Further optimisation is needed with the drug transport studies described 
here.     
7.2 Conclusions 
The most significant finding from this study is that the HEC-1A cell line can be used 
as a model epithelium for the pre-clinical screening of drugs developed for vaginal 
application. Optimal culture conditions results in maximal TEER measurements and 
efficiently restricts mannitol permeability. After a short time of 6-10 days in culture 
on PE permeable supports, barrier integrity of HEC-1A reaches a stable plateau 
producing a 4 day experimental window. Furthermore, drug transporter expression 
as determined by mRNA and protein analyses shows significant similarity to that in 
human vaginal tissue.  
To further determine the usefulness of this model, the permeability of 3 ARV drugs 
were investigated and their permeability properties assessed. While all three drugs 
show transporter-independent permeability, TFV permeates via paracellular 
diffusion and DRV and DPV permeate via transcellular diffusion. Additionally, 
intracellular drug accumulation analysis provided a further insight into the transport 
kinetics of the drugs. Intracellular accumulation was negligible for TFV, low for DRV 
and high for DPV, reflecting the physiochemical properties of these drugs. 
Investigation of double drug combinations shows no drug-drug interactions. The 
vaginal inflammation model, although limited, suggested some resistance to tight 
junction disruption as TEER values were no reduced, mannitol permeability 
remained stable and TFV and DRV permeability were unaffected. Lack of 
transporters present in HEC-1A compared to human tissue such as P-gp and BCRP 
may present limitations but use of plasmid or viral vectors may allow expression of 
selected transporters [160]. 
The second part of the thesis focused on the use of other in vitro/ex vivo systems to 
determine their suitability as alternative drug transport models. With many 
challenges and limitations, permeability properties for TFV and DRV were assessed 
in the primary cell-based MatTek EpiVaginal™ model while DRV permeability was 
assessed in the tissue-based ex vivo rat and macaque models. Permeability of TFV 
was similar to that detected in the HEC-1A model but differences in permeability for 




varying DRV accumulation within all models. As discussed, this may due to the 
varying thicknesses between tissue and cell based models, requiring further 
optimisation. Additionally, high and fluctuating mannitol permeability identified in 
these systems suggest barrier properties are unstable.  
7.2.1 Overall conclusions 
Overall, the limitations for each chapter have been identified and acknowledged with 
solutions suggested for future experiments. In Chapter 4, improved experimental 
control measures and increases in experimental replicates were recognised. In 
Chapter 5, the need to include cytotoxicity studies as well as TEER is necessary to 
confirm cell viability, and P-gp transfections using other cell lines are appropriate to 
investigate the effect of P-gp activity by the cellular environment.  Similar to Chapter 
4, Chapter 6 also acknowledges the low repeat experiments that involved the use of 
animal tissue, with future focus on increasing experimental numbers especially with 
rat tissue. Additionally, the difficulty of individual tissue preparation is taken into 
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3.1 IntroductionCurrent development of microbicides against HIV-1 is largely focused on antiretroviral (ARV) drugs. The relative success of the CAPRISA 004 trial of vaginally applied tenofovir (TFV) gel provides a rationale for developing microbicides that target intracellular events in virus replication [1]. While the reverse transcriptase inhibitors (RTIs) TFV and dapivirine are currently in Phase 3 clinical trials as single drugs, efforts are also under way to 
develop combination microbicides that include two or possibly more drugs. The potential advantages of combinations include increased efficacy and presentation of a higher barrier to drug resistance.
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Development of such products also presents a number of chal-lenges. To date, microbicides under development have targeted earlier events in infection, including HIV-1 attachment and fusion and production of double-stranded complementary DNA (cDNA) 
by reverse transcriptase (RT). Efficacy of microbicides may be im-proved by inclusion of compounds that have not been considered previously but that target later events such as integration of the viral genome or maturation of virus particles. Microbicides must 
deliver effective concentrations of drug to sub-mucosal target cells. In turn, this may need improved understanding of factors that 
influence drug distribution in tissues including the effects of drug 
uptake and efflux transporters. Desirable drugs in combination 
microbicides may have widely differing and incompatible physi-
cochemical properties or may show unfavorable drug–drug interactions. Such incompatibilities present challenges for formula-tion.
In this chapter, we discuss findings from early events in HIV transmission that identify target cells for the prevention of 
infection. We review microbicides and targets currently under 
investigation as well as studies demonstrating in vitro the benefits 
of combining ARV drugs. We also discuss factors that may influence tissue distribution of drugs and challenges that must be addressed in the formulation of microbicides.
3.2 HIV Transmission at Mucosal SurfacesEarly HIV-1 infection events at the mucosal portal of entry have been studied in non-human primate (NHP) models. The similarities 
of simian immunodeficiency virus (SIV) transmission and propagation to HIV-1 and the similarities in anatomy and immunology of the genital tract of macaques to humans have made these models a valuable tool for identifying critical events that 
follow mucosal exposure to HIV-1 and precede clinical signs and symptoms of disease [2].
Transmission studies where rhesus macaques were inoculated 
intra-vaginally with high doses of SIV revealed that virus entry across the epithelial barrier results in productive infection of a small founder population of CD4+ T cells at 3–4 days after challenge 
[3,4]. Exposure to the virus inoculum led to increased expression 
of macrophage inflammatory protein 3α (MIP-3α or CCL20) in 
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endocervial epithelium and recruitment of plasmacytoid dendritic cells (pDC). In turn, pDC may recruit and activate further CD4+ T 
cells through production of MIP-1α (CCL3) and MIP-1β (CCL4) [4]. 
Expansion of the founder CD4+ T cells (stimulated by innate immune 
and inflammatory mediators) then results in infection of draining 
lymph nodes and secondary lymphoid organs from day six on [3].
Ex vivo cervicovaginal tissue explant models of HIV infection 
have confirmed the role of dermal CD4+ T cells as predominant 
targets of virus particles, but also suggested that Langerhans cells and dendritic cells may contribute to viral dissemination to 
lymphoid tissues [5] and enhance amplification of viral replication in CD4+ T cells at mucosal sites [6].
The small size of the infected founder population was also 
confirmed in a study where animals received multiple low dose 
intra-rectal challenges with virus stocks containing a median of 
48 different SIV Env sequences [7]. Single-genome amplification 
confirmed that the founder CD4+ T cells populations were 
productively infected by one or a few viruses. These conclusions 
are in agreement with studies demonstrating that most HIV-1 infections are initiated by a single virus genotype [8].
Early events following rectal mucosa exposure to SIV, as well as 
subsequent kinetics of viral replication and dissemination, exhibit 
significantly different characteristics compared to vaginal infection. 
Breaches within the epithelial barrier and potential interaction 
with intraepithelial migrating cells may be major mechanisms of HIV transmission across the rectal mucosal barrier. HIV may also cross the rectal epithelium by transcytosis through epithelial cells 
[9] and M cells [10], and opening of tight junctions by analogy 
with other viruses [11,12]. The rectal epithelial layer is therefore likely to be more susceptible to virus entry compared to vaginal epithelium. The time required for dissemination of infection 
appears to be significantly shorter than that observed in infection of cervicovaginal mucosae. Analyses of viral dissemination in a 
simian-human immunodeficiency virus (SHIV) challenge model demonstrated proviral DNA in secondary lymphoid organs at 
3 days post-inoculation [13]. In a more recent study where rhesus 
macaques were challenged intra-rectally with relatively low doses 
of pathogenic SIV, infectious virus was recovered in secondary lymphoid organs at four hours after rectal challenge [14]. At this time point virus was present in both lymphoid aggregates and 
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lamina propria of the rectum suggesting viral entry via digestive 
epithelium as well as via follicle-associated epithelium. Similar to vaginal infection, the primary target cells for HIV replication in the 
lamina propria were T cells, but the virus was also found associated 
with dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) positive cells and macrophages. 
These findings have also been confirmed in a further SHIV challenge 
model study where the effect of intravaginal inoculation was 
compared to intravenous and intrarectal challenges with the same SHIV strain [15].
These findings indicate that an effective microbicide must either disable HIV in the vaginal or rectal lumen or be delivered 
submucosally (while preserving integrity of the epithelial barrier) to prevent infection of submucosal CD4+ T cells.
3.3 Microbicides: Current State of the Art
First-generation microbicides were relatively non-specific and aimed at disrupting HIV-1 virus particles (surfactants) or inhibiting 
virus attachment (polyanionic compounds) but did not show 
efficacy in clinical trials [16–20]. The CAPRISA (Centre for the AIDS Programme of Research in South Africa) 004 Phase 2b clinical trial of TFV 1% gel as a vaginal microbicide demonstrated 39% 
protection and provided the first proof-of-principle for the concept that microbicides could prevent infection [1]. Since TFV is a nucleotide RTI (NtRTI), this trial also provides a rationale for the development of microbicides that target intracellular events. 
Current efforts to develop microbicides are focused largely on 
compounds that specifically target different stages of HIV infection. Microbicides in development have been described in a number 
of previous reviews [21–24]. A brief outline with emphasis on 
mechanisms/targets follows.
3.3.1 HIV Fusion
The interactions between HIV-1 envelope protein and host cell receptors (CD4 and CCR5) have been targeted by a range of candidate microbicides including antibodies, single domain (llama-derived) antibodies, peptides and small molecule inhibitors aimed at preventing virus attachment and fusion. That vaginally applied 
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antibodies with neutralizing activity could prevent infection was demonstrated in a NHP challenge model using the monoclonal antibody b12 (directed against the CD4 binding site of gp120) 
[25] and subsequently with a combination of three monoclonal antibodies (2G12, 2F5, and 4E10) [26]. The combination of three 
monoclonal antibodies formulated as a vaginal gel was shown to 
be safe in a Phase 1 clinical trial [27]. A peptide mimic of the site of CD4 that binds to gp120 has also been shown effective in a NHP model of SHIV vaginal challenge [28].Small molecule inhibitors of viral fusion that bind to gp120 are also under investigation as microbicides. The compound 
BMS-806 also showed efficacy in NHP model of SHIV vaginal challenge [29]. Inhibitors of this class do not prevent gp120 binding to CD4 (in contrast to the antibody and peptide inhibitors described above) but bind to gp120 and prevent the confor- mational changes required for membrane fusion [30].
Different classes of microbicides that target the co-receptor CCR5 are under development. A series of analogues of regulated on 
activation, normal T cell expressed and secreted (RANTES or CCL5) protein, a chemokine ligand of CCR5, have been developed that inhibit fusion either by receptor internalization or by receptor blockage [31,32]. Compounds in this series include PSC-RANTES 
[33], 6P4-RANTES, and 5P12-RANTES [34], and have shown protection in NHP vaginal challenge studies. In contrast to PSC-
RANTES, which requires chemical modification of the N-terminus, 
6P4-RANTES and 5P-12 RANTES are modified by inclusion of additional (naturally occurring) amino acids at the N-terminus 
thus allowing for large-scale production by microbial fermentation. Small molecule inhibitors of CCR5 binding are also being investigated as potential microbicides. Maraviroc, the only drug in 
this class approved for therapy, was also protective as a microbicide in a NHP model of vaginal challenge [35].
3.3.2 Reverse TranscriptaseThe HIV-1 enzyme RT, that produces double-stranded viral cDNA, has been successfully targeted by nucleoside and nucleotide RTIs (NRTIs and NtRTIs, respectively) for treatment in HIV infection. As above, TFV (an NtRTI licensed for therapeutic use) is the only 
compound to demonstrate efficacy in humans when tested as a 
96 Challenges in Microbicide Drug Delivery
vaginal microbicide [1]. In pre-clinical studies, TFV had also been 
protective against rectal [36] and vaginal [37] challenge in NHP 
models. However, in a further Phase 2b human safety and efficacy trial (the VOICE trial, MTN-003) that also tested TFV vaginal gel 
(as well as oral forms of TFV) no protection was observed [38]. 
The low level of adherence to TFV use was reported as likely to be 
the most significant factor in the lack of protection. Serum levels of 
drug were determined in a large subset of trial participants and 
TFV was detected in only 23% of participants in the vaginal gel arm [38,39]. Another Phase 3 trial (FACTS 001 study) of TFV gel using the same dosing schedule as CAPRISA 004 began in October 2011 and is in progress [40].Non-nucleoside RTIs (NNRTIs) are non-competitive inhibitors that bind to an induced allosteric hydrophobic pocket 
approximately 15 Å from the RT active site [41]. Four NNRTIs, 
dapivirine (TMC120), UC-781, MIV-150, and MC-1220 are being investigated as potential microbicides. Dapivirine, currently the most advanced in clinical development, has been formulated in a 
vaginal ring (see below) for sustained delivery and is being tested 
in two linked Phase 3 safety and efficacy trials (The Ring Study, International Partnership for Microbicides; ASPIRE, Microbicide 
Trials Network) with completion expected in 2015 [42,43]. UC-
781 formulated as gels has been generally well tolerated in vaginal [44,45] and rectal [46] Phase 1 trials. In pre-clinical studies both 
MIV-150 [47,48] and MC-1220 [49] prevented infection in NHP models of vaginal transmission.
3.3.3 RNase HHIV-1 RT is a heterodimer comprising p66 and p51 polypeptides. The p66 polypeptide includes both RT (N-terminal domain) and RNase H (C-terminal domain) activity. The p51 polypeptide is itself derived by C-terminal proteolytic cleavage of a separate p66 polypeptide and plays a role in RNA/DNA hybrid positioning and hydrolysis [50]. RNase H activity is essential for production of double-stranded viral cDNA and a number of studies have described inhibitors of RNase H that may have potential as 
microbicides. Some NNRTIs show partial inhibition of RNase H activity in addition to inhibiting RT activity with both effects being 
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the result of binding to the single NNRTI  inding site on RT [51]. A synthetic oligonucleotide has been investigated that binds 
specifically to the highly conserved polypurine tract (PPT) in 
the HIV genome and activates RNase H activity within the viral 
particle [52]. Pre-incubation of HIV with the oligonucleotide led to reduced infectivity in vitro [52] and conferred protection in a humanized severe combined immunodeficient (hu-SCID) mouse model of intraperitoneal challenge [53]. The need for improving  oligonucleotide uptake by the virus and the high production cost remain hurdles to be overcome in further development of this class of inhibitors.
3.3.4 IntegraseHIV-1 integrase enzyme integrates reversed-transcribed (viral) DNA into the host genome. Raltegravir is the only inhibitor of 
integrase in use for therapy and has shown efficacy as a vaginal microbicide in a macaque model of SHIV challenge [54]. Since the 
integrase complex involves several (host-derived) cellular co-factors, inhibitors that may prevent binding of integrase to key factors have been investigated in pre-clinical studies. Small molecule inhibitors 
of integrase binding to lens epithelium-derived growth factor 
(LEDGF/p75) have been described as both inhibiting integrase activity and virus replication [55] although again, further 
optimization will be necessary for product development.
3.3.5 ProteaseHIV-1 protease is essential for the conversion of non-infectious immature virus particles to mature infectious virus, a process initiated by cleavage of gag and gag-pol polyproteins. The successful use of protease inhibitors (PIs) as a component in highly active 
antiretroviral therapy (HAART) together with their high potency and high barrier to resistance have stimulated interest in developing 
them as microbicides [56,57]. In vitro studies of saquinavir 
demonstrated neutralizing activity both in cell and tissue explant 
systems with half-maximal inhibitory concentration (IC50) values 
in the low micromolar range.
Microbicides
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3.4 Combination MicrobicidesThe focus on ARV-based microbicides raises concerns regarding 
efficacy against transmission of strains of HIV that are resistant to ARV drug and the possibility of driving resistance to these last. In response to this, the inclusion of ARV drugs in combination in a single microbicide formulation has been investigated. The 
advantages of combinations are that they may be effective in preventing transmission of strains resistant to one of the drugs and that they present a higher barrier to the development of 
resistant strains since more mutations would be required than for 
a single drug. The possibility of drug–drug interactions that reduce 
antiviral activity and the likelihood that drugs with very different physicochemical properties may need to be co-formulated present potential obstacles for product development.Support for the concept of a microbicide incorporating drug 
combinations was provided by a study in which small molecule inhibitors BMS-806 (binds to gp120 and prevents conformational 
changes required for fusion) and CMPD167 (binds to CCR5 
and inhibits binding of gp120) were tested together with C52L 
(bacterially expressed modified form of the fusion inhibitor T-20) 
in a macaque vaginal challenge model with SHIV [29]. Drug 
combinations were tested for neutralizing activity in vitro 
showing additive or synergistic activity. In challenge experiments, 
significant protection was evident whether compounds were 
applied singly or in combination but there were some indications 
that combinations were more effective.Drugs that act on the same target, namely RTIs, have also been investigated in combination. Dual combinations of TFV, dapivirine, 
and UC-781 have been tested in vitro in cell culture and colorectal 
explant tissues [58]. In each case, combination was more potent than individual drugs in tested models and NNRTI (dapivirine or 
UC-781) plus NtRTI (TFV) combinations were effective against 
strains of HIV-1 resistant to either class of drug. In an extension of 
this study, the NRTI emtricitabine was included to allow comparisons of triple and quadruple combinations of RTIs [59]. 
Triple combinations were more effective than double, while 
quadruple combinations showed no significant improvement over 
triple. In these studies, no antagonistic effects of drug combinations 
were evident. Gel formulations of UC-781 plus TFV were tested 
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in ectocervical explants showing both tissue compatibility and antiviral activity [60].
3.5 Factors Affecting Drug Distribution in 
Mucosal Tissues
3.5.1 Drug Transport and Metabolism
To be effective, ARV drug-based microbicides that target intracellular events in HIV-1 infection must be delivered to the sub-mucosal CD4+ T cells that have been identified as forming the initial 
foci of infection (as outlined in Section 3.2) and therefore must first pass through the mucosal epithelium. The distribution of drugs in 
mucosal tissues may be influenced by the activity of specific cell 
membrane transporters whose primary function is the transport 
of nutrients and solutes. Solute transporters are grouped in two 
superfamilies, namely, solute carrier (SLC) transporters and ATP-
binding cassette (ABC) transporters. Human SLC transporters are 
further divided into 52 different sub-families comprising a total of 
395 transporter genes [61] while ABC transporters (48 genes) are 
grouped into 7 subfamilies.
SLC transporters show relatively broad and in some cases 
overlapping substrate specificities and are mainly responsible for the transport of drugs into cells. Those implicated in the transport of ARV drugs include the organic anion-transporting polypeptides 
(OATP, subfamily SLCO), organic anion (OAT, SLC22) and organic 
cation (OCT, SLC22) transporters, concentrative (CNT, SLC28) 
and equilibrative (ENT, SLC29) nucleoside transporters as well as 
peptide transporters (PEPT, SLC15) [62,63]. A common structural 
feature of SLC transporters is the large number (11–13) of predicted 
transmembrane domains. Efflux of drugs is mediated principally by ABC transporters including members of the P-glycoprotein 
(P-gp) subfamily (ABCB) as well as breast cancer resistant proteins (BCRP, ABCG subfamily) and multidrug resistance proteins (MRP, ABCC subfamily).Because of their key role in determining drug distribution after 
systemic or oral administration, the expression and distribution of drug transporters in intestinal epithelia, hepatocytes, and kidney 
proximal tubules have been relatively well characterized and for some transporters the distribution on apical or basolateral surfaces 
100 Challenges in Microbicide Drug Delivery
of epithelia have been described [64,65]. Polarized distribution of 
transporters allows transport of drugs across the epithelium with 
uptake at the apical surface by SLC transporters and efflux at the 
basolateral surface by MRP or other efflux transporters. Conversely, 
expression of P-gp at the apical surface of intestinal lumen may 
restrict net uptake of drugs. In mice deficient in intestinal P-gp, 
bioavailability following oral administration of the anti-cancer drug 
paclitaxel increased significantly compared with wild type mice 
confirming the role of P-gp in efflux of drug back to the intestinal lumen [66].Drug transporters that may be relevant for rectal or vaginal 
microbicides have been described in the colon [67–69] and more 
recently in cervicovaginal tissue [70]. Data are summarized in 
Fig. 3.1. In the colon, while influx organic ion (OCT3 and OATPB) 
transporters are expressed on the apical surface, drug uptake may 
be restricted by the presence of efflux (P-gp and BDRP) transporters on the same surface. Conversely, on the basolateral surface, the 
activity of the efflux transporter (MRP3) may be compromised by 
influx transporters with the potential to reduce net transfer of drug across the epithelium. The apical and basolateral distribution of transporters in cervicovaginal epithelium has not been determined. 
However, the P-gp and BCRP efflux transporters are generally at 
the apical surface of epithelial cells while MRP1 is associated with 
basolateral surfaces [71]. MRP4 and MRP5 have been reported at 
both apical and basolateral surfaces in other tissues. Influx organic cation transporters (OCT2 and OCT3) have been reported on the 
apical surfaces of other epithelial cell types while the organic anion transporters have been reported on both apical and basolateral 
surfaces [71] as has the equilibrative nucleoside transporter ENT1 [62]. Drug transporters in peripheral blood CD4+ T cells are well 
characterized including both influx and efflux transporters as also 
shown in Fig. 3.1 [62].
The influence of mucosal drug transporters on the distribution of topically applied ARV-based microbicides remains to be determined. Of the ARV drugs that are most advanced in clinical development as microbicides, TFV, as a polar small molecule, may cross the epithelium by the paracellular route but has also been 
identified as a substrate for influx organic anion transporters 
OAT1 and OAT3 and efflux transporter MRP4 [72,73]. Maraviroc 
101
is a substrate for the influx transporter OATP1B1 [74], expression 
of which has not been reported for colorectal or cervicovaginal 
epithelium. Maraviroc is a substrate for the efflux transporter P-
gp, which could potentially limit uptake. Hydrophobic drugs such 
as dapivirine and UC-781 may partition directly into epithelial and T cell membranes.
(a) (b) (c)
Figure 3.1 Efflux and uptake drug transporters that may be relevant for rectal or vaginal microbicides have been described in the (a) colon, (b) CD4+ lymphocytes and (c) cervicovaginal tissue. The apical and basolateral distribution of transporters in cervicovaginal epithelium has not been determined.More broadly, several nucleoside analogue ARV drugs are 
substrates for influx transporters of the SLC22 (organic cation 
and anion transporters) and SLC29 (ENT1 and ENT2) families as 
well as MRP4 and MRP5 efflux transporters that are expressed in cervicovaginal or colorectal epithelium [63]. PIs such as lopinavir, saquinavir, and darunavir are substrates for OATP1A1 and OATP1B1 
(members of the SLCO family) and most members of this class of 
ARV drugs are substrates for P-gp as well as MRP1 and MRP2 
efflux transporters [62]. ARV drugs may also modulate activity and 
expression of drug transporters. Several PIs inhibit OATP [75] and 
OCT transporters as well as P-gp, MRP, and BCRP efflux transporters 
[62,76]. In addition, some PIs induce P-gp expression. NRTIs, 
NtRTIs and NNRTIs also inhibit the activity of BCRP [76,77] and 
MRP [77] efflux transporters as well as some influx transporters 
[62]. While these observations point to the complexity of factors that may contribute to tissue disposition of drugs, they also point to the possibility of manipulating drug combinations to improve distribution and retention of ARV drugs at target tissues.
Factors Affecting Drug Distribution in Mucosal Tissues
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Metabolism by cytochrome P450 (CYP) isoforms further alters tissue levels of ARV drugs. Reverse transcription polymerase chain reaction (RT-PCR) analyses of human cervicovaginal tissue 
indicated that, while CYP1A1 and CYP1B1 isoforms were expressed, 
most isoforms, including CYP3A4 (the most highly expressed isoform 
in liver), were not [70]. In contrast, eight members of the UDP-
glucuronosyltransferase (UGT) family of enzymes were expressed. 
Enzymes in this family catalyze the addition of hexose moieties to 
small molecules (including some drugs) which facilitates recognition 
and efflux by drug transporters [78]. Similar findings have been 
reported for colonic tissue where low messenger RNA (mRNA) 
levels were reported for most CYP isoforms, with the exception 
of CYP2J2 and CYP3A5 [79], while RT-PCR analyses suggested that 
11 members of the UGT enzyme family were expressed [80]. 
Relatively low levels of CYP could be advantageous for maintaining tissue levels of locally applied microbicides.
3.5.2 Mucosal Inflammation
Inflammation of the genital tract that may result from alterations 
in microbiota or sexually transmitted diseases is associated with 
increased transmission of HIV-1 [81–83]. Contributing factors include a local increase in the number of HIV-1-susceptible target cells, increased activation of CD4+ T cells and damage to the integrity 
of the epithelial barrier. Pro-inflammatory cytokines impair barrier function either by inducing apoptosis of epithelial cells or 
remodeling of tight junctions, thus resulting in increased 
paracellular leakiness [84,85], which in turn may impact on tissue 
drug distribution. Inflammation may also have an impact on the 
tissue distribution of ARV drugs by altering expression of drug transporters.
Studies of the effects of inflammation on expression of drug transporters generally focus on intestinal, hepatic, or placental transporters, and data for the female reproductive tract are not 
available. In inflamed tissue of duodenal biopsies from patients 
with ulcerative colitis, the expression of P-gp and BCRP efflux 
transporters is reduced as compared to non-affected mucosa or 
normal controls [86]. In colon biopsies from patients with ulcerative colitis, mRNA levels of the nucleoside transporters ENT1, ENT2 
(SLC29 family), and CNT2 (SLC28) were significantly increased 
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as were mRNA levels of the organic anion transporters OATP2B1, 
OATPE (SLCO), and OCTN1 (SLC22) [87]. The net effect of these 
changes has not been determined although reduction in efflux transporters could lead to higher tissue levels of topically applied drugs.
3.6 Formulation StrategiesUnderstanding of the impact of drug transporters may contribute to optimized formulations for the delivery of ARV-based microbicides to target tissues. Potentially inhibitors or activators 
of specific efflux or uptake transporters could be included in formulations for improved delivery. Drug combinations present 
further challenges for formulation where the active pharmaceutical 
ingredients (APIs) may possess widely different physicochemical 
characteristics. Formulations of hydrophobic NNRTIs with TFV in a 
single gel have been reported. Gel formulations of UC-781 with TFV 
were developed that delivered in vitro (organotypic human vaginal-ectocervical tissue) and in vivo (vaginal administration in rabbits) 
tissue drug concentrations that were considerably in excess of in vitro IC50 values for each drug [88]. In this, and in earlier work [89] 
both the poor aqueous solubility and the oxidative degradation of 
UC-781 presented challenges.Co-formulation of ARV drug combinations in intravaginal rings has also been reported. The advantage of these continuous use dosage forms is that incompatible drugs can be segregated. A 
silicone ring in which pods containing different drugs are inserted 
was used to co-formulate TFV and acyclovir [90]. A combination of maraviroc and dapivirine has also been formulated in thermo-plastic (ethylene-vinyl acetate copolymer, EVAc) rings [91].
3.7 Conclusions and Future Perspectives
The challenge facing microbicide developers is to increase efficacy over the levels observed in the CAPRISA 004 trial and to understand 
the lack of protection in some subsequent efficacy trials. As discussed above, compliance is likely to be a key factor in determining 
efficacy. In turn, this points to the need for developing microbicide 
formulations with improved user acceptability. In this regard, 
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results of the Ring Study/ASPIRE trial of dapivirine formulated 
for sustained delivery by intravaginal ring will be of considerable 
interest. Further improvements in efficacy may come from development of combination microbicides. These may be 
particularly important where drugs are in use for both treatment and prevention so as to prevent transmission of resistant virus.
In view of studies (discussed above) that immune activation 
may enhance HIV acquisition and the finding that exposure to HIV-1 
upregulates production of inflammatory cytokines by mucosal 
epithelial cells leading to disruption of tight junctions and translocation of virus [92], inclusion of inhibitors of immune activation in microbicide formulations may be a consideration. Protection against SIV transmission in the macaque model by 
vaginal application of glycerol monolaurate, which inhibits 
production of pro-inflammatory cytokines, provides a rationale for such an approach [4]. In addition, drug delivery may be improved by formulations designed to modulate drug transporter activity.ARV drugs currently being developed as microbicides are either also used for treatment or belong to the same classes of drugs that 
are used for treatment. In the longer term, it would be preferable 
to have different classes of drug for prophylaxis or treatment. It 
would therefore be prudent to continue the development of some of the other classes of microbicide molecules including domain antibodies, peptides, RANTES analogues or small molecules 
(outlined above) that have entirely different mechanisms of action. In the longer term again, other cellular moieties may be targeted 
with novel classes of drugs. Genome wide screening studies 
[93–95] have collectively identified 1,254 cellular factors that may be essential for viral replication in host cells [96]. Meta-analysis of 
the genes identified in screening studies and those in the National Center for Biotechnology Information interaction database 
identified 259 genes that overlapped in at least two studies while 
network analysis identified a total of 1,657 cellular proteins that 
formed interactions with other host cell factors (implicated in HIV replication) or HIV-encoded proteins [96].
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